var title_f36_37_37456="Postural changes in AS";
var content_f36_37_37456=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F55095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F55095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 527px\">",
"   <div class=\"ttl\">",
"    Progression of postural changes with ankylosing spondylitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 507px; height: 267px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This series of photographs shows the progressive postural changes of ankylosing spondylitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Little, H, Swinson, DR, Cruickshank, B. Upward subluxation of the axis in ankylosing spondylitis: a clinical pathologic report. Am J Med 1976, 60:279. Copyright &copy; 1976 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_37_37456=[""].join("\n");
var outline_f36_37_37456=null;
var title_f36_37_37457="Patient information: Guillain-Barré syndrome (The Basics)";
var content_f36_37_37457=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/61/25554\">",
"         Patient information: Advance directives (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?33/16/34050\">",
"         Patient information: Going home from the hospital (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Guillain-Barr&eacute; syndrome (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/guillain-barre-syndrome-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H15641066\">",
"      <span class=\"h1\">",
"       What is Guillain-Barr&eacute; syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Guillain-Barr&eacute; syndrome, or &ldquo;GBS,&rdquo; is a condition that causes mild or severe muscle weakness. There are different types of GBS. The most common type is called &ldquo;acute inflammatory demyelinating polyneuropathy,&rdquo; or &ldquo;AIDP.&rdquo;",
"     </p>",
"     <p>",
"      In GBS, a person&rsquo;s infection-fighting system attacks his or her own nervous system. This damages the nervous system, which can cause symptoms.",
"     </p>",
"     <p>",
"      Both children and adults can get GBS.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15641081\">",
"      <span class=\"h1\">",
"       What are the symptoms of Guillain-Barr&eacute; syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;GBS causes muscle weakness on both sides of the body. The weakness usually starts in the legs, and then spreads to the arms and face. Some people have mild weakness, for example, trouble walking. Other people are unable to move the muscles in their legs, arms, or face. Doctors call this &ldquo;paralysis.&rdquo; In some people, the muscles used for breathing get very weak. This can make it hard to breathe.",
"     </p>",
"     <p>",
"      Other symptoms of GBS can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Tingling or numbness in the hands or feet",
"       </li>",
"       <li>",
"        Pain, especially in the back, legs, or arms",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15641096\">",
"      <span class=\"h1\">",
"       Is there a test for Guillain-Barr&eacute; syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will ask about your symptoms and do an exam. He or she will also do tests to be sure you have GBS. Tests can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A lumbar puncture, sometimes called a &ldquo;spinal tap&rdquo; &ndash; During this procedure, a doctor puts a thin needle in the lower back and removes a small amount of spinal fluid. Spinal fluid is the fluid that surrounds the brain and spinal cord. He or she will do lab tests on the spinal fluid.",
"       </li>",
"       <li>",
"        Nerve conduction studies &ndash; This test can show whether the nerves are carrying electrical signals the correct way.",
"       </li>",
"       <li>",
"        Electromyography, or &ldquo;EMG&rdquo; &ndash; This test shows whether the muscles are responding to the nerves&rsquo; electrical signals in the correct way.",
"       </li>",
"       <li>",
"        Blood tests",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15641111\">",
"      <span class=\"h1\">",
"       How is Guillain-Barr&eacute; syndrome treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment for GBS involves different parts:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Treatments for problems caused by the GBS &ndash; People with GBS are usually treated in the hospital. That&rsquo;s because symptoms of GBS can get worse very quickly. In the hospital, the doctor can monitor a person&rsquo;s breathing, heartbeat, and health. Then he or she can treat any problems that come up, such as:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Breathing problems &ndash; People who are having a very hard time breathing usually need a breathing tube. A breathing tube is a tube that goes down the throat and into the lungs. The other end is attached to a machine that helps with breathing.",
"       </li>",
"       <li>",
"        Pain &ndash; Doctors can use different medicines to treat pain.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Treatment for the GBS itself &ndash; There is no cure for GBS. But there are 2 different treatments that can help improve symptoms and shorten how long GBS lasts. People with GBS usually have 1 or the other of these treatments, depending on their individual situation and other factors. These treatments are:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        IVIG &ndash; This is a medicine that helps strengthen the body&rsquo;s infection-fighting system.",
"       </li>",
"       <li>",
"        Plasma exchange (also called &ldquo;plasmapheresis&rdquo;) &ndash; For this treatment, a machine pumps blood from the body and removes substances from the blood that are attacking the nervous system. Then the machine returns the blood to the body.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Children with GBS usually have the same treatments as adults. But doctors usually use IVIG or plasma exchange only if children have severe symptoms.",
"     </p>",
"     <p>",
"      People whose muscles get very weak might need &ldquo;rehab.&rdquo; During rehab, doctors, nurses, and other health professionals show people ways to strengthen their muscles and move their bodies.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15641126\">",
"      <span class=\"h1\">",
"       How long does Guillain-Barr&eacute; syndrome last?",
"      </span>",
"      &nbsp;&mdash;&nbsp;GBS usually lasts a few weeks. After that, the symptoms slowly get better over weeks to months.",
"     </p>",
"     <p>",
"      Most people will recover completely from their GBS and have no long-term muscle weakness. But some people have muscle weakness that lasts years.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15641141\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/61/25554?source=see_link\">",
"       Patient information: Advance directives (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/16/34050?source=see_link\">",
"       Patient information: Going home from the hospital (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/37/37457?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 82816 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-8B216F4EAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_37_37457=[""].join("\n");
var outline_f36_37_37457=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15641066\">",
"      What is Guillain-Barr&eacute; syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15641081\">",
"      What are the symptoms of Guillain-Barr&eacute; syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15641096\">",
"      Is there a test for Guillain-Barr&eacute; syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15641111\">",
"      How is Guillain-Barr&eacute; syndrome treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15641126\">",
"      How long does Guillain-Barr&eacute; syndrome last?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15641141\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/61/25554?source=related_link\">",
"      Patient information: Advance directives (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/16/34050?source=related_link\">",
"      Patient information: Going home from the hospital (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_37_37458="Nonsense mutation";
var content_f36_37_37458=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F78399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F78399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Nonsense mutation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: United States National Library of Medicine. Available online at: file://ghr.nlm.nih.gov/handbook/illustrations/nonsense (Accessed on 1/12/2009).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_37_37458=[""].join("\n");
var outline_f36_37_37458=null;
var title_f36_37_37459="Grade II subcapsular liver hematoma on ultrasound and CT";
var content_f36_37_37459=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F86845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F86845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 619px\">",
"   <div class=\"ttl\">",
"    Grade II subcapsular liver hematoma on ultrasound and CT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 599px; height: 224px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The CT scan (A) shows a large subcapsular hematoma occupying more than 10 percent of the surface of the liver indicating a Grade II liver injury. The hematoma compresses the normal liver (black double arrow) and contains high density clotted blood (black double arrow). The ultrasound&nbsp;(B)&nbsp;shows the subcapsular hematoma with linear strands of fibrinous material (yellow double arrow) and cystic spaces (white double arrow) of complex clotted blood.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_37_37459=[""].join("\n");
var outline_f36_37_37459=null;
var title_f36_37_37460="Sodium, potassium and magnesium sulfates bowel preparation kit: Patient drug information";
var content_f36_37_37460=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sodium, potassium and magnesium sulfates bowel preparation kit: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/58/38820?source=see_link\">",
"     see \"Sodium, potassium and magnesium sulfates bowel preparation kit: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F11238875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Suprep&reg; Bowel Prep Kit",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F11256244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F11260857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691320",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to clean out the GI (gastrointestinal) tract.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F11256245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2956559",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sodium, potassium, magnesium, sulfates, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Hole in the GI (gastrointestinal) tract, bowel block, or a slow-moving bowel tract.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F11260906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a bowel disease such as Crohn's disease or ulcerative colitis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2956564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have gout, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F11260907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals and good mouth care may help. Older children may suck hard, sugar-free candy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697903",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bloating.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F11260909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698707",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are not able to drink the solution.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699010",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad bleeding from rectum or rectal pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F11260904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696083",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use this drug as ordered by your doctor. Read and follow the dosing on the label closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2956561",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take other drugs within 1 hour of starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694702",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not eat solid food while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2956563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix with water as you have been told before drinking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2956562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After each dose, drink more water as you have been told.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F11260905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F11260910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F11256444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16095 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-125.39.66.147-DB4EA05A22-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_37_37460=[""].join("\n");
var outline_f36_37_37460=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11238875\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11256244\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11260857\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11256245\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11260906\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11260907\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11260909\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11260904\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11260905\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11260910\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11256444\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?37/58/38820?source=related_link\">",
"      Sodium, potassium and magnesium sulfates bowel preparation kit: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_37_37461="Lindane: Patient drug information";
var content_f36_37_37461=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Lindane: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/34/37412?source=see_link\">",
"     see \"Lindane: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/21/40275?source=see_link\">",
"     see \"Lindane: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F188883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Hexit&trade;;",
"     </li>",
"     <li>",
"      PMS-Lindane",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10025989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Lindane may cause seizures. Follow how to use very closely. Use this drug only when you are not helped by some other drug or if you cannot use some other drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691932",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat lice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat scabies.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to lindane or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703819",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have used lindane in the past, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701010",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If the skin you are treating has sores or psoriasis or is broken.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697273",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have HIV infection, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697136",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a history of head injury, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697146",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a tumor in the brain or spinal cord, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697982",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching. Talk to the doctor about what to do.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699106",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A burning or tingling feeling that is not normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696964",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to use carefully.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696233",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wait at least 1 hour after you bathe or shower before putting on this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696239",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash all bedding, towels, and recently worn clothes in hot water or have them dry cleaned.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696424",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Lotion:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake lotion well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694443",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the skin from the neck to the toes. Put in the skin folds, creases, and spaces between the fingers and toes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694527",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put under fingernails.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696155",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trim fingernails short.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694466",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put lotion under nails with a toothbrush. Throw away toothbrush after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear light clothing while this drug is on your skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694727",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not let your skin touch anyone else's skin while wearing the lotion.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After 8 to 12 hours, fully wash lotion from skin using warm, soapy water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705526",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shampoo:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear special gloves while putting this drug on.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695628",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake shampoo well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694811",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not wet hair with water before using shampoo.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Lightly coat hair.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Work into hair and scalp gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695289",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Leave on hair for 4 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695284",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not cover head while shampoo is on hair.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694390",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After 4 minutes, put a little bit of warm water on hair and lather.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695595",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rinse fully.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695568",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take off gloves and wash your hands.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694829",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry with a towel.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696195",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use special nit comb or tweezers to get rid of dead nits (lice eggs) from hair.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any part not used after use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11197 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-C08C8C0CB4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_37_37461=[""].join("\n");
var outline_f36_37_37461=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188883\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025989\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025991\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025990\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025995\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025996\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025998\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025993\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025994\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025999\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026000\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?36/34/37412?source=related_link\">",
"      Lindane: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/21/40275?source=related_link\">",
"      Lindane: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_37_37462="Cephalexin: Drug information";
var content_f36_37_37462=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cephalexin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/39/21108?source=see_link\">",
"    see \"Cephalexin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/5/30804?source=see_link\">",
"    see \"Cephalexin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F148610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Keflex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F148611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Cephalex&reg;;",
"     </li>",
"     <li>",
"      Dom-Cephalexin;",
"     </li>",
"     <li>",
"      Keflex&reg;;",
"     </li>",
"     <li>",
"      Novo-Lexin;",
"     </li>",
"     <li>",
"      Nu-Cephalex;",
"     </li>",
"     <li>",
"      PMS-Cephalexin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F148629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Cephalosporin (First Generation)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F148613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing range:",
"     </b>",
"     Oral: 250-1000 mg every 6 hours (maximum: 4 g/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Indication-specific dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Cellulitis and mastitis:",
"     </b>",
"     Oral 500 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Furunculosis/skin abscess:",
"     </b>",
"     Oral: 250 mg 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Prophylaxis against infective endocarditis (dental, oral, or respiratory tract procedures):",
"     </b>",
"     Oral: 2 g 30-60 minutes prior to procedure.",
"     <b>",
"      Note:",
"     </b>",
"     American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Prophylaxis in total joint replacement patients undergoing dental procedures which produce bacteremia:",
"     </b>",
"     Oral: 2 g 1 hour prior to procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Prosthetic joint infection, chronic oral antimicrobial suppression (unlabeled use):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Propionibacterium spp (alternative to penicillin or amoxicillin):",
"     </i>",
"     500 mg every 6-8 hours (Osmon, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Staphylococci, oxacillin-susceptible (preferred):",
"     </i>",
"     500 mg every 6-8 hours (Osmon, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Streptococci, beta-hemolytic (alternative to penicillin or amoxicillin):",
"     </i>",
"     500 mg every 6-8 hours (Osmon, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Skin and skin structure infections:",
"     </b>",
"     Oral: 500 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Streptococcal pharyngitis:",
"     </b>",
"     Oral: 500 mg every 12 hours.",
"     <b>",
"      Note:",
"     </b>",
"     Recommended by the Infectious Disease Society of America (IDSA) as an alternative agent for group A streptococcal pharyngitis in penicillin-allergic patients (avoid in patients with immediate-type hypersensitivity to penicillin) with a duration of 10 days (Shulman, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Uncomplicated cystitis:",
"     </b>",
"     Oral: 500 mg every 12 hours for 7-14 days",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F148624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/5/30804?source=see_link\">",
"      see \"Cephalexin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Usual dose:",
"     </b>",
"     Children &gt;1 year: Oral: Dosing range: 25-100 mg/kg/day in divided doses every 6-8 hours (maximum: 4 g/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Indication-specific dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Cellulitis and mastitis:",
"     </b>",
"     Adolescents &gt;15 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Community-acquired pneumonia (CAP) (IDSA/PIDS, 2011),",
"      <i>",
"       S. aureus",
"      </i>",
"      (methicillin-susceptible), mild infection or step-down therapy (preferred):",
"     </b>",
"     Infants &gt;3 months and Children: Oral: 75-100 mg/kg/day in 3-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Furunculosis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children: Oral: 25-50 mg/kg/day in 4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adolescents &gt;15 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Impetigo:",
"     </b>",
"     Children: Oral: 25 mg/kg/day in 4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Otitis media:",
"     </b>",
"     Children: 75-100 mg/kg/day in 4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Prophylaxis against infective endocarditis (dental, oral, or respiratory tract procedures):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &gt;1-15 years: 50 mg/kg 30-60 minutes prior to procedure (maximum: 2 g).",
"     <b>",
"      Note:",
"     </b>",
"     American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents &gt;15 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Prophylaxis in total joint replacement patients undergoing dental procedures which produce bacteremia:",
"     </b>",
"     Adolescents &gt;15 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Severe infections:",
"     </b>",
"     Children: Oral: 50-100 mg/kg/day in divided doses every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Skin abscess:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children: Oral: 50 mg/kg/day in 4 divided doses (maximum: 4 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adolescents &gt;15 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Skin and skin structure infections:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &gt;1 year: Oral: 25-50 mg/kg/day divided every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adolescents &gt;15 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Streptococcal pharyngitis:",
"     </b>",
"     Children &gt;1 year: Oral: 25-50 mg/kg/day divided every 12 hours.",
"     <b>",
"      Note:",
"     </b>",
"     Recommended by the Infectious Disease Society of America (IDSA) as an alternative agent for group A streptococcal pharyngitis in penicillin-allergic patients (avoid in patients with immediate-type hypersensitivity to penicillin) at a dose of 40 mg/kg/day divided twice daily (maximum: 1000 mg daily) for 10 days (Shulman, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Uncomplicated cystitis:",
"     </b>",
"     Adolescents &gt;15 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F148614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F148615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: 500 mg every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10: 250-500 mg every 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: 250 mg every 12-24 hours; moderately dialyzable (20% to 50%); give dose after dialysis session",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F148585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Keflex&reg;: 250 mg, 500 mg, 750 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral: 125 mg/5 mL (100 mL, 200 mL); 250 mg/5 mL (100 mL, 200 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 250 mg, 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F148569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F148589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take without regard to food. If GI distress, take with food. Give around-the-clock to promote less variation in peak and trough serum levels.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F148588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible bacterial infections including respiratory tract infections, otitis media, skin and skin structure infections, bone infections, and genitourinary tract infections, including acute prostatitis; alternative therapy for acute infective endocarditis prophylaxis",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F16041932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chronic antimicrobial suppression of prosthetic joint infection",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F148636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cephalexin may be confused with cefaclor, ceFAZolin, ciprofloxacin",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"       Keflex&reg; may be confused with Keppra&reg;, Valtrex&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F148627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, confusion, dizziness, fatigue, hallucinations, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, erythema multiforme (rare), rash, Stevens-Johnson syndrome (rare), toxic epidermal necrolysis (rare), urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, dyspepsia, gastritis, nausea (rare), pseudomembranous colitis, vomiting (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Genital pruritus, genital moniliasis, vaginitis, vaginal discharge",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Eosinophilia, hemolytic anemia, neutropenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased, AST increased, cholestatic jaundice (rare), transient hepatitis (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, arthritis, joint disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Interstitial nephritis (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, anaphylaxis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F148592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cephalexin, any component of the formulation, or other cephalosporins",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F148573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elevated INR: May be associated with increased INR, especially in nutritionally-deficient patients, prolonged treatment, hepatic or renal disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Penicillin allergy: Use with caution in patients with a history of penicillin allergy, especially IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; modify dosage in severe impairment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F148578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetFORMIN: Cephalexin may increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Cephalexin. Specifically, the zinc contained in many multivitamins may decrease cephalexin absorption. Management: Consider administering multivitamins at least 3 hours after cephalexin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Cephalosporins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zinc Salts: May decrease the absorption of Cephalexin. Management: Consider administering oral zinc salts at least 3 hours after cephalexin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Zinc Chloride.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F148606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Peak antibiotic serum concentration is lowered and delayed, but total drug absorbed is not affected. Cephalexin serum levels may be decreased if taken with food.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F148581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3017197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Cephalexin crosses the placenta and produces therapeutic concentrations in the fetal circulation and amniotic fluid. An increased risk of teratogenic effects has not been observed following maternal use of cephalexin. Peak concentrations in pregnant patients are similar to those in nonpregnant patients. Prolonged labor may decrease oral absorption.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F148619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F148595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small amounts of cephalexin are excreted in breast milk. The manufacturer recommends that caution be exercised when administering cephalexin to nursing women. Maximum milk concentration occurs ~4 hours after a single oral dose and gradually disappears by 8 hours after administration. Nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F148596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take without regard to food. If GI distress, take with food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F148594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Cephalexin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $69.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $137.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Cephalexin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg/5 mL (100 mL): $8.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg/5 mL (100 mL): $18.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Cephalexin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $137.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $269.81",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F148583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     With prolonged therapy monitor renal, hepatic, and hematologic function periodically; monitor for signs of anaphylaxis during first dose",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F148597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Airex (PH);",
"     </li>",
"     <li>",
"      Alexin (IN);",
"     </li>",
"     <li>",
"      Bloflex (PH);",
"     </li>",
"     <li>",
"      Cefabiotic (ID);",
"     </li>",
"     <li>",
"      Cefacet (FR);",
"     </li>",
"     <li>",
"      Cefacin-M (HK);",
"     </li>",
"     <li>",
"      Cefadal (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Cefadin (EC);",
"     </li>",
"     <li>",
"      Cefadyl (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Cefalin (ID, PH);",
"     </li>",
"     <li>",
"      Cefalver (MX);",
"     </li>",
"     <li>",
"      Cefaxon (BR);",
"     </li>",
"     <li>",
"      Ceforal (IL);",
"     </li>",
"     <li>",
"      Cefovit (IL);",
"     </li>",
"     <li>",
"      Cepha (TW);",
"     </li>",
"     <li>",
"      Cephabell (AU);",
"     </li>",
"     <li>",
"      Cephalen (SG);",
"     </li>",
"     <li>",
"      Cephalex (DE);",
"     </li>",
"     <li>",
"      Cephalexyl (TH);",
"     </li>",
"     <li>",
"      Cephanmycin (MY, SG);",
"     </li>",
"     <li>",
"      Ceporex (AE, AU, BB, BH, BM, BS, BZ, CY, EG, GB, GY, IQ, IR, IT, JM, JO, KW, LB, LY, MX, NZ, OM, PE, PH, PT, QA, SA, SR, SY, TT, YE, ZA);",
"     </li>",
"     <li>",
"      Ceporex Forte (PT);",
"     </li>",
"     <li>",
"      Ceporexin (AR);",
"     </li>",
"     <li>",
"      Ceprax (CO);",
"     </li>",
"     <li>",
"      Cerexin (ZA);",
"     </li>",
"     <li>",
"      Erocetin (PY, UY);",
"     </li>",
"     <li>",
"      Falexin (KP);",
"     </li>",
"     <li>",
"      Farmalex (TH);",
"     </li>",
"     <li>",
"      Felexin (MY);",
"     </li>",
"     <li>",
"      Fexin (ZA);",
"     </li>",
"     <li>",
"      Ibilex (AU, NZ, TH);",
"     </li>",
"     <li>",
"      Inphalex (ID);",
"     </li>",
"     <li>",
"      Italcefal (EC);",
"     </li>",
"     <li>",
"      Kefacin (AE, BH, CY, EG, IQ, IR, JO, KP, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Kefalex (FI);",
"     </li>",
"     <li>",
"      Kefalospes (GR);",
"     </li>",
"     <li>",
"      Kefaxin (GR, IE);",
"     </li>",
"     <li>",
"      Keflex (AT, BB, BF, BJ, BM, BS, BZ, CI, CO, DK, EE, ET, GB, GH, GM, GN, GR, GY, JM, KE, LR, MA, ML, MR, MU, MW, MX, NE, NG, NO, PE, PK, PL, PT, SC, SD, SE, SL, SN, SR, TH, TN, TT, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Kefloridina (ES);",
"     </li>",
"     <li>",
"      Keforal (AR, BE, FR, IT, NL, VE);",
"     </li>",
"     <li>",
"      Kidolex (TW);",
"     </li>",
"     <li>",
"      LC-Lexin (PH);",
"     </li>",
"     <li>",
"      Lenocef (ZA);",
"     </li>",
"     <li>",
"      Lexin (PE);",
"     </li>",
"     <li>",
"      Lexipron (ID);",
"     </li>",
"     <li>",
"      Madlexin (ID);",
"     </li>",
"     <li>",
"      Medicef (GT, NI);",
"     </li>",
"     <li>",
"      Medolexin (MY);",
"     </li>",
"     <li>",
"      Nafacil-S (MX);",
"     </li>",
"     <li>",
"      Neokef (MY);",
"     </li>",
"     <li>",
"      Nufex (IN);",
"     </li>",
"     <li>",
"      Oracef (CZ);",
"     </li>",
"     <li>",
"      Oriphex (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Ospexin (AE, AT, BG, BH, CY, CZ, EG, HK, IQ, IR, JO, KW, LB, LY, MY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Ospexina (CO);",
"     </li>",
"     <li>",
"      Paferxin (MX);",
"     </li>",
"     <li>",
"      Palitrex (ID);",
"     </li>",
"     <li>",
"      Pectril (PH);",
"     </li>",
"     <li>",
"      Pharmexin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Pyassan (HN);",
"     </li>",
"     <li>",
"      Rancef (AU);",
"     </li>",
"     <li>",
"      Relaxin (PH);",
"     </li>",
"     <li>",
"      Sanaxin (AT);",
"     </li>",
"     <li>",
"      SEF (TR);",
"     </li>",
"     <li>",
"      Sefasin (TH);",
"     </li>",
"     <li>",
"      Sepexin (IN);",
"     </li>",
"     <li>",
"      Septilisin (AR);",
"     </li>",
"     <li>",
"      Servicef (MX);",
"     </li>",
"     <li>",
"      Servispor (TW);",
"     </li>",
"     <li>",
"      Sialexin (TH);",
"     </li>",
"     <li>",
"      Sofilex (HK, MY, SG);",
"     </li>",
"     <li>",
"      Solulexin (MY);",
"     </li>",
"     <li>",
"      Sorlex (PH);",
"     </li>",
"     <li>",
"      Sporicef (TH);",
"     </li>",
"     <li>",
"      Sporidex (IN, PH);",
"     </li>",
"     <li>",
"      Sporidin (TH);",
"     </li>",
"     <li>",
"      Sporidin AF (TH);",
"     </li>",
"     <li>",
"      Uphalexin (MY, SG);",
"     </li>",
"     <li>",
"      Winlex (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F148572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F148591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid (90%); delayed in young children",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely into most body tissues and fluids, including gallbladder, liver, kidneys, bone, sputum, bile, and pleural and synovial fluids; CSF penetration is poor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 6% to 15%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Adults: 0.5-1.2 hours; prolonged with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (80% to 100% as unchanged drug) within 8 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Advisory Statement. Antibiotic Prophylaxis for Dental Patients With Total Joint Replacements. American Dental Association; American Academy of Orthopedic Surgeons,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1997, 128(7):1004-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/37/37462/abstract-text/9231605/pubmed\" id=\"9231605\" target=\"_blank\">",
"        9231605",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Berns JS, Brier ME, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults",
"      </i>",
"      , 4th ed. Philadelphia, PA: American College of Physicians; 1999, p 73.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Brier ME, Berns JS, et al, &ldquo;The Renal Drug Book&reg; Online Edition,&rdquo; available at www.kdp-baptist.louisville.edu/renalbook. Last accessed June 23, 2006.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bergan T, &ldquo;Pharmacokinetic Properties of Cephalosporins,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1987, 34 (Suppl 2):89-104.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/37/37462/abstract-text/3319507/pubmed\" id=\"3319507\" target=\"_blank\">",
"        3319507",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al.  &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/37/37462/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dajani AS, Taubert KA, Wilson W, et al, &ldquo;Prevention of Bacterial Endocarditis Recommendations by the American Heart Association,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1997, 277(22):1794-801.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/37/37462/abstract-text/9178793/pubmed\" id=\"9178793\" target=\"_blank\">",
"        9178793",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Donowitz GR and Mandell GL, &ldquo;Beta-Lactam Antibiotics,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1988, 318(7):419-26 and 318(8):490-500.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/37/37462/abstract-text/3277054/pubmed\" id=\"3277054\" target=\"_blank\">",
"        3277054",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipsky BA, Berendt AR, Cornia PB, et al, \"2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 54(12):e132-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/37/37462/abstract-text/22619242/pubmed\" id=\"22619242\" target=\"_blank\">",
"        22619242",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2013, 56(1):e1-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/37/37462/abstract-text/23223583/pubmed\" id=\"23223583\" target=\"_blank\">",
"        23223583",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saxon A, Beall GN, Rohr AS, et al, &ldquo;Immediate Hypersensitivity Reactions to Beta-Lactam Antibiotics,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1987, 107(2):204-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/37/37462/abstract-text/3300459/pubmed\" id=\"3300459\" target=\"_blank\">",
"        3300459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shulman ST, Bisno AL, Clegg HW, et al, &ldquo;Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 55(10):e86-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/37/37462/abstract-text/22965026/pubmed\" id=\"22965026\" target=\"_blank\">",
"        22965026",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith GH, &ldquo;Oral Cephalosporins in Perspective,&rdquo;",
"      <i>",
"       DICP",
"      </i>",
"      , 1990, 24(1):45-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/37/37462/abstract-text/2405586/pubmed\" id=\"2405586\" target=\"_blank\">",
"        2405586",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilson W, Taubert KA, Gewitz M, et al, &ldquo;Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 115.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/37/37462/abstract-text/17446442/pubmed\" id=\"17446442\" target=\"_blank\">",
"        17446442",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9231 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.96.59.103-DE299E3F9D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_37_37462=[""].join("\n");
var outline_f36_37_37462=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148610\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148611\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148629\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148613\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148624\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148614\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148615\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682567\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148585\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148569\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148589\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148588\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16041932\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148636\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148627\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148592\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148573\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299003\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148578\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148606\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148581\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3017197\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148619\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148595\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148596\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148594\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148583\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148597\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148572\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148591\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9231\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9231|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/39/21108?source=related_link\">",
"      Cephalexin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/5/30804?source=related_link\">",
"      Cephalexin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_37_37463="Equine conjugated estrogens and medroxyprogesterone acetate: Drug information";
var content_f36_37_37463=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Equine conjugated estrogens and medroxyprogesterone acetate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/3/13366?source=see_link\">",
"    see \"Equine conjugated estrogens and medroxyprogesterone acetate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F167446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Premphase&reg;;",
"     </li>",
"     <li>",
"      Prempro&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F167447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Premphase&reg;;",
"     </li>",
"     <li>",
"      Premplus&reg;;",
"     </li>",
"     <li>",
"      Prempro&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F167464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Estrogen and Progestin Combination",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F167450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of moderate-to-severe vasomotor symptoms associated with menopause; treatment of vulvar and vaginal atrophy due to menopause in women with a uterus; osteoporosis prophylaxis in females with an intact uterus",
"     </b>",
"     (",
"     <b>",
"      Note:",
"     </b>",
"     The lowest dose that will control symptoms should be used; medication should be discontinued as soon as possible):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Premphase&reg;: Oral: One maroon conjugated estrogen 0.625 mg tablet daily on days 1 through 14 and 1 light blue conjugated estrogen 0.625 mg/MPA 5 mg tablet daily on days 15 through 28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prempro&reg;: Oral: One conjugated estrogen/MPA tablet once daily; maximum dose: 1 conjugated estrogen 0.625 mg/MPA 5 mg tablet daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F167451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. A higher incidence of stroke and breast cancer was observed in women &gt;75 years in a WHI substudy.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F167428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Premphase&reg; [therapy pack contains 2 separate tablet formulations]: Conjugated estrogens 0.625 mg [14 maroon tablets] and conjugated estrogen 0.625 mg/medroxyprogesterone acetate 5 mg [14 light blue tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prempro&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.3/1.5: Conjugated estrogens 0.3 mg and medroxyprogesterone acetate 1.5 mg (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.45/1.5: Conjugated estrogens 0.45 mg and medroxyprogesterone acetate 1.5 mg (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.625/2.5: Conjugated estrogens 0.625 mg and medroxyprogesterone acetate 2.5 mg (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.625/5: Conjugated estrogens 0.625 mg and medroxyprogesterone acetate 5 mg (28s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F167412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F16360840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F167429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Women with an intact uterus: Treatment of moderate-to-severe vasomotor symptoms associated with menopause; treatment of moderate-to-severe vulvar and vaginal atrophy due to menopause; postmenopausal osteoporosis (prophylaxis)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14853898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high [oral]; Strength of recommendation - strong [oral]).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F167462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (15% to 19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast pain (13% to 36%), dysmenorrhea (3% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (7% to 17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (&le;4%), peripheral edema (2% to 3%), hypertension (2%), vasodilation (&le;2%), chest pain (1%), palpitation (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Depression (7% to 8%), pain (5%), emotional lability (3%), dizziness (2% to 3%), migraine (2% to 3%), nervousness (1% to 3%), anxiety (2%), insomnia (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (2% to 6%), rash (2%), acne (&le;2%), alopecia (&le;2%), skin discoloration (1% to 2%), dry skin (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Leukorrhea (3% to 8%), breast enlargement (2% to 5%), breakthrough bleeding (1% to 4%), breast cancer (&le;1%), breast engorgement (&le;1%), glucose tolerance decreased (&le;1%), menorrhagia (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (6% to 8%), flatulence (4% to 8%), diarrhea (&le;6%), weight gain (3%), constipation (2%), appetite increased (&le;2%), eructation (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Pelvic pain (2% to 5%), vaginal hemorrhage (&le;5%), vaginitis (2% to 4%), monilial vaginitis (1% to 4%), uterine spasm (1% to 4%), cervical changes (1% to 3%), Pap smear suspicious (&le;2%), incontinence (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (3% to 6%), back pain (2% to 7%), leg cramps (2% to 4%), hypertonia (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (&gt;5%), sinusitis (&gt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Moniliasis (&le;2%), diaphoresis (&le;1%), flu-like syndrome (&le;1%), infection (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening; adverse reactions reported with this combination; also see individual monographs): Abnormal uterine bleeding, amenorrhea, anaphylactoid/anaphylactic reactions, angioedema, asthma exacerbation, benign meningioma (possible growth), cholestatic jaundice, chorea exacerbation, contact lens intolerance, dementia, DVT, endometrial cancer, endometrial hyperplasia, epilepsy exacerbation, erythema multiforme, erythema nodosum, fibrocytic breast changes, galactorrhea, gallbladder disease, hirsutism, hypersensitivity, ischemic colitis, MI, ovarian cancer, pancreatitis, PE, retinal vascular thrombosis, stroke, superficial venous thrombosis, thrombophlebitis, upper respiratory infection, uterine leiomyomata (increase in size), vaginal candidiasis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F167432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Angioedema or anaphylactic reaction to estrogens or any component of the formulation; undiagnosed abnormal vaginal bleeding; DVT or PE (current or history of); active or history of arterial thromboembolic disease (eg, stroke, MI); carcinoma of the breast (known, suspected or history of); estrogen-dependent tumor; hepatic dysfunction or disease; known protein C, protein S, antithrombin deficiency or other known thrombophilic disorders; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F167416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis/angioedema: Anaphylaxis requiring emergency medical management has been reported within minutes to hours of taking conjugated estrogen (CE) and medroxyprogesterone acetate (MPA) tablets. Angioedema involving the face, feet, hands, larynx, and tongue has also been reported. Exogenous estrogens may exacerbate symptoms in women with hereditary angioedema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Breast cancer:",
"     <b>",
"      [U.S. Boxed Warning]: Based on data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of invasive breast cancer was observed in postmenopausal women using conjugated estrogens (CE) in combination with medroxyprogesterone acetate (MPA).",
"     </b>",
"     This risk may be associated with duration of use and declines once combined therapy is discontinued (Chlebowski, 2009). The risk of invasive breast cancer was decreased in postmenopausal women with a hysterectomy using CE only, regardless of weight. However, the risk was not significantly decreased in women at high risk for breast cancer (family history of breast cancer, personal history of benign breast disease) (Anderson, 2012). An increase in abnormal mammogram findings has also been reported with estrogen alone or in combination with progestin therapy. Estrogen use may also lead to severe hypercalcemia in patients with breast cancer and bone metastases; discontinue estrogen if hypercalcemia occurs. Use is contraindicated in patients with known or suspected breast cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should not be used to prevent dementia. In the Women&rsquo;s Health Initiative Memory Study (WHIMS), an increased incidence of dementia was observed in women &ge;65 years of age taking CE alone or in combination with MPA.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Endometrial carcinoma:",
"     <b>",
"      [U.S. Boxed Warning]: The use of unopposed estrogen in women with an intact uterus is associated with an increased risk of endometrial cancer. The addition of a progestin to estrogen therapy may decrease the risk of endometrial hyperplasia, a precursor to endometrial cancer. Adequate diagnostic measures, including endometrial sampling if indicated, should be performed to rule out malignancy in postmenopausal women with undiagnosed abnormal vaginal bleeding.",
"     </b>",
"     Estrogens may exacerbate endometriosis. Malignant transformation of residual endometrial implants has been reported posthysterectomy with unopposed estrogen therapy. Consider adding a progestin in women with residual endometriosis posthysterectomy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inherited thrombophilia: Women with inherited thrombophilias (eg, protein C or S deficiency) may have increased risk of venous thromboembolism (DeSancho, 2010; van Vlijmen, 2011). Use is contraindicated in women with protein C, protein S, antithrombin deficiency, or other known thrombophilic disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lipid effects: Estrogen compounds are generally associated with lipid effects such as increased HDL-cholesterol and decreased LDL-cholesterol. Triglycerides may also be increased; use with caution in patients with familial defects of lipoprotein metabolism. Discontinue if pancreatitis occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovarian cancer: Postmenopausal estrogen therapy and combined estrogen/progesterone therapy may increase the risk of ovarian cancer; however, the absolute risk to an individual woman is small. Although results from various studies are not consistent, risk does not appear to be significantly associated with the duration, route, or dose of therapy. In one study, the risk decreased after 2 years following discontinuation of therapy (M&oslash;rch, 2009). Although the risk of ovarian cancer is rare, women who are at an increased risk (eg, family history) should be counseled about the association (NAMS, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Retinal vascular thrombosis: Estrogens may cause retinal vascular thrombosis; discontinue if migraine, loss of vision, proptosis, diplopia, or other visual disturbances occur; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Use caution in patients with asthma; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in women with diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should not be used to prevent cardiovascular disease.",
"     </b>",
"     Using data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of deep vein thrombosis (DVT) and stroke has been reported with CE and an increased risk of DVT, stroke, pulmonary emboli (PE) and myocardial infarction (MI) has been reported with CE with MPA in postmenopausal women. Additional risk factors include diabetes mellitus, hypercholesterolemia, hypertension, SLE, obesity, tobacco use, and/or history of venous thromboembolism (VTE). Risk factors should be managed appropriately; discontinue use if adverse cardiovascular events occur or are suspected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diseases exacerbated by fluid retention: Use with caution in patients with diseases which may be exacerbated by fluid retention, including cardiac or renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Epilepsy: Use caution with epilepsy; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gallbladder disease: Use of postmenopausal estrogen may be associated with an increased risk of gallbladder disease requiring surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic dysfunction: Estrogens are poorly metabolized in patients with hepatic dysfunction. Use caution with a history of cholestatic jaundice associated with prior estrogen use or pregnancy. Discontinue if jaundice develops or if acute or chronic hepatic disturbances occur. Use is contraindicated with hepatic disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic hemangiomas: Use with caution in patients with hepatic hemangiomas; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypocalcemia: Use with caution in patients with severe hypocalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Migraine: Use caution with migraine; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Porphyria: Use with caution in patients with porphyria; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; SLE: Use with caution in patients with SLE; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid replacement therapy: Estrogens may increase thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels. Women on thyroid replacement therapy may require higher doses of thyroid hormone while receiving estrogens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use of oral estrogen (with or without progestins) in this age group due to potential of increased risk of breast and endometrial cancers, and lack of proven cardioprotection and cognitive protection (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children. Prior to puberty, estrogens may cause premature closure of the epiphyses, premature breast development in girls, or gynecomastia in boys. Vaginal bleeding and vaginal cornification may also be induced in girls.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: Whenever possible, should be discontinued at least 4-6 weeks prior to elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Laboratory changes: The use of estrogens and/or progestins may change the results of some laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). The dose, route, and the specific estrogen/progestin influences these changes. In addition, personal risk factors (eg, cardiovascular disease, smoking, diabetes, age) also contribute to adverse events; use of specific products may be contraindicated in women with certain risk factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteoporosis use: For use only in women at significant risk of osteoporosis and for who other nonestrogen medications are not considered appropriate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Risks vs benefits:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should be used for the shortest duration possible at the lowest effective dose consistent with treatment goals.",
"     </b>",
"     Before prescribing estrogen therapy to postmenopausal women, the risks and benefits must be weighed for each patient. Women should be informed of these risks and benefits, as well as possible effects of progestin when added to estrogen therapy. Patients should be reevaluated as clinically appropriate to determine if treatment is still necessary. Available data related to treatment risks are from Women&rsquo;s Health Initiative (WHI) studies, which evaluated oral CE 0.625 mg with or without MPA 2.5 mg relative to placebo in postmenopausal women. Other combinations and dosage forms of estrogens and progestins were not studied.",
"     <b>",
"      Outcomes reported from clinical trials using CE with or without MPA should be assumed to be similar for other doses and other dosage forms of estrogens and progestins until comparable data becomes available.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vulvar and vaginal atrophy use: When used solely for the treatment of vulvar and vaginal atrophy, topical vaginal products should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F167459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F167421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any estrogen derivative.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Estrogenic Properties): May enhance the adverse/toxic effect of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): May enhance the thrombogenic effect of Estrogen Derivatives. NSAID (COX-2 Inhibitor) may increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. Estrogen Derivatives may diminish the therapeutic effect of Ospemifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: Estrogen Derivatives may diminish the therapeutic effect of Somatropin. Shown to be a concern with oral hormone replacement therapy in postmenopausal women.  Management: Monitor for reduced growth hormone efficacy. A larger somatropin dose may be required to reach treatment goal.  This interaction does not appear to apply to non-orally administered estrogens (e.g., transdermal, vaginal ring).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Estrogen Derivatives may enhance the dermatologic adverse effect of Tipranavir. The combination of tipranavir/ritonavir and ethinyl estradiol/norethindrone was associated with a high incidence of skin rash. Tipranavir may decrease the serum concentration of Estrogen Derivatives.  Management: Women using hormonal contraceptives should consider alternative, non-hormonal forms of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F167442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (routine use increases estrogen plasma concentrations and risk of breast cancer). Ethanol may also increase the risk of osteoporosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Folic acid absorption may be decreased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease levels. Avoid black cohosh, dong quai (has estrogenic activity). Avoid red clover, saw palmetto, ginseng (due to potential hormonal effects).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F167436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     See individual agents; use of this combination is contraindicated during pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F167454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F167437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F167438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administration with food decreases nausea, administer with food. Ensure adequate calcium and vitamin D intake when used for the prevention of osteoporosis.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F167435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Premphase Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.625-5 mg (28): $105.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Prempro Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.3-1.5 mg (28): $107.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.45-1.5 mg (28): $107.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.625-2.5 mg (28): $107.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.625-5 mg (28): $107.08",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F167426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Routine physical examination that includes blood pressure and Papanicolaou smear, breast exam, mammogram. Monitor for signs of endometrial cancer. Adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding. Monitor for loss of vision, sudden onset of proptosis, diplopia, migraine; signs and symptoms of thromboembolic disorders; glycemic control in patients with diabetes; lipid profiles in patients being treated for hyperlipidemias; thyroid function in patients on thyroid hormone replacement therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Menopausal symptoms: Assess need for therapy at 3- to 6-month intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prevention of osteoporosis: Bone density measurement",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F167439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Climatrol Continuo (CN, CO);",
"     </li>",
"     <li>",
"      Climatrol HT Ciclico (VE);",
"     </li>",
"     <li>",
"      Climatrol HT Continuo (PE);",
"     </li>",
"     <li>",
"      Climopax (DE);",
"     </li>",
"     <li>",
"      Monosedan Ciclo (BR);",
"     </li>",
"     <li>",
"      Monosedan Fase (BR);",
"     </li>",
"     <li>",
"      Novofac 30 Simple (UY);",
"     </li>",
"     <li>",
"      Plentiva (KP, TW);",
"     </li>",
"     <li>",
"      Plentiva Cycle (KP, TW);",
"     </li>",
"     <li>",
"      Premelle (CL, HK, KP, MX, MY, PH, SG, TW);",
"     </li>",
"     <li>",
"      Premelle Ciclico (AR);",
"     </li>",
"     <li>",
"      Premelle Continuo (AR);",
"     </li>",
"     <li>",
"      Premelle Cycle 5 (SG);",
"     </li>",
"     <li>",
"      Premelle Lite (TW);",
"     </li>",
"     <li>",
"      Premelle Right (KP);",
"     </li>",
"     <li>",
"      Premia (NZ);",
"     </li>",
"     <li>",
"      Prempak (EC, HK, TH);",
"     </li>",
"     <li>",
"      Profemina M.P. (PY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F167415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Conjugated estrogens contain a mixture of estrone sulfate, equilin sulfate, 17 alpha-dihydroequilin, 17 alpha-estradiol, and 17 beta-dihydroequilin. Estrogens are responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Estradiol is the principle intracellular human estrogen and is more potent than estrone and estriol at the receptor level; it is the primary estrogen secreted prior to menopause. Following menopause, estrone and estrone sulfate are more highly produced. Estrogens modulate the pituitary secretion of gonadotropins, luteinizing hormone, and follicle-stimulating hormone through a negative feedback system; estrogen replacement reduces elevated levels of these hormones in postmenopausal women.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     MPA inhibits gonadotropin production which then prevents follicular maturation and ovulation. In women with adequate estrogen, MPA transforms a proliferative endometrium into a secretory endometrium; when administered with conjugated estrogens, reduces the incidence of endometrial hyperplasia and risk of adenocarcinoma.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F167431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/37/37463/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson GL, Chlebowski RT, Aragaki AK, et al, \"Conjugated Equine Oestrogen and Breast Cancer Incidence and Mortality in Postmenopausal Women With Hysterectomy: Extended Follow-Up of the Women's Health Initiative Randomised Placebo-Controlled Trial,\"",
"      <i>",
"       Lancet Oncol,",
"      </i>",
"      2012,13(5):476-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/37/37463/abstract-text/22401913/pubmed\" id=\"22401913\" target=\"_blank\">",
"        22401913",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson GL, Limacher M, Assaf AR, et al, \"Effects of Conjugated Equine Estrogen In Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial.\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2004, 291(14):1701-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/37/37463/abstract-text/15082697/pubmed\" id=\"15082697\" target=\"_blank\">",
"        15082697",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chlebowski RT, Kuller LH, Prentice RL, et al, \"Breast Cancer After Use of Estrogen Plus Progestin in Postmenopausal Women,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(6):573-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/37/37463/abstract-text/19196674/pubmed\" id=\"19196674\" target=\"_blank\">",
"        19196674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeSancho MT, Dorff T, and Rand JH, \"Thrombophilia and the Risk of Thromboembolic Events In Women on Oral Contraceptives and Hormone Replacement Therapy,\"",
"      <i>",
"       Blood Coagul Fibrinolysis",
"      </i>",
"      , 2010, 21(6):534-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/37/37463/abstract-text/20581664/pubmed\" id=\"20581664\" target=\"_blank\">",
"        20581664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grodstein F, Stampfer MJ, Colditz GA, et al, &ldquo;Postmenopausal Hormone Therapy and Mortality,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1997, 336(25):1769-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/37/37463/abstract-text/9187066/pubmed\" id=\"9187066\" target=\"_blank\">",
"        9187066",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hsia J, Langer RD, Manson JE, et al, \"Conjugated Equine Estrogens and Coronary Heart Disease: The Women's Health Initiative,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2006, 166(3):357-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/37/37463/abstract-text/16476878/pubmed\" id=\"16476878\" target=\"_blank\">",
"        16476878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hulley S, Grady D, Bush T, et al, &ldquo;Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1998, 280(7):605-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/37/37463/abstract-text/9718051/pubmed\" id=\"9718051\" target=\"_blank\">",
"        9718051",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      M&oslash;rch LS, L&oslash;kkegaard E, Andreasen AH, et al, &ldquo;Hormone Therapy and Ovarian Cancer,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2009, 302(3):298-305.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/37/37463/abstract-text/19602689/pubmed\" id=\"19602689\" target=\"_blank\">",
"        19602689",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      North American Menopause Society [NAMS], \"The 2012 Hormone Therapy Position Statement of The North American Menopause Society,\"",
"      <i>",
"       Menopause",
"      </i>",
"      , 2012, 19(3):257-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/37/37463/abstract-text/22367731/pubmed\" id=\"22367731\" target=\"_blank\">",
"        22367731",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al, &ldquo;Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principle Results From the Women's Health Initiative Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(3):321-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/37/37463/abstract-text/12117397/pubmed\" id=\"12117397\" target=\"_blank\">",
"        12117397",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shumaker SA, Legault C, Rapp SR, et al, &ldquo;Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(20):2651-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/37/37463/abstract-text/12771112/pubmed\" id=\"12771112\" target=\"_blank\">",
"        12771112",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      U.S. Food and Drug Administration, Department of Health and Human Services, &ldquo;WHIMS Study on Estrogen/Progestin,&rdquo; May 27, 2003. Available at",
"      <a href=\"file://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318.htm\" target=\"_blank\">",
"       file://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Vlijmen EF, Veeger NJ, Middeldorp S, et al, \"Thrombotic Risk During Oral Contraceptive Use and Pregnancy in Women With Factor V Leiden or Prothrombin Mutation: A Rational Approach to Contraception,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(8):2055-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/37/37463/abstract-text/21659542/pubmed\" id=\"21659542\" target=\"_blank\">",
"        21659542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wassertheil-Smoller S, Hendrix S, Limacher M, et al, &ldquo;Effect of Estrogen Plus Progestin on Stroke in Postmenopausal Women: The Women's Health Initiative: A Randomized Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289:2673-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/37/37463/abstract-text/12771114/pubmed\" id=\"12771114\" target=\"_blank\">",
"        12771114",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8738 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-B4DFEB0FC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_37_37463=[""].join("\n");
var outline_f36_37_37463=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708756\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167446\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167447\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167464\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167450\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167451\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167428\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167412\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16360840\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167429\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14853898\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167462\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167432\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167416\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167459\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167421\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167442\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167436\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167454\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167437\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167438\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167435\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167426\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167439\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167415\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167431\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8738\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8738|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/3/13366?source=related_link\">",
"      Equine conjugated estrogens and medroxyprogesterone acetate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_37_37464="Epidemiology, pathogenesis, and microbiology of intravascular catheter infections";
var content_f36_37_37464=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, pathogenesis, and microbiology of intravascular catheter infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/37/37464/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/37/37464/contributors\">",
"     Robert Gaynes, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/37/37464/contributors\">",
"     Jeffrey D Band, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/37/37464/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/37/37464/contributors\">",
"     Anthony Harris, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/37/37464/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/37/37464/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/37/37464/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nosocomial (hospital-acquired) bloodstream infections (BSIs) are an important cause of morbidity and mortality, with an estimated 250,000 cases occurring each year in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/1\">",
"     1",
"    </a>",
"    ]. BSIs may be either primary or secondary. Secondary infections are related to infections at other sites, such as the urinary tract, lung, postoperative wounds, and skin. Most nosocomial BSIs are primary, as illustrated by the United States Centers for Disease Control and Prevention&rsquo;s National Nosocomial Infection Surveillance (NNIS) system, in which 64 percent of the nosocomial BSIs reported were primary BSIs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/2\">",
"     2",
"    </a>",
"    ]. While some primary BSIs have no identifiable source, most are associated with intravascular catheters, and central venous catheters in particular [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Central venous catheters (CVCs) are increasingly used in the inpatient and outpatient setting to provide long-term venous access. Infection of CVCs remains a major problem. It is estimated, for example, that approximately 90 percent of the 50,000 to 100,000 annual catheter-related bloodstream infections in the United States occur with CVCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, risk factors, microbiology, and pathogenesis of intravascular catheter infections will be reviewed here. The diagnosis, treatment, and prevention of CVC-associated infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/23/375?source=see_link\">",
"     \"Diagnosis of intravascular catheter-related infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7498?source=see_link\">",
"     \"Treatment of intravascular catheter-related infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=see_link\">",
"     \"Prevention of intravascular catheter-related infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catheter-related bloodstream infections (CR-BSI) are an important cause of morbidity and mortality worldwide, although may be decreasing in incidence in some areas, possibly as a result of widespread prevention efforts. As an example, the incidence of CR-BSI associated with central lines among patients hospitalized in intensive care units (ICUs) in the United States decreased from 3.64 to 1.65 infections per 1000 central line days between 2001 and 2009 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/5\">",
"     5",
"    </a>",
"    ]. This amounted to an estimated 18,000 central line-related infections in 2009. A similar trend of decreasing incidence has been observed in Canada [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/6\">",
"     6",
"    </a>",
"    ]. In contrast, the reported pooled incidence of central line-associated BSI across 422 ICUs in 36 countries in Latin America, Asia, Africa, and Europe from 2004 to 2009 was substantially higher, 6.8 events per 1000 central line days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/7\">",
"     7",
"    </a>",
"    ]. Many of these sites are in resource-limited areas, and the high incidence is thought to be related to a lack of official regulations regarding catheter care. &nbsp;",
"   </p>",
"   <p>",
"    Although ICU patients are generally exposed to more medical devices and are more severely ill than other hospitalized patients, CR-BSIs remain common in hospital wards outside the ICU. As an example, an estimated 23,000 central line-associated BSIs occurred among patients in inpatient wards in the United States in 2009 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/5\">",
"     5",
"    </a>",
"    ]. In a prospective analysis from the SCOPE (Surveillance and Control of Pathogens of Epidemiologic Importance) database, which evaluated the characteristics of 24,179 nosocomial BSI from 49 hospitals in the United States between 1995 and 2002, the following findings were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of nosocomial BSI was 60 cases per 10,000 hospital admissions. Approximately 15 percent of cases occurred in children.",
"     </li>",
"     <li>",
"      Approximately 51 percent of cases occurred in the intensive care unit (ICU).",
"     </li>",
"     <li>",
"      Intravascular devices were the most common predisposing factor. A central venous catheter was in place in 72 percent, peripheral intravenous catheter in 35 percent, and an arterial catheter in 16 percent. (See",
"      <a class=\"local\" href=\"#H1532914\">",
"       'Catheter factors'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The mean time from admission to BSI onset ranged from 12 to 26 days and depended on the isolated pathogen.",
"     </li>",
"     <li>",
"      The crude mortality rate was 27 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Indwelling catheters are also a frequent source of infection in many populations who required long term venous access, including hemodialysis and oncology patients as well as those receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    . In 2008 in the United States, an estimated 37,000 CR-BSI occurred among patients receiving outpatient hemodialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/8/29834?source=see_link\">",
"     \"Tunneled, cuffed hemodialysis catheter-related bacteremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bloodstream infections associated with the widespread use of indwelling catheters have possibly contributed to the changing epidemiology of other infections. As an example, Staphylococcus aureus has emerged as a leading microbial cause of infective endocarditis in tertiary care centers, as illustrated by a study of a large international cohort of patients with both native and prosthetic valve endocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/8\">",
"     8",
"    </a>",
"    ]. Infection with S. aureus versus other pathogens was independently associated with the presumed presence of an intravascular device. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/31/14840?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology, risk factors and microbiology of infective endocarditis\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The distribution of pathogens associated with CR-BSI is described below. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Microbiology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Host factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Host factors commonly associated with nosocomial bloodstream infections (BSIs) include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chronic illness",
"     </li>",
"     <li>",
"      Bone marrow transplantation",
"     </li>",
"     <li>",
"      Immune deficiency, especially neutropenia",
"     </li>",
"     <li>",
"      Malnutrition",
"     </li>",
"     <li>",
"      TPN administration",
"     </li>",
"     <li>",
"      Previous BSI",
"     </li>",
"     <li>",
"      Extremes of age",
"     </li>",
"     <li>",
"      Loss of skin integrity, as with burns",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients hospitalized with burns are at particularly increased risk for nosocomial BSIs, as the necrotic tissue in the burn wounds increases the susceptibility to infection, thermal trauma decreases host resistance, and the body exhibits an inflammatory reaction to these processes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neutropenic patients are also at high risk for infections, including catheter-related BSIs (CR-BSIs). Those with an absolute neutrophil count (bands plus polymorphonuclear leukocytes) below 100",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    appear to be at the greatest risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/12\">",
"     12",
"    </a>",
"    ]. Hematologic malignancies have been associated more highly with CR-BSI than solid tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among pediatric intensive care unit (ICU) patients, underlying gastrointestinal and oncologic diagnoses have also been associated with increased risk for CR-BSI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1532914\">",
"    <span class=\"h2\">",
"     Catheter factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prospective studies have shown that every intravascular device confers a risk of infection to patients, although some (eg, non-tunneled central venous catheters and pulmonary artery catheters) carry greater risk than others (eg, peripheral intravenous catheters) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/15\">",
"     15",
"    </a>",
"    ]. For central venous catheters, the site of catheter placement affects the risk of infection, with the subclavian site being associated with less risk than others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=see_link&amp;anchor=H3#H3\">",
"     \"Prevention of intravascular catheter-related infections\", section on 'Type of catheter'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=see_link&amp;anchor=H4#H4\">",
"     \"Prevention of intravascular catheter-related infections\", section on 'Location'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other than the type and location of the catheter, the most important extrinsic risk factors associated with the development of intravascular catheter-associated bloodstream infections include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Duration of catheterization (although there is no indication for routine line changing based on number of catheter days)",
"     </li>",
"     <li>",
"      Type of catheter material",
"     </li>",
"     <li>",
"      Conditions of insertion",
"     </li>",
"     <li>",
"      Catheter-site care",
"     </li>",
"     <li>",
"      Skill of the catheter inserter",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The importance of these factors varies with the site and type of intravascular catheter (",
"    <a class=\"graphic graphic_table graphicRef63562 \" href=\"mobipreview.htm?27/44/28364\">",
"     table 1",
"    </a>",
"    ). In general, the risk of CR-BSI is comparatively elevated in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Femoral or internal jugular placement compared with subclavian [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/17-20\">",
"       17-20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Use for hyperalimentation or hemodialysis compared with other indications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/9,21\">",
"       9,21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Submaximal compared with maximal (mask, cap, sterile gloves, gown, large drape) barrier precautions during insertion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Nontunneled compared with tunneled insertion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Tunneled insertion compared with a totally implantable device [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/26-28\">",
"       26-28",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Bare compared with antibiotic impregnated catheter [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/29\">",
"       29",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other factors that may increase the risk of infection include thrombosis of the catheter, repeated catheterization, increased manipulation of the catheter (including catheter repair), and presence of septic foci elsewhere [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/17,18,30,31\">",
"     17,18,30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Detailed data describing modifiable catheter risk factors and methods of reducing the risk of infection are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=see_link\">",
"     \"Prevention of intravascular catheter-related infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2354186\">",
"    <span class=\"h1\">",
"     SOURCES OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bloodstream infection associated with central venous catheters (CVCs) can be attributable to four major sources: colonization from the skin, intraluminal or hub contamination, secondary seeding from a bloodstream infection, and, rarely, contamination of the infusate (",
"    <a class=\"graphic graphic_figure graphicRef64065 \" href=\"mobipreview.htm?43/13/44241\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2354193\">",
"    <span class=\"h2\">",
"     Skin colonization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common source of CVC-related infections is colonization of the intracutaneous and intravascular portions of the catheter by microorganisms from the patient's skin and occasionally the hands of healthcare workers (on insertion or as a result of manipulation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Furthermore, a number of studies have found a strong correlation between heavy skin colonization and both catheter colonization and subsequent catheter-related infection, especially with short-term intravascular devices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/34,36-38\">",
"     34,36-38",
"    </a>",
"    ]. Microorganisms gain access to the catheter wound and migrate along the catheter-subcutaneous tract into the fibrin sheath that surrounds intravascular catheters. Scanning electron micrographs reveal that both the external and internal surfaces of catheters can become colonized with microorganisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The deposition of biofilm on the external and internal surface of vascular catheters is thought to play an important role in the colonization process. The biofilm is produced by a combination of host factors (eg, fibrinogen and fibrin) and microbial products (eg, glycocalyx or \"slime\").",
"   </p>",
"   <p>",
"    Thus, it is not surprising that common skin commensals, such as Staphylococcus aureus and coagulase-negative staphylococci, are often isolated from colonized catheters and patients with primary bloodstream infections. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Microbiology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2354200\">",
"    <span class=\"h2\">",
"     Intraluminal contamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraluminal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hub contamination is an important source of bloodstream infection in patients with centrally-inserted CVCs that are in place for more than two weeks or in patients with a surgically implanted device [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. In one report in neonates, for example, catheter-related sepsis occurred with 26 percent of 113 catheters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/43\">",
"     43",
"    </a>",
"    ]. The infecting organism was grown from the catheter hub before or at the time of diagnosis of bacteremia in 54 percent of cases. A study from Spain found that a hub chamber containing iodinated alcohol significantly reduced both colonization and bloodstream infections related to CVCs in intensive care unit (ICU) patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=see_link&amp;anchor=H1923683666#H1923683666\">",
"     \"Prevention of intravascular catheter-related infections\", section on 'Antimicrobial impregnated catheters'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2354207\">",
"    <span class=\"h2\">",
"     Hematogenous seeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematogenous seeding of the device can occur during a bloodstream infection originating from another focus of infection, often from a gastrointestinal site; this is most likely to occur in critically ill patients or those with long-term catheters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/17,36\">",
"     17,36",
"    </a>",
"    ]. The secondary seeding of CVCs may result in a relapse of the bloodstream infection due to the same organism. Recurrent bacteremia from the catheter may be difficult to distinguish from worsening of the primary focus of infection; removal of the catheter may help distinguish between these possibilities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2354214\">",
"    <span class=\"h2\">",
"     Infusate contamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of contaminated infusate or additives, such as a contaminated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    flush, can result in a bloodstream infection. Organisms may contaminate infusate by several mechanisms: during manufacture, during solution preparation, via retrograde contamination from a contaminated catheter, or handling by healthcare workers. This is now a rare source of bloodstream infection and generally causes epidemic infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/45-49\">",
"     45-49",
"    </a>",
"    ]. Use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    via contaminated atomizers for cutaneous disinfection has similarly been associated with at least two outbreaks of bloodstream infections and should be avoided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Particular features can suggest the diagnosis. Infusate-related infections should be suspected when sepsis occurs in an otherwise low-risk patient receiving an intravenous solution or when there is a cluster of primary bloodstream infections with an unusual organism. The infection is confirmed by the isolation of the same organism from both the infusate and percutaneous blood culture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the 1980s, gram-negative aerobes were the predominant organisms associated with nosocomial bloodstream infections. Since then, gram-positive aerobes (eg, coagulase-negative staphylococci, S. aureus, and enterococcus), and Candida species have increased in relative importance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/3,51\">",
"     3,51",
"    </a>",
"    ]. As an example, the following distribution of pathogens was noted in the prospective analysis from the SCOPE database cited above of 24,179 nosocomial bloodstream infections (BSIs) occurring in 49 hospitals in the United States between 1995 and 2002 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Coagulase-negative staphylococci &ndash; 31 percent",
"     </li>",
"     <li>",
"      Staphylococcus aureus &ndash; 20 percent",
"     </li>",
"     <li>",
"      Enterococci &ndash; 9 percent",
"     </li>",
"     <li>",
"      Candida species &ndash; 9 percent",
"     </li>",
"     <li>",
"      Escherichia coli &ndash; 6 percent",
"     </li>",
"     <li>",
"      Klebsiella species &ndash; 5 percent",
"     </li>",
"     <li>",
"      Pseudomonas species &ndash; 4 percent",
"     </li>",
"     <li>",
"      Enterobacter species &ndash; 4 percent",
"     </li>",
"     <li>",
"      Serratia species &ndash; 2 percent",
"     </li>",
"     <li>",
"      Acinetobacter baumannii &ndash; 1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subsequent surveillance reports in the United States and Europe have documented similar microbiological distributions, with coagulase-negative staphylococci, S. aureus, enterococci, and candidal species accounting for the majority of catheter-related bloodstream infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most likely explanations for the increased incidence of coagulase-negative staphylococcal infections are enhanced recognition and reporting of these organisms as valid bloodstream pathogens (as opposed to contaminants), the use of broad-spectrum antibiotics (selection pressure), and the increased use of intravascular devices.",
"   </p>",
"   <p>",
"    Additionally, the predominance of staphylococcal species, which are common constituents of the skin flora, reflects the observation that central venous catheter (CVC) infections are most commonly attributable to the patient's skin flora [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/54\">",
"     54",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H2354193\">",
"     'Skin colonization'",
"    </a>",
"    above). Besides the staphylococci, enterococci and other gram-positive bacilli (Bacillus or Corynebacterium species, particularly Corynebacterium JK-1) are occasionally isolated from catheter-related BSIs. Cryptogenic bacteremia due to these gram-positive organisms frequently originates from an intravascular device.",
"   </p>",
"   <p>",
"    Gram-negative bacilli may account for at least 20 percent of CVC-related BSIs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/3\">",
"     3",
"    </a>",
"    ]. The most commonly isolated organisms include E. coli, K. pneumoniae, Pseudomonas species, Enterobacter species, Serratia species, and Acinetobacter species. Stenotrophomonas maltophilia bacteremia is a particular problem in cancer patients and is commonly CVC-related [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/55\">",
"     55",
"    </a>",
"    ]. A cluster of cases of catheter-related infections with gram-negative bacilli should prompt suspicion of an infusate contamination. (See",
"    <a class=\"local\" href=\"#H2354214\">",
"     'Infusate contamination'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    BSIs caused by multidrug-resistant gram-negative bacilli have become a major concern because of increased rates of treatment failure and death. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/12/20681?source=see_link&amp;anchor=H8#H8\">",
"     \"Gram-negative bacillary bacteremia in adults\", section on 'Antibiotic resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fungi, especially Candida species, account for up to 10 percent of systemic infections associated with CVCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/3\">",
"     3",
"    </a>",
"    ]. Fungal infections are a particular concern in patients receiving a high concentration of glucose in intravenous hyperalimentation. Candida species also produce glycocalyx, which enhances their ability to colonize CVCs.",
"   </p>",
"   <p>",
"    Bloodstream infection related to CVCs occasionally may be due to more than one microorganism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/54\">",
"     54",
"    </a>",
"    ]. CVC-related infection due to anaerobic bacteria is exceedingly rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1533861\">",
"    <span class=\"h2\">",
"     Special populations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain patient populations have a different epidemiology of BSI with regard to microbial etiology:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among burn patients, Pseudomonas aeruginosa is the most frequently isolated gram-negative pathogen, and in one series accounted for 16 percent of all cases of bloodstream infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/56\">",
"       56",
"      </a>",
"      ]. In a prospective study of 45 bacteremic burn patients in India, Pseudomonas species were the most common isolates, responsible for 42 percent of cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with hematologic and non-hematologic malignancies, gram-negative pathogens predominate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/58\">",
"       58",
"      </a>",
"      ]. This association may be due to the translocation of gut bacteria in patients with altered mucosal barriers.",
"     </li>",
"     <li>",
"      In hemodialysis patients, gram-positive organisms reflecting skin flora are responsible for most catheter-related infections. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/8/29834?source=see_link\">",
"       \"Tunneled, cuffed hemodialysis catheter-related bacteremia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/3/16442?source=see_link\">",
"       \"Overview of central catheters for acute and chronic hemodialysis access\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In infections associated with needleless access devices, hydrophilic gram-negative pathogens such as Pseudomonas species, Klebsiella species, Stenotrophomonas (Xanthomonas) species, Acinetobacter species, and Serratia marcescens appear to be the most frequently isolated pathogens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/59-61\">",
"       59-61",
"      </a>",
"      ]. It is thought that the devices are exposed to these pathogens during patient bathing or showering.",
"     </li>",
"     <li>",
"      In the ambulatory setting, children younger than three years or without recent hospitalization (within the week prior to presentation) may have an increased likelihood of polymicrobial catheter-related BSIs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients, particularly very young infants, receiving intravenous lipids, Malassezia furfur, a lipophilic yeast, has been identified as a cause of BSIs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients receiving a high concentration of glucose in intravenous hyperalimentation, fungal infections, and Candida species in particular, are a particular concern.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1533822\">",
"    <span class=\"h2\">",
"     Infusate contamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;BSIs related to infusion of contaminated fluids generally involve gram-negative bacilli, including Klebsiella, Citrobacter, or non-aeruginosa Pseudomonas species. Enterobacteriaceae, specifically, are usually associated with contaminated glucose-containing infusates. Fungi, especially Candida parapsilosis, are often associated with contaminated hypertonic parenteral nutrition infusate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37464/abstract/32\">",
"     32",
"    </a>",
"    ]. A cluster of cases of BSI involving the same gram-negative or fungal organism should prompt an investigation into the possibility of contaminated infusate. (See",
"    <a class=\"local\" href=\"#H2354214\">",
"     'Infusate contamination'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28543658\">",
"    <span class=\"h2\">",
"     Local infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections of the insertion or exit site, pocket, or tunnel are generally due to the same organisms listed above (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Microbiology'",
"    </a>",
"    above). S. aureus and P. aeruginosa may be isolated in a greater proportion of these local infections than in central venous catheter-related bloodstream infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/33/35345?source=see_link\">",
"       \"Patient information: Central line infections (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H425855\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      About half of nosocomial bloodstream infections (BSIs) occur in intensive care units, and the majority are associated with the presence of an intravascular device. Catheter-related bloodstream infections (CR-BSI) are an important cause of morbidity and mortality worldwide, including resource-limited settings. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hospitalized patients with burns or neutropenia are at particularly increased risk for nosocomial bloodstream infections. Other host risk factors include immune deficiencies in general, chronic illness, and malnutrition. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Host factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All types of intravascular catheters pose significant but varying risk of infection. Duration of catheterization, catheter material, insertion conditions, and site care also impact the risk of catheter-associated infections (",
"      <a class=\"graphic graphic_table graphicRef63562 \" href=\"mobipreview.htm?27/44/28364\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1532914\">",
"       'Catheter factors'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=see_link\">",
"       \"Prevention of intravascular catheter-related infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bloodstream infection associated with central venous catheters can be attributed to four major sources: colonization from the skin, intraluminal or hub contamination, secondary seeding from a bloodstream infection, and contamination of the infusate (",
"      <a class=\"graphic graphic_figure graphicRef64065 \" href=\"mobipreview.htm?43/13/44241\">",
"       figure 1",
"      </a>",
"      ). Infections related to the administration of contaminated intravenous fluids are rare but should be suspected when bacteremia occurs in an otherwise low-risk patient or when there is a cluster of bloodstream infections with unusual organisms. (See",
"      <a class=\"local\" href=\"#H2354186\">",
"       'Sources of infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The skin flora is probably the most important source of intravascular catheter infection. Thus, coagulase-negative staphylococci and Staphylococcus aureus, common skin commensals, are the most common isolates from nosocomial bloodstream infections. Gram-negative pathogens predominate in patients with hematologic and non-hematologic malignancies. Infections with multidrug-resistant organisms are associated with high rates of treatment failure and death. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/1\">",
"      Pittet D, Li N, Woolson RF, Wenzel RP. Microbiological factors influencing the outcome of nosocomial bloodstream infections: a 6-year validated, population-based model. Clin Infect Dis 1997; 24:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/2\">",
"      Martone WJ, Gaynes RP, Horan TC, et al. National Nosocomial Infections Surveillance (NNIS) semiannual report, May 1995. A report from the National Nosocomial Infections Surveillance (NNIS) System. Am J Infect Control 1995; 23:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/3\">",
"      Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/4\">",
"      Mermel LA. Prevention of intravascular catheter-related infections. Ann Intern Med 2000; 132:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/5\">",
"      Centers for Disease Control and Prevention (CDC). Vital signs: central line-associated blood stream infections--United States, 2001, 2008, and 2009. MMWR Morb Mortal Wkly Rep 2011; 60:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/6\">",
"      Fontela PS, Platt RW, Rocher I, et al. Epidemiology of central line-associated bloodstream infections in Quebec intensive care units: a 6-year review. Am J Infect Control 2012; 40:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/7\">",
"      Rosenthal VD, Bijie H, Maki DG, et al. International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004-2009. Am J Infect Control 2012; 40:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/8\">",
"      Fowler VG Jr, Miro JM, Hoen B, et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 2005; 293:3012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/9\">",
"      Tokars JI, Cookson ST, McArthur MA, et al. Prospective evaluation of risk factors for bloodstream infection in patients receiving home infusion therapy. Ann Intern Med 1999; 131:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/10\">",
"      Reunes S, Rombaut V, Vogelaers D, et al. Risk factors and mortality for nosocomial bloodstream infections in elderly patients. Eur J Intern Med 2011; 22:e39.",
"     </a>",
"    </li>",
"    <li>",
"     Tompkins RG, Burke JF. Infections of burn wounds. In: Hospital Infections, 3rd Ed, Bennett JV, Brachman PS (Eds), Little, Brown, Boston 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/12\">",
"      Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/13\">",
"      Mollee P, Jones M, Stackelroth J, et al. Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: a prospective cohort study. J Hosp Infect 2011; 78:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/14\">",
"      Niedner MF, Huskins WC, Colantuoni E, et al. Epidemiology of central line-associated bloodstream infections in the pediatric intensive care unit. Infect Control Hosp Epidemiol 2011; 32:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/15\">",
"      Maki DG, Kluger DM, Crnich CJ. The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies. Mayo Clin Proc 2006; 81:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/16\">",
"      Parienti JJ, du Cheyron D, Timsit JF, et al. Meta-analysis of subclavian insertion and nontunneled central venous catheter-associated infection risk reduction in critically ill adults. Crit Care Med 2012; 40:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/17\">",
"      Mermel LA, McCormick RD, Springman SR, Maki DG. The pathogenesis and epidemiology of catheter-related infection with pulmonary artery Swan-Ganz catheters: a prospective study utilizing molecular subtyping. Am J Med 1991; 91:197S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/18\">",
"      Richet H, Hubert B, Nitemberg G, et al. Prospective multicenter study of vascular-catheter-related complications and risk factors for positive central-catheter cultures in intensive care unit patients. J Clin Microbiol 1990; 28:2520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/19\">",
"      Merrer J, De Jonghe B, Golliot F, et al. Complications of femoral and subclavian venous catheterization in critically ill patients: a randomized controlled trial. JAMA 2001; 286:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/20\">",
"      Ronco C. The place of early haemoperfusion with polymyxin B fibre column in the treatment of sepsis. Crit Care 2005; 9:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/21\">",
"      Wilcox TA. Catheter-related bloodstream infections. Semin Intervent Radiol 2009; 26:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/22\">",
"      Raad II, Hohn DC, Gilbreath BJ, et al. Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. Infect Control Hosp Epidemiol 1994; 15:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/23\">",
"      Maki DG. Yes, Virginia, aseptic technique is very important: maximal barrier precautions during insertion reduce the risk of central venous catheter-related bacteremia. Infect Control Hosp Epidemiol 1994; 15:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/24\">",
"      Pessa ME, Howard RJ. Complications of Hickman-Broviac catheters. Surg Gynecol Obstet 1985; 161:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/25\">",
"      Darbyshire PJ, Weightman NC, Speller DC. Problems associated with indwelling central venous catheters. Arch Dis Child 1985; 60:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/26\">",
"      Groeger JS, Lucas AB, Thaler HT, et al. Infectious morbidity associated with long-term use of venous access devices in patients with cancer. Ann Intern Med 1993; 119:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/27\">",
"      Ross MN, Haase GM, Poole MA, et al. Comparison of totally implanted reservoirs with external catheters as venous access devices in pediatric oncologic patients. Surg Gynecol Obstet 1988; 167:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/28\">",
"      Carde P, Cosset-Delaigue MF, Laplanche A, Chareau I. Classical external indwelling central venous catheter versus totally implanted venous access systems for chemotherapy administration: a randomized trial in 100 patients with solid tumors. Eur J Cancer Clin Oncol 1989; 25:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/29\">",
"      Veenstra DL, Saint S, Saha S, et al. Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: a meta-analysis. JAMA 1999; 281:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/30\">",
"      Barzaghi A, Dell'Orto M, Rovelli A, et al. Central venous catheter clots: incidence, clinical significance and catheter care in patients with hematologic malignancies. Pediatr Hematol Oncol 1995; 12:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/31\">",
"      Lundgren IS, Zhou C, Malone FR, et al. Central venous catheter repair is associated with an increased risk of bacteremia and central line-associated bloodstream infection in pediatric patients. Pediatr Infect Dis J 2012; 31:337.",
"     </a>",
"    </li>",
"    <li>",
"     Maki DG. Infections due to infusion therapy. In: Hospital Infections, 3rd Ed, Bennett JV, Brachman PS (Eds), Little, Brown, Boston 1992. p.849.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/33\">",
"      Snydman DR, Gorbea HF, Pober BR, et al. Predictive value of surveillance skin cultures in total-parenteral-nutrition-related infection. Lancet 1982; 2:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/34\">",
"      Bjornson HS, Colley R, Bower RH, et al. Association between microorganism growth at the catheter insertion site and colonization of the catheter in patients receiving total parenteral nutrition. Surgery 1982; 92:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/35\">",
"      Cooper GL, Hopkins CC. Rapid diagnosis of intravascular catheter-associated infection by direct Gram staining of catheter segments. N Engl J Med 1985; 312:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/36\">",
"      Raad II, Baba M, Bodey GP. Diagnosis of catheter-related infections: the role of surveillance and targeted quantitative skin cultures. Clin Infect Dis 1995; 20:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/37\">",
"      Guidet B, Nicola I, Barakett V, et al. Skin versus hub cultures to predict colonization and infection of central venous catheter in intensive care patients. Infection 1994; 22:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/38\">",
"      Armstrong CW, Mayhall CG, Miller KB, et al. Clinical predictors of infection of central venous catheters used for total parenteral nutrition. Infect Control Hosp Epidemiol 1990; 11:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/39\">",
"      Raad I, Costerton W, Sabharwal U, et al. Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement. J Infect Dis 1993; 168:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/40\">",
"      Li&ntilde;ares J, Sitges-Serra A, Garau J, et al. Pathogenesis of catheter sepsis: a prospective study with quantitative and semiquantitative cultures of catheter hub and segments. J Clin Microbiol 1985; 21:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/41\">",
"      Tenney JH, Moody MR, Newman KA, et al. Adherent microorganisms on lumenal surfaces of long-term intravenous catheters. Importance of Staphylococcus epidermidis in patients with cancer. Arch Intern Med 1986; 146:1949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/42\">",
"      Miller JJ, Venus B, Mathru M. Comparison of the sterility of long-term central venous catheterization using single lumen, triple lumen, and pulmonary artery catheters. Crit Care Med 1984; 12:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/43\">",
"      Salzman MB, Isenberg HD, Shapiro JF, et al. A prospective study of the catheter hub as the portal of entry for microorganisms causing catheter-related sepsis in neonates. J Infect Dis 1993; 167:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/44\">",
"      Le&oacute;n C, Alvarez-Lerma F, Ruiz-Santana S, et al. Antiseptic chamber-containing hub reduces central venous catheter-related infection: a prospective, randomized study. Crit Care Med 2003; 31:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/45\">",
"      Maki DG. Nosocomial bacteremia. An epidemiologic overview. Am J Med 1981; 70:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/46\">",
"      Kimura AC, Calvet H, Higa JI, et al. Outbreak of Ralstonia pickettii bacteremia in a neonatal intensive care unit. Pediatr Infect Dis J 2005; 24:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/47\">",
"      Ostrowsky BE, Whitener C, Bredenberg HK, et al. Serratia marcescens bacteremia traced to an infused narcotic. N Engl J Med 2002; 346:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/48\">",
"      Centers for Disease Control and Prevention (CDC). Pseudomonas bloodstream infections associated with a heparin/saline flush--Missouri, New York, Texas, and Michigan, 2004-2005. MMWR Morb Mortal Wkly Rep 2005; 54:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/49\">",
"      Centers for Disease Control and Prevention (CDC). Update: Delayed onset Pseudomonas fluorescens bloodstream infections after exposure to contaminated heparin flush--Michigan and South Dakota, 2005-2006. MMWR Morb Mortal Wkly Rep 2006; 55:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/50\">",
"      Tena D, Carranza R, Barber&aacute; JR, et al. Outbreak of long-term intravascular catheter-related bacteremia due to Achromobacter xylosoxidans subspecies xylosoxidans in a hemodialysis unit. Eur J Clin Microbiol Infect Dis 2005; 24:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/51\">",
"      Banerjee SN, Emori TG, Culver DH, et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med 1991; 91:86S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/52\">",
"      Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008; 29:996.",
"     </a>",
"    </li>",
"    <li>",
"     ECDC surveillance report: Surveillance of healthcare-associated infections in Europe, 2007. file://www.ecdc.europa.eu/en/publications/Publications/120215_SUR_HAI_2007.pdf (Accessed on November 28, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/54\">",
"      Haslett TM, Isenberg HD, Hilton E, et al. Microbiology of indwelling central intravascular catheters. J Clin Microbiol 1988; 26:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/55\">",
"      Boktour M, Hanna H, Ansari S, et al. Central venous catheter and Stenotrophomonas maltophilia bacteremia in cancer patients. Cancer 2006; 106:1967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/56\">",
"      Brusselaers N, Monstrey S, Snoeij T, et al. Morbidity and mortality of bloodstream infections in patients with severe burn injury. Am J Crit Care 2010; 19:e81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/57\">",
"      Mir MA, Anjum S, Mir RA, et al. Prevalence of various bacteria and their susceptibility pattern in burn unit of governmental medical college and hospital Srinagar. The Internet Journal of Microbiology 2012; 10:5580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/58\">",
"      N&oslash;rgaard M, Larsson H, Pedersen G, et al. Short-term mortality of bacteraemia in elderly patients with haematological malignancies. Br J Haematol 2006; 132:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/59\">",
"      Do AN, Ray BJ, Banerjee SN, et al. Bloodstream infection associated with needleless device use and the importance of infection-control practices in the home health care setting. J Infect Dis 1999; 179:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/60\">",
"      Toscano CM, Bell M, Zukerman C, et al. Gram-negative bloodstream infections in hematopoietic stem cell transplant patients: the roles of needleless device use, bathing practices, and catheter care. Am J Infect Control 2009; 37:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/61\">",
"      Jarvis WR, Murphy C, Hall KK, et al. Health care-associated bloodstream infections associated with negative- or positive-pressure or displacement mechanical valve needleless connectors. Clin Infect Dis 2009; 49:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/62\">",
"      Downes KJ, Metlay JP, Bell LM, et al. Polymicrobial bloodstream infections among children and adolescents with central venous catheters evaluated in ambulatory care. Clin Infect Dis 2008; 46:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37464/abstract/63\">",
"      Long JG, Keyserling HL. Catheter-related infection in infants due to an unusual lipophilic yeast--Malassezia furfur. Pediatrics 1985; 76:896.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3806 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-218.189.88.190-50AA3700D9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_37_37464=[""].join("\n");
var outline_f36_37_37464=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H425855\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Host factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1532914\">",
"      Catheter factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2354186\">",
"      SOURCES OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2354193\">",
"      Skin colonization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2354200\">",
"      Intraluminal contamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2354207\">",
"      Hematogenous seeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2354214\">",
"      Infusate contamination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1533861\">",
"      Special populations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1533822\">",
"      Infusate contamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28543658\">",
"      Local infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H425855\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3806\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3806|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/13/44241\" title=\"figure 1\">",
"      Sources of CVC infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3806|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/44/28364\" title=\"table 1\">",
"      Risk factors primary BSI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/23/375?source=related_link\">",
"      Diagnosis of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/31/14840?source=related_link\">",
"      Epidemiology, risk factors and microbiology of infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/12/20681?source=related_link\">",
"      Gram-negative bacillary bacteremia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/3/16442?source=related_link\">",
"      Overview of central catheters for acute and chronic hemodialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/33/35345?source=related_link\">",
"      Patient information: Central line infections (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=related_link\">",
"      Prevention of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7498?source=related_link\">",
"      Treatment of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/8/29834?source=related_link\">",
"      Tunneled, cuffed hemodialysis catheter-related bacteremia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_37_37465="ACE inhibitor-induced angioedema";
var content_f36_37_37465=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   ACE inhibitor-induced angioedema",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/37/37465/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/37/37465/contributors\">",
"     Autumn Chandler Guyer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/37/37465/contributors\">",
"     Aleena Banerji, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/37/37465/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/37/37465/contributors\">",
"     Sarbjit Saini, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/37/37465/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/37/37465/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/37/37465/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H9838011\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiotensin converting enzyme (ACE) inhibitors are the leading cause of drug-induced angioedema in the United States because they are so widely prescribed. Patients most commonly present with swelling of the lips, tongue, or face, although another presentation is episodic abdominal pain due to intestinal angioedema. Urticaria and itching are notably absent.",
"   </p>",
"   <p>",
"    This topic reviews the clinical features, diagnostic evaluation, differential diagnosis, pathophysiology, risk factors, and management of ACE inhibitor-induced angioedema. The use of angiotensin receptor blockers (ARBs) and renin inhibitors is also reviewed. An overview of angioedema, from all causes, is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/17/15641?source=see_link\">",
"     \"An overview of angioedema: Clinical features, diagnosis, and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38391?source=see_link\">",
"     \"An overview of angioedema: Pathogenesis and causes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20394732\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiotensin converting enzyme (ACE) inhibitors induce angioedema in 0.1 to 0.7 percent of recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. Approximately 35 percent of all prescriptions written for antihypertensive medications in the United States are for ACE inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/7\">",
"     7",
"    </a>",
"    ], and more than 40 million patients in the United States are currently taking these agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/1\">",
"     1",
"    </a>",
"    ]. ACE inhibitors are routinely used in patients with hypertension, myocardial infarction, heart failure with systolic dysfunction, diabetes, and chronic kidney disease.",
"   </p>",
"   <p>",
"    ACE inhibitors are the leading cause of drug-induced angioedema in the United States, accounting for 20 to 40 percent of all emergency room visits for angioedema each year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Angioedema can occur with any ACE inhibitor and is not thought to be related to dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/2,11\">",
"     2,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The overall incidence of angioedema related to ACE inhibitors has been estimated between 0.1 percent and 0.7 percent. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/1-5,12-14\">",
"     1-5,12-14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the OCTAVE trial, a prospective six month study evaluating over 12,500 patients with hypertension treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=see_link\">",
"       enalapril",
"      </a>",
"      , the calculated risk of developing angioedema related to the use of enalapril was 0.68 percent over six months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The ONTARGET trial compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"       ramipril",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/38/27239?source=see_link\">",
"       telmisartan",
"      </a>",
"      , and combination therapy with both agents in over 25,000 patients with vascular disease or diabetes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. The overall incidence was 0.3 percent in the 8500 patients on ACE inhibitors, with a median follow-up of 56 months.",
"     </li>",
"     <li>",
"      In a retrospective analysis of 1,845,138 patients 18 years of age and older initiating ACE inhibitor therapy, there were 3301 total angioedema events associated with the use of ACE inhibitor therapy after a mean follow-up duration of 149 days. The overall recorded rate of angioedema was 0.18 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a meta-analysis of 26 randomized clinical trials, 394 out of 74,857 patients on ACE inhibitors developed angioedema during a mean duration of 129 weeks with a weighted incidence of 0.30 percent (95% CI 0.28-0.32) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20393568\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angioedema is an asymmetric, non-pitting swelling of the subcutaneous or submucosal tissues that most commonly affects nondependent areas. There is an absence of itching or urticaria in ACE inhibitor-induced angioedema, and the presence of urticaria suggests a different group of etiologies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/15\">",
"     15",
"    </a>",
"    ]. The different mechanisms of angioedema and the etiologies associated with each mechanism are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/17/15641?source=see_link&amp;anchor=H3#H3\">",
"     \"An overview of angioedema: Clinical features, diagnosis, and management\", section on 'Types of angioedema'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20395468\">",
"    <span class=\"h2\">",
"     Affected areas",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACE inhibitor-induced angioedema most commonly affects the lips, tongue, face, and upper airway. Less often, the intestine can be involved, presenting as acute abdominal pain with diarrhea or other gastrointestinal symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20393889\">",
"    <span class=\"h3\">",
"     Face, mouth, and upper airway",
"    </span>",
"    &nbsp;&mdash;&nbsp;The edema that occurs from ACE inhibitors usually affects the lips, tongue, and face (",
"    <a class=\"graphic graphic_picture graphicRef82803 \" href=\"mobipreview.htm?25/11/25781\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/16\">",
"     16",
"    </a>",
"    ]. Angioedema of the pharynx, larynx, and subglottic area have also been reported. Early signs of laryngeal edema may include hoarseness of the throat and inspiratory stridor, which may progress to airway obstruction in up to 10 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/8,17\">",
"     8,17",
"    </a>",
"    ]. Rarely, fatalities due to massive tongue swelling and asphyxiation are reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/8,9,18\">",
"     8,9,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20394022\">",
"    <span class=\"h3\">",
"     Intestine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visceral angioedema due to ACE inhibitors has been described in a handful of case reports and reviews [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/19-23\">",
"     19-23",
"    </a>",
"    ]. Most commonly, this presents as diffuse abdominal pain and diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/19-30\">",
"     19-30",
"    </a>",
"    ]. Other symptoms include vomiting, anorexia, or ascites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/31\">",
"     31",
"    </a>",
"    ]. In most of these reports, diagnosis was delayed by months to years, because clinicians were not as aware of this potential presentation of ACE-inhibitor angioedema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/19-23\">",
"     19-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In more than half of the case reports of visceral angioedema, symptoms began within 72 hours of starting ACE inhibitor therapy, although in other reports, angioedema developed after weeks or years of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/24,30\">",
"     24,30",
"    </a>",
"    ]. The jejunum is most often involved, followed by the ileum and duodenum. At least one case report documented swelling of the distal antrum and pylorus of the stomach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20393796\">",
"    <span class=\"h2\">",
"     Time course",
"    </span>",
"   </p>",
"   <p>",
"    ACE inhibitor-induced angioedema occurs episodically but each episode follows a relatively predictable time course. Swelling usually develops over minutes to hours, peaks, and then resolves over 24 to 72 hours, although complete resolution may take many days in some cases, even if the ACE inhibitor has been discontinued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/8,25,32\">",
"     8,25,32",
"    </a>",
"    ]. A history of preceding episodes with long symptom free intervals is not unusual, especially in the case of abdominal or visceral angioedema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/19,24\">",
"     19,24",
"    </a>",
"    ]. If the ACE inhibitor is",
"    <strong>",
"     not",
"    </strong>",
"    discontinued, the episode will still resolve, although the frequency and severity of future episodes appears to escalate and the condition can become life-threatening. (See",
"    <a class=\"local\" href=\"#H1070522\">",
"     'Discontinue ACE inhibitor'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the large retrospective study mentioned previously, two-thirds of angioedema episodes occurred within the first three months of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/6\">",
"     6",
"    </a>",
"    ]. However, in the majority of cases, angioedema occurs during the first week of exposure, although it may occur anytime during the course of therapy from hours to years after treatment. In more than one-half of cases, angioedema occurs during the first week of exposure, although it may occur any time during the course of therapy from hours to years after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/11,26,33\">",
"     11,26,33",
"    </a>",
"    ]. Case reports have documented episodes of angioedema related to ACE inhibitor use after years of stable therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20393882\">",
"    <span class=\"h2\">",
"     Recurrence after stopping ACE inhibitor therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients experience one or more recurrent angioedema episodes in the months after the causative ACE inhibitor has been discontinued. In a long-term retrospective study, 111 patients with ACE inhibitor-induced angioedema were followed for at least one year and up to 14 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/29\">",
"     29",
"    </a>",
"    ]. Approximately 88 percent of patients with relapses in angioedema experienced symptoms within the first month after the ACE inhibitor was discontinued and in some cases, these relapses continued for six months or more. However, in cases where angioedema persisted beyond several weeks, it is also possible that patients had angioedema unrelated to the ACE inhibitor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9838053\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of ACE inhibitor angioedema are related to elevated levels of bradykinin, an inflammatory vasoactive peptide which leads to vasodilation of blood vessels. The pathways involved in bradykinin generation are described briefly here and in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/25/13720?source=see_link\">",
"     \"Chapter 2B: Renin-angiotensin system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4335290\">",
"    <span class=\"h2\">",
"     ACE inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACE inhibitors block the effects of the enzyme ACE, also known as kininase II, and impact both the renin&ndash;angiotensin-aldosterone pathway (RAA) and the degradation of bradykinin. The RAA cascade is important for regulating renal blood flow and blood pressure. Angiotensinogen, produced in the liver, is converted by renin in the kidney to produce angiotensin I. Angiotensin I is then metabolized to angiotensin II in the lungs by the enzyme ACE (kininase II). Angiotensin II acts as a vasoconstrictor through stimulation of angiotensin I and II receptors.",
"   </p>",
"   <p>",
"    Angiotensin II is also responsible for inactivating bradykinin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/34\">",
"     34",
"    </a>",
"    ] while ACE (kininase II) is the primary peptidase involved in the degradation of bradykinin. Bradykinin is a peptide made of nine amino acids that increases capillary permeability and acts as a potent vasodilator. The production of bradykinin occurs after the precursor kininogen is cleaved by kallikrein which leads to production of the active form of bradykinin (",
"    <a class=\"graphic graphic_algorithm graphicRef82805 \" href=\"mobipreview.htm?4/47/4862\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Bradykinin has a very short half-life, approximately 17 seconds, and is metabolized primarily by: ACE (kininase II), neutral endopeptidase (NEP), and aminopeptidase P (APP) and secondarily by the enzymes dipeptidyl peptidase IV (DPPIV) and kininase I. Des&ndash;Arg9&ndash;BK is an active metabolite of bradykinin formed primarily due to the kininase I enzyme. The pharmacological activities of des-Arg9-BK, similar to those of bradykinin, are short-lived because of its breakdown by ACE and APP.",
"   </p>",
"   <p>",
"    Thus, ACE inhibitor therapy has the following effects in all patients:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Initially, vasodilation due to inhibited production of angiotensin II",
"     </li>",
"     <li>",
"      Chronically, angiotensin II returns to pretreatment levels through alternative pathways of production by tissue chymases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/35\">",
"       35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Elevated levels of bradykinin due to impaired metabolism, which leads to release of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/29/11732?source=see_link\">",
"       nitrous oxide",
"      </a>",
"      and prostaglandins and results in vasodilatation and hypotension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/36\">",
"       36",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Elevated levels of des-Arg9-BK, the breakdown product of bradykinin",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4335305\">",
"    <span class=\"h2\">",
"     Development of angioedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated plasma bradykinin activity has been demonstrated in patients with ACE inhibitor angioedema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/37\">",
"     37",
"    </a>",
"    ]. A case report demonstrated a 10-fold increase in bradykinin levels during an episode of angioedema due to use of the ACE inhibitor,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    , and returned to normal levels during remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/34,38\">",
"     34,38",
"    </a>",
"    ]. High levels of bradykinin stimulate vasodilation and increased vascular permeability of the post-capillary venules and allows for plasma extravasation into the submucosal tissue leading to angioedema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/34,39\">",
"     34,39",
"    </a>",
"    ]. Substance P can also increase vascular permeability leading to angioedema.",
"   </p>",
"   <p>",
"    ACE inhibitor-induced angioedema is thought to result from defective degradation of at least three vasoactive peptides: bradykinin, Des-Arg9-BK (a metabolite of bradykinin), and substance P [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Normally, bradykinin is inactivated by ACE, aminopeptidase P (APP), dipeptidyl peptidase IV (DPPIV), and neutral endopeptidase (NEP), as mentioned previously. The APP-inactivated bradykinin metabolite, des&ndash;Arg9&ndash;BK, is also degraded by DPPIV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/42\">",
"     42",
"    </a>",
"    ]. Substance P is inactivated primarily by the enzyme DPPIV, although ACE and NEP play a secondary role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Decreased activity of DPPIV correlated to a prolonged half-life of substance P, but only in the presence of ACE inhibition, suggesting a requirement for multiple enzyme defects to inhibit degradation.",
"   </p>",
"   <p>",
"    When ACE is inhibited by drug therapy, the secondary bradykinin metabolic enzymes (APP, kininase I, NEP, and DPPIV) play a relatively larger role in degrading bradykinin, des&ndash;Arg9&ndash;BK, and substance P. Thus, defects or deficiencies in these enzymes theoretically predispose patients to developing angioedema when taking an ACE inhibitor. Studies that support this mechanism include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreased APP activity was demonstrated in the sera of 39 white patients with a history of ACE inhibitor-induced angioedema, as compared to 39 ACE inhibitor-exposed controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Decreased DPPIV antigen and activity levels were found in the sera of 50 patients with a history of ACE inhibitor-induced angioedema as compared to 176 ACE inhibitor-exposed controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the above, approximately half of patients experiencing ACE inhibitor-induced angioedema also have an enzyme defect involved in des&ndash;Arg9&ndash;BK metabolism, leading to its accumulation when ACE is inhibited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9838060\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both genetic and environmental factors have been shown to influence the development of ACE inhibitor-induced angioedema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/8,42-45,47-54\">",
"     8,42-45,47-54",
"    </a>",
"    ]. However, at this time, there is no standardized genetic or lab evaluation that can identify, in advance, individual patients who are at an increased risk for developing ACE inhibitor-induced angioedema.",
"   </p>",
"   <p>",
"    The following factors are believed to impact the risk of ACE inhibitor-induced angioedema:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of ACE inhibitor-induced angioedema is up to five times greater in people of African descent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/48-50\">",
"       48-50",
"      </a>",
"      ]. Genetic polymorphisms in the enzymes APP and NEP occur at a greater rate in African-Americans [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/44\">",
"       44",
"      </a>",
"      ]. These polymorphisms lead to lower circulating levels of these enzymes which are responsible for degradation of bradykinin and its active metabolite, des&ndash;Arg9&ndash;BK [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/42\">",
"       42",
"      </a>",
"      ]. Levels of bradykinin are further increased in the presence of an ACE inhibitor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/42,45\">",
"       42,45",
"      </a>",
"      ]. Despite these polymorphisms, ACE inhibitors are considered beneficial in the treatment of hypertension in patients of African descent. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/14/15592?source=see_link&amp;anchor=H273484#H273484\">",
"       \"Treatment of hypertension in blacks\", section on 'ACE inhibitors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Genetic polymorphisms in the gene that encodes APP (XPNPEP2) lead to decreased APP activity and higher levels of bradykinin and des-Arg9-BK, which have been associated with a higher prevalence of ACE inhibitor angioedema [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/52,53\">",
"       52,53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Insertion/deletion",
"      </span>",
"      polymorphisms have been described in the ACE gene and have been associated with reduced expression of ACE and a decrease in the degradation of bradykinin. Despite a decrease in the degradation of bradykinin, there does not appear to be a link between ACE gene polymorphisms and the occurrence of ACE inhibitor-induced angioedema [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Use of the mTOR inhibitors",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      in renal transplant recipients has been shown to decrease the metabolism of bradykinin and predispose to angioedema in combination with ACE inhibitor use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/51\">",
"       51",
"      </a>",
"      ]. This study looked only at renal transplant patients, however increased rates of angioedema has also been reported in cardiac transplant patients taking everolimus and ACE inhibitors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/55\">",
"       55",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"       Ramipril",
"      </a>",
"      was restarted at lower doses in all patients at lower sirolimus levels with no adverse effects, suggesting a dose-dependent effect of this combination of drugs on the development of angioedema. In general, transplant patients are thought to be at increased risk of ACE inhibitor-induced angioedema because of the effects of immunosuppressants on decreasing the activity of circulating levels of DPPIV [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Underlying C1 inhibitor deficiency or dysfunction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/37\">",
"       37",
"      </a>",
"      ]: both hereditary (aka, hereditary angioedema) and acquired forms of C1 inhibitor disorders exist. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/4/33864?source=see_link\">",
"       \"Hereditary angioedema: Pathogenesis and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/12/26824?source=see_link\">",
"       \"Acquired C1 inhibitor deficiency: Clinical manifestations, epidemiology, pathogenesis, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Female sex [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/8,47,48\">",
"       8,47,48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      History of previous episodes of angioedema [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/8,47,48\">",
"       8,47,48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Age older than 65 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Smoking [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      or other nonsteroidal antiinflammatory (NSAID) use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/8,47,48\">",
"       8,47,48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Seasonal allergies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      History of ACE inhibitor-induced cough was found to be an independent risk factor for developing ACE inhibitor-related angioedema in one retrospective cohort study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/37\">",
"       37",
"      </a>",
"      ]. However, a mechanism relating these two adverse effects has not been proposed. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/2/18473?source=see_link&amp;anchor=H6#H6\">",
"       \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\", section on 'Cough'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, the risk of angioedema is not related to the agent administered or dose, as previously mentioned [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/2,11\">",
"     2,11",
"    </a>",
"    ]. There appears to be a",
"    <strong>",
"     reduced",
"    </strong>",
"    risk of angioedema due to ACE inhibitors in people with diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/3,45\">",
"     3,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20395298\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of ACE inhibitor-induced angioedema is made clinically, based upon the presence of angioedema in a characteristic anatomic site, without itching or urticaria, in a patient taking ACE inhibitors. There are no definitive laboratory tests to diagnose ACE inhibitor-induced angioedema.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some authors have advised screening all patients for underlying defects in the complement system with a serum C4 level [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/57\">",
"       57",
"      </a>",
"      ], while others advocate for complete laboratory evaluation to include C1 inhibitor function and protein levels, C4 levels, and C1q levels. However, the likelihood of finding such a disorder is low [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/58\">",
"       58",
"      </a>",
"      ]. A C4 is definitely indicated if the patient has a family history of angioedema, or has an underlying lymphoproliferative disorder (such as monoclonal gammopathy of uncertain significance or lymphoma) or other malignancy. If any of these features are present, a C4 level should be obtained to screen for hereditary or acquired C1 inhibitor disorders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/57,58\">",
"       57,58",
"      </a>",
"      ]. A low C4 level requires further evaluation. (See",
"      <a class=\"local\" href=\"#H20396597\">",
"       'Referral'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Discontinuation of the ACE inhibitor and monitoring for resolution of symptoms confirms the diagnosis. However, the impact of discontinuation may only be clear after several months, as some patients will have a small number of recurrent episodes, particularly in the first few months after the ACE inhibitor was discontinued, as mentioned previously. Referral to an allergy expert should be considered for patients who continue to have episodes of angioedema after six months. (See",
"      <a class=\"local\" href=\"#H20393882\">",
"       'Recurrence after stopping ACE inhibitor therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4335620\">",
"    <span class=\"h2\">",
"     Evaluation of abdominal pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;If visceral angioedema is suspected in a patient taking an ACE inhibitor and presenting with acute abdominal pain, noninvasive imaging such as ultrasonography or computed tomography (CT) should be performed to confirm bowel edema",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ascites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/32\">",
"     32",
"    </a>",
"    ]. CT and abdominal ultrasound are diagnostic in most cases. Typical findings include dilated bowel loops, thickened mucosal folds, perihepatic fluid, ascites, mesenteric edema, and a &ldquo;doughnut&rdquo; or &ldquo;stacked coin&rdquo; appearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/21,59\">",
"     21,59",
"    </a>",
"    ]. Magnetic resonance imaging (MRI) and invasive endoscopy should be reserved for use only when ultrasound and CT are nondiagnostic and there is still a high clinical suspicion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20395305\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, angioedema can be caused by either the generation of bradykinin or by activation of mast cells and release of various mast cell mediators (including histamine). Other disorders of bradykinin-mediated angioedema present similarly, and include hereditary angioedema (HAE), acquired angioedema with deficiency of C1 inhibitor, and hereditary angioedema with normal C1 inhibitor (",
"    <a class=\"graphic graphic_algorithm graphicRef82804 \" href=\"mobipreview.htm?19/41/20125\">",
"     algorithm 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/17/15641?source=see_link&amp;anchor=H3#H3\">",
"     \"An overview of angioedema: Clinical features, diagnosis, and management\", section on 'Types of angioedema'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9838067\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary treatments of ACE inhibitor-induced angioedema are discontinuation of the drug and airway management if the mouth or throat is involved. Additional therapies may be helpful for severe or persistent symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17308940\">",
"    <span class=\"h2\">",
"     Airway management",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the mouth or throat is involved, the airway should be immediately evaluated and repeatedly monitored until the swelling is clearly resolving. Prompt intubation and mechanical ventilation may be required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1070522\">",
"    <span class=\"h2\">",
"     Discontinue ACE inhibitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angioedema caused by ACE inhibitors usually resolves within 24 to 72 hours. If ACE inhibitors are continued, there is an increased and unpredictable rate of angioedema recurrence and attacks may become more severe or life threatening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/29,60\">",
"     29,60",
"    </a>",
"    ]. Patients who have experienced angioedema attributed to an ACE inhibitor should never again be treated with this group of medications.",
"   </p>",
"   <p>",
"    If the cause of a patient&rsquo;s angioedema is unclear, we would still advise discontinuation of ACE inhibitors. If the patient experiences recurrent episodes of angioedema beyond four to six weeks, then the cause of the angioedema is likely",
"    <strong>",
"     not",
"    </strong>",
"    the ACE inhibitor and other etiologies should be explored. (See",
"    <a class=\"local\" href=\"#H20396597\">",
"     'Referral'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17308947\">",
"    <span class=\"h2\">",
"     Other interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antihistamines, glucocorticoids, and epinephrine are commonly used to treat allergic, histamine-induced angioedema. These medications are not known to alter levels of bradykinin and are usually considered ineffective or minimally effective in treating ACE inhibitor-induced angioedema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/61\">",
"     61",
"    </a>",
"    ]. Despite this, a small number of studies have reported the apparent benefit with antihistamines in ACE inhibitor-induced angioedema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/17,62\">",
"     17,62",
"    </a>",
"    ], and intubated patients who were treated with antihistamines were extubated significantly earlier than those who were not in one small study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/17\">",
"     17",
"    </a>",
"    ]. The data in support of glucocorticoids is even weaker, and one report described a patient who was on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    when she developed ACE inhibitor-induced intestinal angioedema, suggesting that glucocorticoids did not have a preventative effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1070652\">",
"    <span class=\"h2\">",
"     Additional therapies for severe or persistent symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional therapies to speed the resolution of ACE inhibitor-induced angioedema should be considered if the swelling is threatening the patient&rsquo;s airway, or if the angioedema is severe and not improving by 24 hours.",
"   </p>",
"   <p>",
"    Evidence to support use of the various therapies listed below to treat ACE inhibitor-related angioedema is limited to case reports and small series, and the relative efficacy of these agents is unknown. Thus, the choice of agent is largely dependent upon availability until additional data from ongoing clinical studies are available. A more detailed discussion of each of the therapies, including dose, administration, and adverse effects, is found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33657?source=see_link&amp;anchor=H2#H2\">",
"     \"Hereditary angioedema: Treatment of acute attacks\", section on 'Medication options'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9838095\">",
"    <span class=\"h3\">",
"     Icatibant",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/36/4675?source=see_link\">",
"     Icatibant",
"    </a>",
"    is a synthetic bradykinin B2 receptor antagonist that is approved for the treatment of hereditary angioedema (",
"    <a class=\"graphic graphic_algorithm graphicRef82805 \" href=\"mobipreview.htm?4/47/4862\">",
"     algorithm 1",
"    </a>",
"    ). In a series of eight patients presenting with acute laryngopharyngeal or tongue angioedema while taking an ACE inhibitor, a single dose of icatibant provided initial symptom improvement in 51 &plusmn; 21 minutes and provided complete relief of symptoms in 4.4 hours, compared to 33 hours in a historical control group of 47 patients treated with glucocorticoids or antihistamines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/61\">",
"     61",
"    </a>",
"    ]. No patients in the treatment group received tracheal intubation, other drug treatment, tracheotomy, or needed a second icatibant injection. In the control group, 3 of 47 and 2 of 47 required tracheostomy and intubation, respectively. Additional case reports further support the effectiveness of icatibant in the treatment of ACE inhibitor angioedema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. Icatibant was well tolerated in the above studies with reports of only mild injection site reactions that resolved spontaneously within two hours of treatment. The adult dose of icatibant is 30 mg given subcutaneously. Dosing and administration are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33657?source=see_link&amp;anchor=H2297196#H2297196\">",
"     \"Hereditary angioedema: Treatment of acute attacks\", section on 'Bradykinin B2 receptor antagonist'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A randomized trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/36/4675?source=see_link\">",
"     icatibant",
"    </a>",
"    for the treatment of ACE inhibitor-induced angioedema was underway at the time of this review [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9838102\">",
"    <span class=\"h3\">",
"     Ecallantide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/23/23923?source=see_link\">",
"     Ecallantide",
"    </a>",
"    is a recombinant protein that is approved for use in hereditary angioedema. Ecallantide inhibits the conversion of high molecular weight kininogen to bradykinin by inhibiting plasma kallikrein (",
"    <a class=\"graphic graphic_algorithm graphicRef82805 \" href=\"mobipreview.htm?4/47/4862\">",
"     algorithm 1",
"    </a>",
"    ). However, ACE inhibitor-induced angioedema is caused by the persistence of bradykinin due to lack of metabolism rather than overproduction, so it is not entirely intuitive that ecallantide would be effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/27\">",
"     27",
"    </a>",
"    ]. An unpublished case report describes prompt improvement in airway obstruction after treatment with subcutaneous ecallantide. At the time of this review, a phase 2 clinical trial was underway to examine the efficacy of ecallantide for the treatment of ACE inhibitor-induced angioedema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/68\">",
"     68",
"    </a>",
"    ]. Dosing and administration are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33657?source=see_link&amp;anchor=H7#H7\">",
"     \"Hereditary angioedema: Treatment of acute attacks\", section on 'Kallikrein inhibitor (US only)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1071035\">",
"    <span class=\"h3\">",
"     Fresh frozen plasma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma (FFP in the US or solvent-detergent treated plasma in some countries) contains the enzyme ACE, and the administration of plasma is thought to degrade high levels of bradykinin with subsequent resolution of angioedema. Case reports have described administration of FFP leading to rapid improvement of ACE inhibitor-induced angioedema without further recurrence of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. The usual dose of FFP is 2 units for adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33657?source=see_link&amp;anchor=H18#H18\">",
"     \"Hereditary angioedema: Treatment of acute attacks\", section on 'Plasma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1071042\">",
"    <span class=\"h3\">",
"     Purified C1-inhibitor concentrate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Purified C1-inhibitor concentrate",
"    <strong>",
"    </strong>",
"    has been shown to be effective for ACE inhibitor-induced angioedema in case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/71-74\">",
"     71-74",
"    </a>",
"    ]. One of the functions of C1-inhibitor is the inhibition of kallikrein. Dosing is weight-based and described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33657?source=see_link&amp;anchor=H3#H3\">",
"     \"Hereditary angioedema: Treatment of acute attacks\", section on 'C1-inhibitor (plasma-derived)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33657?source=see_link&amp;anchor=H2297494#H2297494\">",
"     \"Hereditary angioedema: Treatment of acute attacks\", section on 'Recombinant C1-inhibitor (EU only)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20395068\">",
"    <span class=\"h1\">",
"     FUTURE USE OF OTHER RELATED DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient who developed angioedema from one ACE inhibitor should strictly avoid all other ACE inhibitors. To prevent patients from being given ACE inhibitors in the future, we suggest they obtain a medical alert bracelet (or similar device) indicating that angioedema developed in response to ACE inhibitors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9838109\">",
"    <span class=\"h2\">",
"     Angiotensin II receptor blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of angioedema with ARB therapy is small as demonstrated in a large study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/6,75,76\">",
"     6,75,76",
"    </a>",
"    ]. The mechanism by which ARBs would theoretically precipitate angioedema is not clear (",
"    <a class=\"graphic graphic_algorithm graphicRef82805 \" href=\"mobipreview.htm?4/47/4862\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The following studies evaluated the incidence of angioedema in patients receiving ARBs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a large study of 467,313 patients who were initiated on ARB therapy, there were 288 angioedema events, although the cumulative incidence was similar in ARBs and B-blockers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a meta-analysis of data from 19 trials, the overall incidence of angioedema with ARBs was not significantly different from placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/14\">",
"       14",
"      </a>",
"      ]. This analysis included 35,479 patients (mean age 61 years, 59 percent men), of whom 52 developed angioedema during a mean duration of 120 weeks, for a weighted incidence of 0.11 percent (95% CI 0.09-0.13).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Systematic reviews of the literature describe a 1.5 to 10 percent rate of recurrent angioedema in patients with a history of ACE inhibitor-induced angioedema that were switched to an ARB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. This relatively high rate of recurrence may be misleading and may be attributable to the phenomena discussed previously, ie, that patients with ACE inhibitor-induced angioedema may have one or more additional episodes of angioedema in the weeks to months after the ACE inhibitor is discontinued. (See",
"    <a class=\"local\" href=\"#H20393882\">",
"     'Recurrence after stopping ACE inhibitor therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    ACE inhibitors and ARBs share many of their cardioprotective effects. Given the current evidence, we do not feel that use of ARBs should be avoided in patients with ACE inhibitor-induced angioedema, if ARBs offer an advantage over other antihypertensives for that individual patient. We do recommend routine monitoring of patients to evaluate for potential side effects, as should be done for any patient who is started on a new medication. In addition, we specifically counsel patients that they could have a recurrence of angioedema and review with them how to proceed if this should occur. Another approach is to wait at least four weeks after an ACE inhibitor is discontinued before starting an ARB. However, this is only appropriate if the patient can safely go without the medication for this period of time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9838116\">",
"    <span class=\"h2\">",
"     Renin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9142?source=see_link\">",
"     Aliskiren",
"    </a>",
"    was the first oral direct rennin inhibitor approved by the United States Food and Drug Administration (FDA) in 2007 for the treatment of hypertension, and several other direct renin inhibitors are in the early stages of development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/76\">",
"     76",
"    </a>",
"    ]. Renin inhibitors are thought to provide a more comprehensive inhibition of the renin-angiotensin system compared with ACE inhibitors and ARBs, and are thought to have different safety profiles. Theoretically, aliskiren should not confer a risk of bradykinin-induced angioedema because, unlike ACE inhibitors, it has no known effect on bradykinin metabolism. In a case series, a patient with life-threatening angioedema while receiving an ACE inhibitor did not experience subsequent angioedema episodes when treated with long-term aliskiren [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the above conceptual differences between ACE inhibitors and renin inhibitors, angioedema has been reported with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9142?source=see_link\">",
"     aliskiren",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/6,14,80,81\">",
"     6,14,80,81",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a meta-analysis that pooled data from 12 randomized controlled trials of 12,188 patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9142?source=see_link\">",
"       aliskiren",
"      </a>",
"      for hypertension, the incidence of angioedema with aliskiren treatment was 0.4 percent and similar to the risk with ACE inhibitors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A subsequent study followed 4867 adult patients initiated on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9142?source=see_link\">",
"       aliskiren",
"      </a>",
"      therapy, among whom there were seven associated angioedema events and one case of serious angioedema [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a meta-analysis of 5141 patients on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9142?source=see_link\">",
"       aliskiren",
"      </a>",
"      , seven developed angioedema during a mean duration of 24 weeks with an incidence of 0.13 percent (95% CI 0.07-0.19) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, more clinical experience with the use of renin inhibitors is needed to understand the risk of angioedema with these agents. Until more information is available, caution is warranted. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/40/25224?source=see_link&amp;anchor=H13#H13\">",
"     \"Renin-angiotensin system inhibition in the treatment of hypertension\", section on 'Direct renin inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2419915\">",
"    <span class=\"h2\">",
"     Dipeptidyl peptidase IV inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The DPP-IV inhibitors are a group of medications used in the management of type 2 diabetes.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/31/5622?source=see_link\">",
"     Sitagliptin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/26/26022?source=see_link\">",
"     saxagliptin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35157?source=see_link\">",
"     linagliptin",
"    </a>",
"    are available in the United States and often used in combination with ACE inhibitor and ARB therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/82\">",
"     82",
"    </a>",
"    ]. The incidence and prevalence of DPP-VI inhibitor-associated angioedema is unknown. However, health care providers should be aware that angioedema has been associated with DPP-IV inhibitors, either alone or when used concomitantly with certain classes of medications, including ACE inhibitors and ARBs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37465/abstract/82-84\">",
"     82-84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20396597\">",
"    <span class=\"h1\">",
"     REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe angioedema, as well as those in whom C4 levels were measured and found to be low, should be referred to a drug allergy expert for further evaluation. In addition, patients in whom angioedema continues to occur beyond the first few months after ACE inhibitor therapy was stopped should be evaluated further by an allergy or hematology expert for underlying disorders that predispose to angioedema (eg, acquired C1 inhibitor deficiency). (See",
"    <a class=\"local\" href=\"#H20395305\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9838123\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall incidence of angioedema in patients receiving ACE inhibitors is between 0.1 percent and 0.7 percent. ACE inhibitors are the leading cause of drug-induced angioedema, accounting for up to 40 percent of emergency visits for angioedema. (See",
"      <a class=\"local\" href=\"#H20394732\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ACE inhibitor-induced angioedema usually affects the lips, tongue, and face, although visceral edema presenting as acute abdominal pain is also possible. Urticaria and itching are absent. Symptoms typically begin during the first week of treatment, although some cases develop after years of uneventful therapy. (See",
"      <a class=\"local\" href=\"#H20393568\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical features of ACE inhibitor angioedema are related to elevated levels of bradykinin, an inflammatory vasoactive peptide which leads to vasodilation of blood vessels. Lower levels or defects in enzymes that degrade bradykinin and similar compounds may predispose certain patients to angioedema, which is one identified reason that patients of African descent are more susceptible. (See",
"      <a class=\"local\" href=\"#H9838053\">",
"       'Pathophysiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9838060\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of ACE inhibitor-induced angioedema is made clinically, as there are no definitive laboratory tests that are routinely available to diagnose ACE inhibitor-induced angioedema. Resolution upon discontinuation of the ACE inhibitor confirms the diagnosis. (See",
"      <a class=\"local\" href=\"#H20395298\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The primary treatment of ACE inhibitor-induced angioedema is discontinuation of the drug. Careful attention to the airway is critical if tongue or laryngeal swelling is present because airway obstruction occurs in up to 10 percent of cases. Intubation and mechanical ventilation may be required. (See",
"      <a class=\"local\" href=\"#H9838067\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with angioedema that threatens the airway or is severe and fails to improve within 24 hours, we suggest additional treatment with an agent that can lower bradykinin levels (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Options include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/36/4675?source=see_link\">",
"       icatibant",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/23/23923?source=see_link\">",
"       ecallantide",
"      </a>",
"      , plasma, or purified C1-inhibitor concentrate. (See",
"      <a class=\"local\" href=\"#H1070652\">",
"       'Additional therapies for severe or persistent symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <strong>",
"       not",
"      </strong>",
"      avoiding angiotensin receptor blockers (ARBs) in patients with a history of ACE inhibitor-induced angioedema if an ARB has advantages over other agents for that patient (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, the risk of recurrent angioedema may be as great as 10 percent, so patients should be informed about how to proceed if symptoms develop. (See",
"      <a class=\"local\" href=\"#H9838109\">",
"       'Angiotensin II receptor blockers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Angioedema has been reported with renin inhibitors at rates comparable to those with ACE inhibitors, although the mechanism is likely different. Angioedema has also been reported with dipeptidyl peptidase IV inhibitors (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/31/5622?source=see_link\">",
"       sitagliptin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/26/26022?source=see_link\">",
"       saxagliptin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35157?source=see_link\">",
"       linagliptin",
"      </a>",
"      ), although these agents are often used in combination with ACE inhibitors and data are limited. (See",
"      <a class=\"local\" href=\"#H9838116\">",
"       'Renin inhibitors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2419915\">",
"       'Dipeptidyl peptidase IV inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/1\">",
"      Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet 2000; 356:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/2\">",
"      Quan M. Case study. ACE inhibitor-induced angioedema. Clin Cornerstone 2009; 9 Suppl 3:S34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/3\">",
"      Miller DR, Oliveria SA, Berlowitz DR, et al. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension 2008; 51:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/4\">",
"      Vleeming W, van Amsterdam JG, Stricker BH, de Wildt DJ. ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Saf 1998; 18:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/5\">",
"      Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004; 17:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/6\">",
"      Toh S, Reichman ME, Houstoun M, et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med 2012; 172:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/7\">",
"      Ma J, Lee KV, Stafford RS. Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension between 1993 and 2004. Hypertension 2006; 48:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/8\">",
"      Banerji A, Clark S, Blanda M, et al. Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department. Ann Allergy Asthma Immunol 2008; 100:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/9\">",
"      Gabb GM, Ryan P, Wing LM, Hutchinson KA. Epidemiological study of angioedema and ACE inhibitors. Aust N Z J Med 1996; 26:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/10\">",
"      Sarkar P, Nicholson G, Hall G. Brief review: angiotensin converting enzyme inhibitors and angioedema: anesthetic implications. Can J Anaesth 2006; 53:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/11\">",
"      Sabroe RA, Black AK. Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema. Br J Dermatol 1997; 136:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/12\">",
"      Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/13\">",
"      Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/14\">",
"      Makani H, Messerli FH, Romero J, et al. Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. Am J Cardiol 2012; 110:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/15\">",
"      Kanani A, Schellenberg R, Warrington R. Urticaria and angioedema. Allergy Asthma Clin Immunol 2011; 7 Suppl 1:S9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/16\">",
"      Kaplan AP, Greaves MW. Angioedema. J Am Acad Dermatol 2005; 53:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/17\">",
"      Grant NN, Deeb ZE, Chia SH. Clinical experience with angiotensin-converting enzyme inhibitor-induced angioedema. Otolaryngol Head Neck Surg 2007; 137:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/18\">",
"      Bork K, Wulff K, Hardt J, et al. Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy. J Allergy Clin Immunol 2009; 124:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/19\">",
"      Schmidt TD, McGrath KM. Angiotensin-converting enzyme inhibitor angioedema of the intestine: a case report and review of the literature. Am J Med Sci 2002; 324:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/20\">",
"      Eck SL, Morse JH, Janssen DA, et al. Angioedema presenting as chronic gastrointestinal symptoms. Am J Gastroenterol 1993; 88:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/21\">",
"      Marmery H, Mirvis SE. Angiotensin-converting enzyme inhibitor-induced visceral angioedema. Clin Radiol 2006; 61:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/22\">",
"      Oudit G, Girgrah N, Allard J. ACE inhibitor-induced angioedema of the intestine: Case report, incidence, pathophysiology, diagnosis and management. Can J Gastroenterol 2001; 15:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/23\">",
"      Byrne TJ, Douglas DD, Landis ME, Heppell JP. Isolated visceral angioedema: an underdiagnosed complication of ACE inhibitors? Mayo Clin Proc 2000; 75:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/24\">",
"      Orr KK, Myers JR. Intermittent visceral edema induced by long-term enalapril administration. Ann Pharmacother 2004; 38:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/25\">",
"      Chiu AG, Newkirk KA, Davidson BJ, et al. Angiotensin-converting enzyme inhibitor-induced angioedema: a multicenter review and an algorithm for airway management. Ann Otol Rhinol Laryngol 2001; 110:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/26\">",
"      Malde B, Regalado J, Greenberger PA. Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Ann Allergy Asthma Immunol 2007; 98:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/27\">",
"      Bas M, Adams V, Suvorava T, et al. Nonallergic angioedema: role of bradykinin. Allergy 2007; 62:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/28\">",
"      Brown NJ, Snowden M, Griffin MR. Recurrent angiotensin-converting enzyme inhibitor--associated angioedema. JAMA 1997; 278:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/29\">",
"      Beltrami L, Zanichelli A, Zingale L, et al. Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema. J Hypertens 2011; 29:2273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/30\">",
"      Mullins RJ, Shanahan TM, Dobson RT. Visceral angioedema related to treatment with an ACE inhibitor. Med J Aust 1996; 165:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/31\">",
"      Warner KK, Visconti JA, Tschampel MM. Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema. Ann Pharmacother 2000; 34:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/32\">",
"      Korniyenko A, Alviar CL, Cordova JP, Messerli FH. Visceral angioedema due to angiotensin-converting enzyme inhibitor therapy. Cleve Clin J Med 2011; 78:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/33\">",
"      Slater EE, Merrill DD, Guess HA, et al. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA 1988; 260:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/34\">",
"      Nussberger J, Cugno M, Amstutz C, et al. Plasma bradykinin in angio-oedema. Lancet 1998; 351:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/35\">",
"      Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/36\">",
"      Marceau F, Hess JF, Bachvarov DR. The B1 receptors for kinins. Pharmacol Rev 1998; 50:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/37\">",
"      Morimoto T, Gandhi TK, Fiskio JM, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract 2004; 10:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/38\">",
"      Nussberger J, Cugno M, Cicardi M. Bradykinin-mediated angioedema. N Engl J Med 2002; 347:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/39\">",
"      Kaplan AP, Ghebrehiwet B. The plasma bradykinin-forming pathways and its interrelationships with complement. Mol Immunol 2010; 47:2161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/40\">",
"      Byrd JB, Adam A, Brown NJ. Angiotensin-converting enzyme inhibitor-associated angioedema. Immunol Allergy Clin North Am 2006; 26:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/41\">",
"      Emanueli C, Grady EF, Madeddu P, et al. Acute ACE inhibition causes plasma extravasation in mice that is mediated by bradykinin and substance P. Hypertension 1998; 31:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/42\">",
"      Moreau ME, Garbacki N, Molinaro G, et al. The kallikrein-kinin system: current and future pharmacological targets. J Pharmacol Sci 2005; 99:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/43\">",
"      Russell JS, Chi H, Lantry LE, et al. Substance P and neurokinin A metabolism by cultured human skeletal muscle myocytes and fibroblasts. Peptides 1996; 17:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/44\">",
"      Adam A, Cugno M, Molinaro G, et al. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet 2002; 359:2088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/45\">",
"      Byrd JB, Touzin K, Sile S, et al. Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. Hypertension 2008; 51:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/46\">",
"      Molinaro G, Cugno M, Perez M, et al. Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin. J Pharmacol Exp Ther 2002; 303:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/47\">",
"      Hoover T, Lippmann M, Grouzmann E, et al. Angiotensin converting enzyme inhibitor induced angio-oedema: a review of the pathophysiology and risk factors. Clin Exp Allergy 2010; 40:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/48\">",
"      Kostis JB, Kim HJ, Rusnak J, et al. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med 2005; 165:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/49\">",
"      Brown NJ, Ray WA, Snowden M, Griffin MR. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 1996; 60:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/50\">",
"      Gibbs CR, Lip GY, Beevers DG. Angioedema due to ACE inhibitors: increased risk in patients of African origin. Br J Clin Pharmacol 1999; 48:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/51\">",
"      Duerr M, Glander P, Diekmann F, et al. Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. Clin J Am Soc Nephrol 2010; 5:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/52\">",
"      Cilia La Corte AL, Carter AM, Rice GI, et al. A functional XPNPEP2 promoter haplotype leads to reduced plasma aminopeptidase P and increased risk of ACE inhibitor-induced angioedema. Hum Mutat 2011; 32:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/53\">",
"      Duan QL, Nikpoor B, Dube MP, et al. A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. Am J Hum Genet 2005; 77:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/54\">",
"      Gulec M, Caliskaner Z, Tunca Y, et al. The role of ace gene polymorphism in the development of angioedema secondary to angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Allergol Immunopathol (Madr) 2008; 36:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/55\">",
"      Fuchs U, Zittermann A, Berthold HK, et al. Immunosuppressive therapy with everolimus can be associated with potentially life-threatening lingual angioedema. Transplantation 2005; 79:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/56\">",
"      Byrd JB, Woodard-Grice A, Stone E, et al. Association of angiotensin-converting enzyme inhibitor-associated angioedema with transplant and immunosuppressant use. Allergy 2010; 65:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/57\">",
"      Kyrmizakis DE, Papadakis CE, Liolios AD, et al. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists. Arch Otolaryngol Head Neck Surg 2004; 130:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/58\">",
"      Vasekar M, Craig TJ. ACE inhibitor-induced angioedema. Curr Allergy Asthma Rep 2012; 12:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/59\">",
"      Ciaccia D, Brazer SR, Baker ME. Acquired C1 esterase inhibitor deficiency causing intestinal angioedema: CT appearance. AJR Am J Roentgenol 1993; 161:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/60\">",
"      Beltrami L, Zingale LC, Carugo S, Cicardi M. Angiotensin-converting enzyme inhibitor-related angioedema: how to deal with it. Expert Opin Drug Saf 2006; 5:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/61\">",
"      Bas M, Greve J, Stelter K, et al. Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series. Ann Emerg Med 2010; 56:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/62\">",
"      Roberts DS, Mahoney EJ, Hutchinson CT, et al. Analysis of recurrent angiotensin converting enzyme inhibitor-induced angioedema. Laryngoscope 2008; 118:2115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/63\">",
"      Rosenberg EI, Mishra G, Abdelmalek MF. Angiotensin-converting enzyme inhibitor-induced isolated visceral angioedema in a liver transplant recipient. Transplantation 2003; 75:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/64\">",
"      Illing EJ, Kelly S, Hobson JC, Charters S. Icatibant and ACE inhibitor angioedema. BMJ Case Rep 2012; 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/65\">",
"      Gallitelli M, Alzetta M. Icatibant: a novel approach to the treatment of angioedema related to the use of angiotensin-converting enzyme inhibitors. Am J Emerg Med 2012; 30:1664.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/66\">",
"      Bas M, Kojda G, Stelter K. [Angiotensin-converting enzyme inhibitor induced angioedema : new therapy options]. Anaesthesist 2011; 60:1141.",
"     </a>",
"    </li>",
"    <li>",
"     A multicenter study, randomized, double-blind with 2 groups as proof of concept for the treatment of ACEI induced angioedema with subcutaneous icatibant. file://clinicaltrials.gov/ct2/show/NCT01154361 (Accessed on December 22, 2011).",
"    </li>",
"    <li>",
"     Dyax announces treatment of first patient in phase 2 trial of ecallantide for acute treatment of ACE inhibitor-induced angioedema; Dyax Corp. (NASDAQ: DYAX) announced today treatment of the first patient in a Phase 2 trial evaluating the efficacy and safety of ecallantide, a potent, selective, reversible inhibitor of plasma kallikrein, for acute treatment of angiotensin converting enzyme (ACE) inhibitor-induced angioedema. This form of angioedema, or rapid swelling of the dermis, mucosa or other tissues, most commonly occurs in the head, face and tongue, and can be severe or life threatening. Ecallantide is approved under the brand name KALBITOR&reg; in the United States for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older]. file://investor.dyax.com/releasedetail.cfm?ReleaseID=596655 (Accessed on August 04, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/69\">",
"      Karim MY, Masood A. Fresh-frozen plasma as a treatment for life-threatening ACE-inhibitor angioedema. J Allergy Clin Immunol 2002; 109:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/70\">",
"      Warrier MR, Copilevitz CA, Dykewicz MS, Slavin RG. Fresh frozen plasma in the treatment of resistant angiotensin-converting enzyme inhibitor angioedema. Ann Allergy Asthma Immunol 2004; 92:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/71\">",
"      Nielsen EW, Gramstad S. Angioedema from angiotensin-converting enzyme (ACE) inhibitor treated with complement 1 (C1) inhibitor concentrate. Acta Anaesthesiol Scand 2006; 50:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/72\">",
"      Steinbach O, Schweder R, Freitag B. [C1-esterase inhibitor in ACE inhibitor-induced severe angioedema of the tongue]. Anaesthesiol Reanim 2001; 26:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/73\">",
"      Gel&eacute;e B, Michel P, Haas R, Boishardy F. [Angiotensin-converting enzyme inhibitor-related angioedema: emergency treatment with complement C1 inhibitor concentrate]. Rev Med Interne 2008; 29:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/74\">",
"      Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med 1996; 334:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/75\">",
"      Flais MJ. Literature reports of angiotensin receptor antagonist-induced angioedema in patients with a history of angiotensin-converting enzyme inhibitor-induced angioedema. Arch Intern Med 2003; 163:1488; author reply 1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/76\">",
"      Siragy HM. A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors. Vasc Health Risk Manag 2011; 7:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/77\">",
"      Haymore BR, Yoon J, Mikita CP, et al. Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis. Ann Allergy Asthma Immunol 2008; 101:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/78\">",
"      Beavers CJ, Dunn SP, Macaulay TE. The role of angiotensin receptor blockers in patients with angiotensin-converting enzyme inhibitor-induced angioedema. Ann Pharmacother 2011; 45:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/79\">",
"      Anzaldua DA, Schmitz PG. Aliskiren as an alternative in a patient with life-threatening ACE inhibitor-induced angioedema. Am J Kidney Dis 2008; 51:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/80\">",
"      Ali AK. Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor. Ther Clin Risk Manag 2011; 7:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/81\">",
"      White WB, Bresalier R, Kaplan AP, et al. Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension. J Clin Hypertens (Greenwich) 2010; 12:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/82\">",
"      Byrd JS, Minor DS, Elsayed R, Marshall GD. DPP-4 inhibitors and angioedema: a cause for concern? Ann Allergy Asthma Immunol 2011; 106:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/83\">",
"      Rosenstock J, Brazg R, Andryuk PJ, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006; 28:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37465/abstract/84\">",
"      Brown NJ, Byiers S, Carr D, et al. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension 2009; 54:516.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16380 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-A58E39C754-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_37_37465=[""].join("\n");
var outline_f36_37_37465=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9838123\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9838011\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20394732\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20393568\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20395468\">",
"      Affected areas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20393889\">",
"      - Face, mouth, and upper airway",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20394022\">",
"      - Intestine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20393796\">",
"      Time course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20393882\">",
"      Recurrence after stopping ACE inhibitor therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9838053\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4335290\">",
"      ACE inhibition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4335305\">",
"      Development of angioedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9838060\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20395298\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4335620\">",
"      Evaluation of abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20395305\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9838067\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17308940\">",
"      Airway management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1070522\">",
"      Discontinue ACE inhibitor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17308947\">",
"      Other interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1070652\">",
"      Additional therapies for severe or persistent symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9838095\">",
"      - Icatibant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9838102\">",
"      - Ecallantide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1071035\">",
"      - Fresh frozen plasma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1071042\">",
"      - Purified C1-inhibitor concentrate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20395068\">",
"      FUTURE USE OF OTHER RELATED DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9838109\">",
"      Angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9838116\">",
"      Renin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2419915\">",
"      Dipeptidyl peptidase IV inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20396597\">",
"      REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9838123\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/16380\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/16380|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?4/47/4862\" title=\"algorithm 1\">",
"      Mechanisms of drugs for angioedema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?19/41/20125\" title=\"algorithm 2\">",
"      Types of bradykinin-mediated angioedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/16380|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/11/25781\" title=\"picture 1\">",
"      ACE inhibitor-induced angioedema",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/12/26824?source=related_link\">",
"      Acquired C1 inhibitor deficiency: Clinical manifestations, epidemiology, pathogenesis, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/17/15641?source=related_link\">",
"      An overview of angioedema: Clinical features, diagnosis, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38391?source=related_link\">",
"      An overview of angioedema: Pathogenesis and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/25/13720?source=related_link\">",
"      Chapter 2B: Renin-angiotensin system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/4/33864?source=related_link\">",
"      Hereditary angioedema: Pathogenesis and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33657?source=related_link\">",
"      Hereditary angioedema: Treatment of acute attacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/2/18473?source=related_link\">",
"      Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/40/25224?source=related_link\">",
"      Renin-angiotensin system inhibition in the treatment of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/14/15592?source=related_link\">",
"      Treatment of hypertension in blacks",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_37_37466="Therapy of diffuse or focal proliferative lupus nephritis";
var content_f36_37_37466=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Therapy of diffuse or focal proliferative lupus nephritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/37/37466/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/37/37466/contributors\">",
"     Ronald J Falk, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/37/37466/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/37/37466/contributors\">",
"     Gerald B Appel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/37/37466/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/37/37466/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/37/37466/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/37/37466/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/37/37466/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment of lupus nephritis (LN) varies with the type of disease that is present. Immunosuppressive therapy is indicated in the great majority of patients with diffuse or focal proliferative LN (class III or IV lupus nephritis) and in some selected patients with membranous LN (class V lupus nephritis) including those with a severe nephrotic syndrome, an elevated serum creatinine,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    associated proliferative disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Immunosuppressive therapy is usually not indicated for minimal mesangial and mesangial proliferative LN. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnosis and classification of renal disease in systemic lupus erythematosus\", section on 'Classification'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/12/44233?source=see_link\">",
"     \"Clinical features and therapy of membranous lupus nephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Induction and maintenance immunosuppressive therapy of proliferative LN as well as nonimmunosuppressive therapies will be reviewed here. The treatment of resistant or relapsing proliferative LN and issues related to end-stage LN are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/3/12345?source=see_link\">",
"     \"Therapy of resistant or relapsing diffuse or focal proliferative lupus nephritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39352?source=see_link\">",
"     \"End-stage renal disease due to lupus nephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR PROGRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even with aggressive therapy, some patients with proliferative lupus nephritis (LN) will have a progressive decline in renal function leading to end-stage renal disease (ESRD). Clinical risk factors for progression, evident at the time of initial presentation, include an elevated serum creatinine at the time of renal biopsy, hypertension, nephrotic range proteinuria, anemia with a hematocrit below 26 percent, and black and Hispanic race and ethnicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Race and ethnicity'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The severity of chronic tubulointerstitial disease and extensive crescent formation also correlate with long-term prognosis in LN, as they do in many other chronic progressive glomerular diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/5,6,8\">",
"     5,6,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=see_link&amp;anchor=H7#H7\">",
"     \"Secondary factors and progression of chronic kidney disease\", section on 'Tubulointerstitial fibrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk factors for progression that become evident after initial presentation and during therapy are the frequency and severity of relapses (renal flares) and the degree to which the abnormal features of renal involvement are controlled (complete or partial remission of proteinuria and hematuria). (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Failure to achieve clinical remission'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Delayed therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likelihood of a successful initial outcome is greater if therapy for LN is initiated relatively early in the course of the disease. Delaying therapy because of presumed mild disease can be associated with increased glomerular injury and progressive tubulointerstitial fibrosis and glomerulosclerosis and therefore a lesser response to immunosuppressive drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/6,9,10\">",
"     6,9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with persistent or relapsing or remitting mild hematuria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    subnephrotic proteinuria often have a \"smoldering\" but active disease that causes progressive renal injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/4\">",
"     4",
"    </a>",
"    ]. At first, there may be little or no elevation in the serum creatinine since adaptive glomerular hyperfiltration in the less involved nephrons can initially maintain the glomerular filtration rate (GFR) despite marked nephron loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, prompt diagnosis after the onset of nephritis and subsequent initiation of appropriate therapy are associated with improved outcomes regardless of the histologic subclass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/6,10\">",
"     6,10",
"    </a>",
"    ]. This issue was addressed in a study of 91 patients with LN who were followed for a median of six years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/10\">",
"     10",
"    </a>",
"    ]. There was a much higher rate of ESRD among patients who had clinically recognized renal disease for &ge;6 months prior to biopsy (47 versus 14 per 1000 patient-years in patients who had an earlier biopsy; hazard ratio 9.3, 95% CI 1.8 to 47.0).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Failure to achieve clinical remission",
"    </span>",
"    &nbsp;&mdash;&nbsp;A better long-term prognosis is associated with attaining clinical remission of active proliferative LN. Either a complete or partial remission is associated with an improved outcome compared to no remission. Partial remission is associated with a much greater likelihood of a subsequent relapse than complete remission and thus a poorer long-term outcome than those who achieve a complete remission. The criteria used for complete and partial remission are discussed below. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Criteria for clinical remission'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The importance of attaining a complete clinical remission was illustrated in a report from the Lupus Nephritis Collaborative Study Group of 86 patients with severe LN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/12\">",
"     12",
"    </a>",
"    ]. Complete remission was defined as an inactive urine sediment, a serum creatinine &le;1.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (124",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    and protein excretion &le;330",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    The 43 percent of patients who attained a complete clinical remission had much higher renal survival rates than those who did not attain remission at 5 years (94 versus 46 percent) and 10 years (94 versus 31 percent). Improvement was also noted in patient survival (95 versus 60 percent at 10 years). Similar findings have been reported by others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The value of partial remission was evaluated in a 10-year study of 86 adults with severe LN that evaluated the correlation between clinical outcomes and partial remission (defined as a 50 percent reduction in proteinuria to less than 1.5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    and stable serum creatinine), complete remission, and no response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/13\">",
"     13",
"    </a>",
"    ]. Compared with no response, partial remission was associated with significantly higher rates of renal (45 versus 19 percent) and patient (76 versus 46 percent) survival. As in the above study, the best outcomes were observed in those who attained complete remission (renal and patient survival of 94 and 96 percent, respectively).",
"   </p>",
"   <p>",
"    Features generally predictive of attaining a clinical remission are stable renal function after four weeks on therapy, lower chronicity index on renal biopsy, white race, and lower baseline proteinuria and serum creatinine concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/15\">",
"     15",
"    </a>",
"    ]. On the other hand, male gender and earlier development of nephritis from the time of diagnosis of lupus may be associated with a lower likelihood of sustained remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Relapses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapses of active nephritis (also called nephritic flares) and lack of response to therapy are associated with an increased risk of progressive chronic kidney disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/12,17,18\">",
"     12,17,18",
"    </a>",
"    ]. In a series of 70 patients, for example, the likelihood of doubling of the serum creatinine was increased in patients with nephritic relapses (relative risk 6.8), particularly when the relapses were associated with an acute elevation in serum creatinine (relative risk 27) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/18\">",
"     18",
"    </a>",
"    ]. Relapses tend to occur within the first five years after induction of remission. The average relapse rate is about 8 per 100 patient years of follow-up but depends upon the nature of the maintenance therapy and whether a complete or partial remission was obtained during induction therapy.",
"   </p>",
"   <p>",
"    The high risk of relapse provides the rationale for maintenance immunosuppressive therapy. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Maintenance immunosuppression'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8472681\">",
"    <span class=\"h2\">",
"     Class of lupus nephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somewhat controversial has been the prognostic and therapeutic significance of the degree of activity (active inflammation) and chronicity (glomerular scarring, and tubulointerstitial fibrosis and atrophy) in diffuse LN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/8,19-21\">",
"     8,19-21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnosis and classification of renal disease in systemic lupus erythematosus\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although some investigators have proposed that high levels of chronicity are associated with progressive renal failure that is less likely to respond to immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/8\">",
"     8",
"    </a>",
"    ], others have noted that the degree of activity and chronicity are often similar in patients who progress to renal failure and in those who maintain stable renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/21\">",
"     21",
"    </a>",
"    ]. The limited utility of these features is in part due to the subjective nature of their determination and to potential sampling errors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies based upon the 2004 classification system are likely to help clarify the usefulness of the new subclasses defined by the presence or absence of active and chronic lesions. Conflicting findings have been reported in retrospective studies. Little clinical or prognostic difference between the IV-S (segmental) and IV-G (global) subgroups was reported in some studies, whereas another noted worse 10-year renal survival in those with persistent class IV-G biopsy findings after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/22-25\">",
"     22-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, some investigators postulate that class IV-G (A [active lesions present]) will have the best prognosis with current immunosuppressive regimens, while class IV-S",
"    <span class=\"nowrap\">",
"     (A/C",
"    </span>",
"    [both active and chronic lesions present]) will be less responsive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/26\">",
"     26",
"    </a>",
"    ]. At present, we do",
"    <strong>",
"     not",
"    </strong>",
"    routinely use these indices to guide therapeutic decisions or to risk stratify patients.",
"   </p>",
"   <p>",
"    The following clinical correlations are based largely upon the previous characterization of class IV disease, which is most closely associated with classes IV-G (A and",
"    <span class=\"nowrap\">",
"     A/C)",
"    </span>",
"    and IV-S (A and",
"    <span class=\"nowrap\">",
"     A/C)",
"    </span>",
"    disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a pilot study of 135 class IV biopsies, global and segmental diffuse nephritis was observed in 65 and 35 percent of cases, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Despite effective immunosuppressive therapy, progressive scarring can occur over a period of years after the inflammation has resolved. This late decline in function is generally associated with a bland urine sediment and, on renal biopsy, marked scarring with little or no active inflammation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=see_link&amp;anchor=H13#H13\">",
"       \"Diagnosis and classification of renal disease in systemic lupus erythematosus\", section on 'Advanced sclerosing lupus nephritis (class VI)'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Race and ethnicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have noted worse outcomes in black (Afro-American or Afro-Caribbean) and Hispanic patients compared with non-Hispanic white patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/5,15,17,27-32\">",
"     5,15,17,27-32",
"    </a>",
"    ]. The following observations illustrate the range of findings.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report from the Glomerular Disease Collaborative Network, for example, the renal survival rate after",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      therapy for diffuse proliferative LN was 95 percent at five years in white patients compared to 79 percent at one year and 58 percent at five years in black patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/27\">",
"       27",
"      </a>",
"      ]. This difference was independent of other risk factors such as age, hypertension, and the activity or chronicity index. Similar findings were reported from the Collaborative Study Group of 86 patients with severe LN [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/15\">",
"       15",
"      </a>",
"      ]. At 10 years, blacks had, compared with whites, significantly lower rates of renal survival (38 versus 68 percent) and patient survival (59 versus 81 percent).",
"     </li>",
"     <li>",
"      In a retrospective study of 213 patients with LN, doubling of the serum creatinine or the development of ESRD was significantly higher among both black and Hispanic patients compared with non-Hispanic white patients at a mean follow-up of 37 months (31 and 18 versus 10 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The adverse outcomes in black and Hispanic patients may be due to socioeconomic factors, biologic-genetic factors,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    more severe disease at disease onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/15,27-30,33\">",
"     15,27-30,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     NONIMMUNOSUPPRESSIVE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late progression in lupus nephritis, as with any form of chronic kidney disease, is often due at least in part to nonimmunologic factors such as intraglomerular hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/11,34,35\">",
"     11,34,35",
"    </a>",
"    ]. Chronic kidney disease is also associated with a marked increase in coronary heart disease morbidity and mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=see_link\">",
"     \"Secondary factors and progression of chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=see_link\">",
"     \"Chronic kidney disease and coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result, patients with chronic kidney disease are typically treated with the following regimen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aggressive antihypertensive and, in patients with proteinuria, antiproteinuric therapy with blockade of the renin-angiotensin system (eg, angiotensin-converting enzyme [ACE] inhibitor or angiotensin II receptor blocker [ARB]). The goal blood pressure is less than",
"      <span class=\"nowrap\">",
"       130/80",
"      </span>",
"      mmHg, and goal protein excretion is less than 500 to 1000 mg per day or at least 60 percent below baseline. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H11#H11\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Effect of renin-angiotensin system inhibitors on progression of CKD'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H149378842#H149378842\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Proteinuria goal'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H24#H24\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Blood pressure goal'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lipid lowering with statin therapy, since chronic kidney disease is considered a coronary equivalent. In addition, there is weak and inconsistent evidence that statins may slow the progression of the underlying renal disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link\">",
"       \"Secondary prevention of cardiovascular disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30824?source=see_link\">",
"       \"Statins and chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     IMMUNOSUPPRESSIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressive therapy for proliferative lupus nephritis (LN) consists of induction and maintenance phases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Induction therapy involves the administration of potent immunosuppressive drugs to achieve remission of immunologic disease. The duration of the induction period varies; it can be as short as three months or as long as a year but averages about six months.",
"     </li>",
"     <li>",
"      Once remission is achieved, less aggressive maintenance immunosuppressive therapy is given for a prolonged period to prevent relapse. Nonimmunosuppressive therapies are also given to slow nonimmunologic progression of the renal disease. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Criteria for clinical remission'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H24\">",
"       'Maintenance immunosuppression'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aggressive immunosuppressive therapy is indicated in patients with proliferative LN who are at high risk for progressive renal failure. This includes virtually all patients with diffuse proliferative glomerulonephritis and most patients with focal proliferative glomerulonephritis. Such patients may also have evidence of membranous LN, but treatment is directed against the proliferative component of the disease. This recommendation is broadly similar to that made by the Kidney Disease: Improving Global Outcomes",
"    <sup>",
"    </sup>",
"    (KDIGO) clinical practice guideline for glomerulonephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/1\">",
"     1",
"    </a>",
"    ] and by the American College of Rheumatology Guidelines for LN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Focal proliferative disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of immunosuppressive therapy is less well-studied in patients with focal proliferative LN, which is present in approximately 10 to 20 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/4,36\">",
"     4,36",
"    </a>",
"    ]. An important issue is the accuracy of diagnosis. Focal proliferative LN is defined as fewer than 50 percent of glomeruli being affected on light microscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/19\">",
"     19",
"    </a>",
"    ]. However, the accuracy of this determination may be limited by the potential for sampling error induced by the relatively small number of glomeruli that are obtained on a typical percutaneous renal biopsy. It has been estimated that as many as 100 glomeruli may be necessary to be confident that focal disease is truly present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=see_link&amp;anchor=H10#H10\">",
"     \"Diagnosis and classification of renal disease in systemic lupus erythematosus\", section on 'Focal lupus nephritis (class III)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For these reasons, the clinical findings play an important role in the decision regarding immunosuppressive therapy for focal proliferative LN. Hematuria and proteinuria are seen in almost all patients, some of whom also have the nephrotic syndrome, hypertension,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an elevated serum creatinine concentration.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The long-term prognosis is similar to that of diffuse proliferative LN in patients who have widespread or severe involvement on renal biopsy (eg, 40 to 50 percent of glomeruli affected with areas of necrosis, crescent formation,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      subendothelial deposits) and clinical findings such as nephrotic range proteinuria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypertension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/4,36\">",
"       4,36",
"      </a>",
"      ]. Such patients should be treated as if they have diffuse proliferative disease.",
"     </li>",
"     <li>",
"      In contrast, progressive renal dysfunction appears to be uncommon (at least in the first five years) when less than 25 percent of the glomeruli are affected on light microscopy and most affected glomeruli show only segmental areas of proliferation without necrosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/36\">",
"       36",
"      </a>",
"      ]. The serum creatinine is relatively stable for at least five years in most of these patients, with progression to end-stage renal disease (ESRD) or renal death occurring in less than 5 percent in one report [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimal therapeutic approach in these patients is not known. Most of the authors and peer reviewers of this topic would consider a trial of one of the following options (in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    therapy) for patients who are normotensive, have subnephrotic proteinuria, a normal serum creatinine, and",
"    <strong>",
"     no",
"    </strong>",
"    necrotizing or crescentic lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucocorticoids alone &ndash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      60",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for one week, tapered to 15",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      during the first three months of therapy, and then continued for another three months. Thereafter, the prednisone dose can be gradually decreased by 2.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      every two to three weeks, assuming that there is no flare or worsening of the renal disease.",
"     </li>",
"     <li>",
"      Glucocorticoids plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      &ndash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      (using the regimen described in the preceding bullet) in combination with azathioprine 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, which is continued for at least two years (possibly indefinitely, unless serious side effects such as recurrent skin cancers occur).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, because of the potential for sampling error on kidney biopsy, it is difficult to be certain that necrotizing or crescentic lesions are absent. Thus, some experts would treat patients who had focal proliferative LN and a relatively benign clinical presentation with glucocorticoids in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF) as if the patient had either diffuse proliferative nephritis or a more worrisome clinical presentation. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Mycophenolate mofetil'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If glucocorticoids alone or glucocorticoids plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    are used to treat patients with focal proliferative LN and a relatively benign clinical presentation, the therapeutic goals are loss of hematuria and reduced proteinuria. However, standard induction therapy with a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    -based or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    -based regimen is warranted if such patients treated with these two less aggressive strategies either do not respond or develop signs of more severe disease, such as extensive focal necrotizing lesions, increasing proteinuria, hypertension,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a rise in serum creatinine. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Induction therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Criteria for clinical remission",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, failure to achieve clinical remission, particularly complete remission, is associated with worse long-term outcomes in patients with proliferative LN. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Failure to achieve clinical remission'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There has been no consensus on the optimal definition of remission with immunosuppressive therapy in patients with proliferative LN. The goal of such therapy is resolution of immunologic activity. Among patients with proliferative LN, cessation of inflammation is characterized by resolution of hematuria, pyuria, and cellular casts, a reduction in protein excretion, and a reduction in or stabilization of the serum creatinine. The serum creatinine and protein excretion may not return to normal due to irreversible injury during the active phase of the disease and, as can occur in most forms of proteinuric chronic kidney disease, progressive glomerulosclerosis with increasing nonnephrotic proteinuria can occur over time in the absence of inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=see_link\">",
"     \"Secondary factors and progression of chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We believe that attaining an inactive urinary sediment is an essential component of a complete immunologic remission. We agree with the criteria used in a large randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/37\">",
"     37",
"    </a>",
"    ]. An inactive urinary sediment was defined as &le;5 red blood cells per high power field, &le;5 white blood cells per high power field, a reading of 0 to 1+ on the urine dipstick for heme, and no red cell casts. Complete remission in this and other trials also required normalization of the serum creatinine and protein excretion below 500",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    However, some patients may be in complete immunologic remission without attaining these latter two criteria due to irreversible injury induced during the active phase of the disease.",
"   </p>",
"   <p>",
"    A potential problem in defining an inactive urine sediment in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    is that bladder toxicity from such therapy can cause hematuria that is unrelated to the glomerulonephritis and would not produce either dysmorphic red cells or red cell and other cellular casts. Thus, some have suggested that disappearance of dysmorphic red cells and red cell and other cellular casts could be a surrogate for an inactive sediment in cyclophosphamide-treated patients with persistent hematuria. However, the identification of dysmorphic red cells and cellular casts requires considerable experience. Hematuria due to bladder toxicity is not an issue with other drugs used in the treatment of proliferative LN, such as MMF. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=see_link&amp;anchor=H1824471562#H1824471562\">",
"     \"Etiology and evaluation of hematuria in adults\", section on 'Red cell morphology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=see_link&amp;anchor=H15#H15\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\", section on 'Bladder toxicity with CYC'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although reduced proteinuria is an important marker of a successful response to immunosuppressive therapy, the maximum reduction in protein excretion is typically seen much later (ie, by many months) than resolution of the activity of the urine sediment. In several trials of diffuse proliferative lupus nephritis, proteinuria ranging from 1 to 1.6",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    after six months of induction therapy was associated with satisfactory long-term renal outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Delayed renal recovery after removal of the offending stimulus is well described in other settings. As an example, studies in patients with drug-induced membranous nephropathy have shown that the average time to resolve proteinuria is one year after discontinuation of the offending drug, with some patients requiring three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Similar findings are described among patients with poststreptococcal glomerulonephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=see_link\">",
"     \"Causes and diagnosis of membranous nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35304?source=see_link\">",
"     \"Poststreptococcal glomerulonephritis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to pregnancy in women with LN and the safety of immunosuppressive drugs to treat active lupus during pregnancy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/45/39641?source=see_link&amp;anchor=H4#H4\">",
"     \"Pregnancy in women with systemic lupus erythematosus\", section on 'Lupus nephritis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     INDUCTION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induction therapy refers to the initial intensive therapeutic regimen given in an attempt to produce remission of active disease. We agree with the Kidney Disease: Improving Global Outcomes",
"    <sup>",
"    </sup>",
"    (KDIGO) clinical practice guidelines and the joint European League Against Rheumatism and European Renal Assocaition-European Dialysis and Transplant Association",
"    <span class=\"nowrap\">",
"     (EULAR/ERA-EDTA)",
"    </span>",
"    guidelines that induction therapy should consist of glucocorticoids combined with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. If, during the first three months of induction therapy, there is clinical progression of renal disease (eg, worsening serum creatinine",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    proteinuria), the immunosuppressive agent should be changed (ie, cyclophosphamide changed to MMF or MMF changed to cyclophosphamide).",
"   </p>",
"   <p>",
"    Induction therapy is followed in almost all patients by a more prolonged period of maintenance therapy, designed to reduce the frequency of relapses, usually with less toxic drugs.",
"   </p>",
"   <p>",
"    The relevant data for the different induction therapies will be briefly reviewed here. The individual clinical trials are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/55/4985?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical trials of immunosuppressive therapy in proliferative lupus nephritis\", section on 'Induction therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described in the following section, glucocorticoid therapy alone is significantly less effective than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    plus glucocorticoids for induction therapy. In patients with severe active disease (eg, acute kidney injury, florid crescentic glomerulonephritis, severe extrarenal disease), glucocorticoid therapy is initiated with intravenous pulse",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (500 to 1000 mg given over 30 minutes daily for three days) to induce a rapid immunosuppressive effect. Conventional doses of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    may be ineffective in these patients, and a response to intravenous cyclophosphamide, which is begun at the same time as glucocorticoid therapy, is not seen for 10 to 14 days. In patients without severe active disease, we use conventional doses of oral glucocorticoids (eg, 0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of prednisone) without a pulse; the doses are described below. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Dosing'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H18\">",
"     'Mycophenolate mofetil'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The benefit of pulse",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    to induce a rapid remission among patients with severe lupus nephritis (LN) is derived primarily from demonstration of efficacy in patients with rapidly progressive (crescentic) glomerulonephritis of all causes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/51/18231?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of the classification and treatment of rapidly progressive (crescentic) glomerulonephritis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of clinical trials have demonstrated a benefit of intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    plus glucocorticoids compared to glucocorticoids alone or with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    on renal survival among patients with proliferative LN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Landmark trials performed at the National Institutes of Health (NIH) compared monthly intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    plus prednisone or prednisone alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. At 10 to 12 years, the probability of avoiding renal failure among survivors was 90 percent with intravenous cyclophosphamide, 60 percent with azathioprine, and 20 percent with prednisone alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/43\">",
"     43",
"    </a>",
"    ]. In the NIH and other trials, the outcomes with azathioprine were better than those with prednisone alone during the first 10 years of follow-up, but not during longer follow-up, and were clearly inferior to cyclophosphamide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/43,45\">",
"     43,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These differences in outcome between intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    plus glucocorticoids and glucocorticoids alone became apparent after several years. In one of the NIH trials, for example, treatment failure (defined as doubling of the serum creatinine, requiring supplemental immunosuppression, or death) was significantly less likely with combination therapy than with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/46\">",
"     46",
"    </a>",
"    ]. However, the treatment failure curves did not diverge until two to three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/46\">",
"     46",
"    </a>",
"    ], and the end-stage renal disease (ESRD) curve did not diverge until five or more years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a 2004 meta-analysis,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    plus glucocorticoids compared with glucocorticoids alone (most patients were from NIH trials) significantly reduced the risk of doubling of the serum creatinine in four trials of 228 patients (24 versus 40 percent, risk ratio [RR] 0.59, 95% CI 0.40-0.88), had no effect on mortality in five trials of 226 patients (21 versus 17 percent, RR 0.98, 95% CI 0.53-1.82), and increased the risk of ovarian failure in three trials of 147 patients (47 versus 19 percent, RR 2.18, 95% CI 1.10-4.34) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although pulse intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    has been best studied for induction therapy in diffuse proliferative LN and is most widely used, daily oral cyclophosphamide has also induced remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/38,47,48\">",
"     38,47,48",
"    </a>",
"    ], including a short course regimen followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    maintenance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    regimen used in the NIH trials was pulse intravenous cyclophosphamide (0.5 to 1",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    monthly for six months and then quarterly for at least two years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. This regimen is associated with an appreciable incidence of adverse events. In one trial, for example, osteonecrosis occurred almost as frequently as with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    alone, infections and amenorrhea were more frequent with cyclophosphamide, and all three deaths were in the cyclophosphamide groups (",
"    <a class=\"graphic graphic_table graphicRef62047 \" href=\"mobipreview.htm?31/27/32187\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result of concerns about toxicity, both less intensive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    regimens and, as described below, induction therapy with MMF have been evaluated. The efficacy of less intensive regimens has been evaluated in a number of relatively small trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/39,47,49,50\">",
"     39,47,49,50",
"    </a>",
"    ]. The Euro-Lupus trial, for example, was a comparative trial of primarily white patients with mild to moderate renal insufficiency (mean serum creatinine 1.15",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [102",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    that showed equivalent outcomes at a median of 41 months with the shorter (lower-dose, ie 500 mg intravenously every two weeks for a total of six doses) and longer (higher-dose) intravenous cyclophosphamide regimens, each followed by maintenance therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/49\">",
"     49",
"    </a>",
"    ]. The similarity in outcomes persisted at 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/51\">",
"     51",
"    </a>",
"    ]. On multivariate analysis, a good early response to therapy was predictive of better long-term outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20804573\">",
"    <span class=\"h4\">",
"     Dosing according to ancestry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are no randomized, controlled data, our clinical experience suggests that African-American, Afro-Caribbean, and Hispanic patients do not respond as well as white patients to shorter (lower-dose)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    induction regimens, such as the one used in the Euro-Lupus trial. In that trial, only 9 percent of patients were characterized as Afro-Caribbean or black [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/49\">",
"     49",
"    </a>",
"    ], and the majority of those were randomly assigned to longer (higher-dose) therapy; only three Afro-Caribbean or black patients received shorter (lower-dose) cyclophosphamide.",
"   </p>",
"   <p>",
"    Thus, in black or Hispanic patients requiring induction immunosuppressive therapy, most of us use either MMF or a longer (higher-dose) course of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (0.5 to 1",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    monthly for six or seven months) in combination with glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/39\">",
"     39",
"    </a>",
"    ]. In contrast, when cyclophosphamide is used for induction in white patients of European ancestry, we use a short course, lower-dose regimen.",
"   </p>",
"   <p>",
"    In patients in the Euro-Lupus trial mentioned above, those assigned to a shorter (lower-dose) therapy had similar outcomes as compared with those assigned a longer (higher-dose) course of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , regardless of the baseline severity in renal function. Thus, in white patients who are selected for therapy with cyclophosphamide, we use a shorter (lower-dose) regimen.",
"   </p>",
"   <p>",
"    After induction with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , maintenance therapy commences with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or MMF rather than the longer course of cyclophosphamide used in the NIH trials. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Maintenance immunosuppression'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    To summarize, when using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    as the induction agent (rather than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil), we use different regimens according to ancestry:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In African-Americans, Afro-Caribbeans, and Hispanics, we use a longer (higher-dose) course of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (0.5 to 1",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      intravenous pulses monthly for six or seven months) in combination with glucocorticoids.",
"     </li>",
"     <li>",
"      In whites, we use a shorter (lower-dose) course of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (six 500 mg intravenous pulses every two weeks) in combination with glucocorticoids, as was used in Euro-Lupus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several glucocorticoid regimens have been used in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . After three daily pulses (if needed),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is given at 0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for one to three months, followed by a taper toward maintenance doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;MMF is an alternative to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    as initial therapy for proliferative LN. Several prospective trials have addressed this issue with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    being at least equivalent (but not superior) to cyclophosphamide. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/55/4985?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical trials of immunosuppressive therapy in proliferative lupus nephritis\", section on 'Mycophenolate mofetil'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The best data are from an international trial (ALMS) that compared induction therapy with MMF or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    in 370 patients with LN: diffuse proliferative with or without membranous LN was present in 68 percent; focal proliferative with or without membranous LN in 16 percent; and pure membranous LN in 16 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/37\">",
"     37",
"    </a>",
"    ]. The mean urine protein-to-creatinine ratio was 4.1, and the mean serum creatinine was 1.1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (100",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"   </p>",
"   <p>",
"    The following regimens were used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MMF (0.5 g twice daily in week one, 1 g twice daily in week two, and a target of 1.5 g twice daily thereafter or, if not tolerated, 1 g three to two times daily). MMF was taken before meals and with a glass of water.",
"     </li>",
"     <li>",
"      Monthly intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (0.75",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      first dose, followed by five infusions of 0.5 to 1",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"       ).",
"      </span>",
"     </li>",
"     <li>",
"      All patients were also treated with oral daily glucocorticoids (using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      or an equivalent dose of another preparation). The prednisolone regimen began at a dose of 60",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      tapered every two weeks by 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      until 40",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      was reached, followed by tapering by 5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      until 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      was reached. Further tapering was allowed if the patient was stable for four weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The primary outcome was a prespecified reduction in the urine protein-to-creatinine ratio to less than three or by at least 50 percent. Secondary outcomes included stabilization or improvement of the serum creatinine, reduction of protein excretion to less than 0.5",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    and attainment of an inactive urinary sediment.",
"   </p>",
"   <p>",
"    At 24 weeks, there was no difference between groups in the percentage of patients who achieved the primary end point (56 versus 53 percent) or secondary end points, in the response rate between patients with focal or diffuse proliferative and those with membranous LN, or in the rate of adverse effects. On subset analysis, MMF therapy was associated with a significantly higher response rate in black and Latino patients (60 versus 39 percent, odds ratio 2.4, 95% CI 1.1-5.4) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/53\">",
"     53",
"    </a>",
"    ]. The worse outcomes associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    in blacks have been observed by others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a meta-analysis that included 45 trials involving 2846 patients, there were no significant differences between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    -based and MMF-based induction therapy with respect to mortality, incidence of end-stage renal disease, and relapse during induction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. However, MMF produced a numerically higher rate of complete remissions (19.5 versus 13.8 percent), although this was not statistically significant. Major infections were also similar with both drugs, but MMF therapy resulted in less ovarian failure and alopecia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The findings from these trials and the meta-analyses of these trials suggest that, compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , an MMF induction regimen provides similar efficacy and possibly fewer adverse effects. In addition, MMF may be more effective than cyclophosphamide and therefore preferred in black and Hispanic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/27,53\">",
"     27,53",
"    </a>",
"    ], although this is based upon a post-hoc analysis of trials.",
"   </p>",
"   <p>",
"    There are several limitations to the findings in the MMF trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/56\">",
"     56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was a short duration of follow-up of 6 to 12 months in most of the trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/37,57\">",
"       37,57",
"      </a>",
"      ]. The potential importance of prolonged follow-up was illustrated in an NIH trial cited above [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/46\">",
"       46",
"      </a>",
"      ]. Although treatment failure (defined as doubling of the serum creatinine, requiring supplemental immunosuppression, or death) was significantly less likely with combination pulse therapy or with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      alone than with pulse",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      alone; the outcome curves did not diverge until two to three years.",
"     </li>",
"     <li>",
"      The patients did not have severe disease, as the mean serum creatinine was approximately 1.1",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (97",
"      <span class=\"nowrap\">",
"       micromol/L),",
"      </span>",
"      and mean protein excretion ranged from 3 to 4.7",
"      <span class=\"nowrap\">",
"       g/day.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Plasmapheresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasmapheresis was of",
"    <strong>",
"     no",
"    </strong>",
"    added benefit to immunosuppressive therapy in patients with LN (LN) in randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/58,59\">",
"     58,59",
"    </a>",
"    ], although benefit has been suggested in observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/60\">",
"     60",
"    </a>",
"    ]. In addition, plasmapheresis plus cytotoxic therapy compared to cytotoxic therapy alone has been associated with increased number of significant adverse events, including serious infection and death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest randomized controlled trial of 86 patients with diffuse proliferative LN with or without membranous LN showed that treatment with plasmapheresis,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , and short-term oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    led to a more rapid decline in circulating autoantibody levels but no difference in outcome when compared with treatment with prednisone and cyclophosphamide alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/59\">",
"     59",
"    </a>",
"    ]. The percentage of patients progressing to renal failure (25 versus 17 percent) and attaining clinical remission (30 versus 28 percent) was the same in both groups. A similar lack of significant benefit was noted in a 2004 systematic review [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not advocate plasmapheresis for most patients with diffuse proliferative LN in view of the limited evidence of efficacy and possible increased toxicity when performed in those treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . However, plasmapheresis may have a role in selected patients, such as those with severe crescentic LN who require dialysis (especially those with concomitant ANCA, extrapolating from the MEPEX trial of patients with granulomatosis with polyangiitis [Wegener&rsquo;s]) or those with proliferative LN and a microangiopathy due to thrombotic thrombocytopenic purpura associated with antiphospholipid antibodies or auto-antibodies to ADAMTS13. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/32/34314?source=see_link&amp;anchor=H21#H21\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Role of plasma exchange'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35287?source=see_link&amp;anchor=H11#H11\">",
"     \"Antiphospholipid syndrome and the kidney\", section on 'Acute renal failure'",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18812642\">",
"    <span class=\"h2\">",
"     Tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    has been compared with both intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and MMF as induction therapy in small trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       Tacrolimus",
"      </a>",
"      was compared to intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      for induction therapy in a multicenter noninferiority trial that included 61 Chinese patients with focal or diffuse proliferative LN [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/62\">",
"       62",
"      </a>",
"      ]. Patients received glucocorticoids plus either tacrolimus (titrated to a trough level of 5 to 10",
"      <span class=\"nowrap\">",
"       ng/mL)",
"      </span>",
"      or cyclophosphamide (500 to 1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      monthly for six pulse treatments). At six months, there was no difference among groups in the number who achieved complete remission (defined as protein excretion less than 300",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      normal urinalysis, and stable kidney function).",
"     </li>",
"     <li>",
"      In a similar study, 60 Chinese patients with focal or diffuse proliferative LN or membranous lupus were randomly assigned to induction therapy with glucocorticoids combined with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      , MMF, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/63\">",
"       63",
"      </a>",
"      ]. There were no differences in the proportion who achieved complete or partial remission and no differences in the occurrence of adverse events.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Largely due to short-term follow-up, these limited data are insufficient to support the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    as induction therapy for severe LN, except possibly for patients who cannot tolerate either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or MMF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8472617\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    therapy combined with glucocorticoids and MMF for induction therapy in proliferative LN was evaluated in the multinational LUpus Nephritis Assessment with Rituximab (LUNAR) study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/64\">",
"     64",
"    </a>",
"    ]. Patients (n = 144) with class III or class IV LN were randomly assigned to receive an intravenous infusion of placebo or 1 g of rituximab on baseline, 2 weeks, 24 weeks, and 26 weeks. All patients also received MMF 1 g given thrice daily for at least 52 weeks, intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    1000 mg given twice during the first three days of therapy, and a tapering dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . Patients were followed for 52 weeks for the occurrence of complete or partial remission. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of complete or partial remission was numerically higher with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      as compared with placebo (57 versus 46 percent), but this difference was not statistically significant.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"      produced greater reductions in anti-DNA titers and larger improvements in complement levels as compared with placebo.",
"     </li>",
"     <li>",
"      Two patients died, both in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      group, although these were not considered to be related to rituximab. The frequency of serious infections and hospitalizations, at least over the short term, were similar with rituximab and placebo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, there are insufficient data to support the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    as initial induction therapy for proliferative LN. The use of rituximab in patients with resistant or relapsing LN is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/3/12345?source=see_link&amp;anchor=H7#H7\">",
"     \"Therapy of resistant or relapsing diffuse or focal proliferative lupus nephritis\", section on 'Rituximab for cyclophosphamide and MMF resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressive therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and glucocorticoids has both infectious and noninfectious toxicities that warrant prophylaxis. The recommended regimens are discussed elsewhere:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For prevention of Pneumocystis pneumonia (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9289?source=see_link&amp;anchor=H16#H16\">",
"       \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Systemic lupus erythematosus'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For prevention of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      -induced bladder and gonadal toxicity (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=see_link&amp;anchor=H12#H12\">",
"       \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\", section on 'Prevention of gonadal toxicity'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=see_link&amp;anchor=H16#H16\">",
"       \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\", section on 'Prevention of bladder toxicity'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For minimizing glucocorticoid-induced bone loss and other adverse effects (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link\">",
"       \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"       \"Major side effects of systemic glucocorticoids\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Choice of induction agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;For initial induction therapy in patients with diffuse or moderate to severe focal proliferative LN, we recommend immunosuppressive therapy with either an intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    - or MMF-based regimen. This recommendation is in agreement with both the KDIGO and",
"    <span class=\"nowrap\">",
"     EULAR/ERA-EDTA",
"    </span>",
"    guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The choice between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and MMF depends upon a variety of factors. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Ancestry",
"      </strong>",
"      &ndash; Limited studies suggest that black and Hispanic patients may be more likely to achieve remission with MMF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/37\">",
"       37",
"      </a>",
"      ]. Among such patients, it is important to recognize that long-term data on the efficacy of MMF are limited since most of the trials had a follow-up of less than one year. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Mycophenolate mofetil'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Disease severity",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      may be preferred in patients with more severe disease (eg, substantial elevation in serum creatinine",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      crescents on renal biopsy). The patients in the MMF trials did not have severe disease at presentation, as the mean serum creatinine was approximately 1.1",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (97",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      and mean protein excretion ranged from 3 to 4.7",
"      <span class=\"nowrap\">",
"       g/day.",
"      </span>",
"     </li>",
"     <li>",
"      <strong>",
"       Patient preference",
"      </strong>",
"      &ndash; Patient preference is important. As an example, a woman of child-bearing age may want to avoid the ovarian toxicity of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    -based induction regimen is chosen, our suggestions pertaining to the specific regimens are discussed above. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Dosing'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Both are given with an initial pulse of intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (3 daily pulses of 750 mg), followed by oral glucocorticoids (initial dose of 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    for four weeks, which is subsequently tapered to low-dose maintenance therapy). Maintenance immunosuppression with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or MMF is given to all patients. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Maintenance immunosuppression'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If the leukocyte nadir after the first pulse of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (usually 10 to 14 days post-infusion) is less than",
"    <span class=\"nowrap\">",
"     4000/microL",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the absolute neutrophil count is less than",
"    <span class=\"nowrap\">",
"     1500/microL,",
"    </span>",
"    the dose at the next infusion should be reduced by 0.25",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    body surface area or even transiently withheld if the counts are very low. If, on the other hand, the total white cell nadir is greater than",
"    <span class=\"nowrap\">",
"     4000/microL,",
"    </span>",
"    the absolute neutrophil count is greater than",
"    <span class=\"nowrap\">",
"     1500/microL,",
"    </span>",
"    and the patient has not improved, the cyclophosphamide dose at the next infusion may be increased by 0.25",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    body surface area. The maximum dose is 1",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    body surface area.",
"   </p>",
"   <p>",
"    If an MMF-based regimen is chosen as initial therapy, the preferred regimen is the one used in the ALMS trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MMF is started at a dose of 500 mg twice daily, which is increased by increments of 500 mg per week to a maximum dose of 3",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      based upon clinical response and the ability to tolerate side effects.",
"     </li>",
"     <li>",
"      Concurrent therapy with oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      is started a dose of 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (maximum 60",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      which should not be continued for more than eight weeks. This is tapered over a period of weeks to months in initial decrements of 5 to 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      per week and then much more slowly (as little as 1",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      per month at doses below 10",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      The goal is to attain the minimum prednisone dose required for control of extrarenal symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The MMF plus glucocorticoid induction regimen is given for six months, which is followed by a maintenance regimen. If remission is not achieved by six months, the patient is considered resistant to MMF and should be treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    We suggest plasmapheresis in selected patients with diffuse proliferative LN. Such patients include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those with severe LN and underlying crescentic glomerulonephritis who have already progressed to require dialysis (extrapolating from the MEPEX trial of patients with granulomatosis with polyangiitis [Wegener&rsquo;s]). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Plasmapheresis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Those with antiphospholipid antibodies or thrombotic thrombocytopenic purpura. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/32/34314?source=see_link&amp;anchor=H21#H21\">",
"       \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Role of plasma exchange'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35287?source=see_link&amp;anchor=H11#H11\">",
"       \"Antiphospholipid syndrome and the kidney\", section on 'Acute renal failure'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Combined diffuse proliferative and membranous LN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with combined diffuse proliferative and membranous LN have a worse prognosis than those with diffuse proliferative disease alone, which has raised the possibility that such patients may benefit from more intensive therapy. These observations led to a clinical trial of 40 such patients showing significantly better outcomes with MMF plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    compared to intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ; all patients were treated with glucocorticoids. Twenty-six of the 40 patients had previously been treated with cyclophosphamide or MMF. As a result, we have elected to present the data in the topic on resistant or relapsing disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/3/12345?source=see_link&amp;anchor=H15#H15\">",
"     \"Therapy of resistant or relapsing diffuse or focal proliferative lupus nephritis\", section on 'Diffuse proliferative plus membranous LN'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     MAINTENANCE IMMUNOSUPPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 50 percent of patients with proliferative lupus nephritis (LN) relapse following reduction in or cessation of immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/65-70\">",
"     65-70",
"    </a>",
"    ]. The relapse rates range from 5 to 15 per 100 patient years, with an average of about 8 per 100 patient years for the first five years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/70\">",
"     70",
"    </a>",
"    ]. Relapse is more common when partial rather than complete remission is obtained with induction therapy. Thus, once a patient has attained a complete or partial remission, immunosuppression is continued to help maintain the remission and decrease the risk of developing end-stage renal disease (ESRD) (maintenance therapy). This recommendation is consistent with that made by the Kidney Disease: Improving Global Outcomes",
"    <sup>",
"    </sup>",
"    (KDIGO) clinical practice guidelines for glomerulonephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/3/12345?source=see_link&amp;anchor=H9#H9\">",
"     \"Therapy of resistant or relapsing diffuse or focal proliferative lupus nephritis\", section on 'Relapsing disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Choice of maintenance agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal choice of immunosuppressive agent following induction of remission is not well defined although, as discussed below, we prefer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF) as a maintenance agent. In addition, the optimal duration of maintenance therapy is not well defined, although 12 to 24 months of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or MMF have been best studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/39,48,49,65,71\">",
"     39,48,49,65,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternatives to MMF or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    include cyclosporin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . In one trial,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    was as effective as azathioprine but was associated with more adverse effects and is cumbersome to administer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/48\">",
"     48",
"    </a>",
"    ]. In another trial, intravenous cyclophosphamide every three months was less effective than azathioprine or MMF maintenance and was associated with a significantly higher rate of infection and amenorrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/55/4985?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical trials of immunosuppressive therapy in proliferative lupus nephritis\", section on 'Maintenance therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The preference for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or MMF for maintenance immunosuppression is primarily based upon a randomized trial of 59 patients with severe LN (46 with diffuse proliferative, 12 with focal proliferative, and 1 with membranous lupus) who received induction therapy with four to a maximum of seven consecutive monthly cycles of intravenous pulse",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/39\">",
"     39",
"    </a>",
"    ]. All but three of the patients were black or Hispanic, who typically have a worse prognosis than whites and respond less well to cyclophosphamide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/27\">",
"     27",
"    </a>",
"    ]. The applicability of the findings to white patients is uncertain. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Race and ethnicity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Remission was induced in 83 percent, and patients who remitted early had fewer cycles of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . The patients were then randomly assigned to maintenance therapy with one of the following plus low-dose oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (0.1 to 0.2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day): MMF (500 to 3000",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (1 to 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day), or intravenous cyclophosphamide (0.5 to 1",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three months). The median treatment duration was 24, 29, and 30 months for the cyclophosphamide, MMF, and azathioprine groups, respectively.",
"   </p>",
"   <p>",
"    The primary end points were renal and patient survival. At six year follow-up, the event-free survival rate for the composite end point for patient and renal survival was significantly higher with MMF and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (90 and 80 versus 45 percent) which was also associated with more infections and a higher incidence of amenorrhea. Seventeen patients (29 percent) had a renal relapse (three, six, and eight patients in the MMF, azathioprine, and cyclophosphamide groups, respectively). The relapse rate was significantly higher with cyclophosphamide compared with MMF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H135586886\">",
"    <span class=\"h3\">",
"     Azathioprine versus mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and MMF, the two preferred agents for maintenance therapy in patients with proliferative LN, was best evaluated in a meta-analysis of six trials involving 514 patients, three of which compared azathioprine with MMF for maintenance therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Although there were no significant differences in the risk of mortality or end-stage renal disease, MMF therapy resulted in a significantly lower rate of renal relapse (16.4 versus 30.2 percent). The rate of adverse effects was similar with both drugs. Of the three randomized trials included in this meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/39,71,72\">",
"     39,71,72",
"    </a>",
"    ], MAINTAIN Nephritis and ALMS Maintenance were the largest:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The MAINTAIN Nephritis Trial was a randomized open label trial that included 105 European patients (83 Caucasian) with biopsy-proven LN and protein excretion exceeding 500",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/71\">",
"       71",
"      </a>",
"      ]. Diffuse proliferative was present in 61, focal proliferative LN in 33, and membranous LN in 11. All patients were treated with three daily 750 mg doses of intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      followed by oral glucocorticoids plus six 500 mg intravenous doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      over ten weeks. On week 12, maintenance therapy was initiated with either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) or MMF (2",
"      <span class=\"nowrap\">",
"       g/day).",
"      </span>",
"      Renal relapse was defined as one or more of the following: recurrence or development of nephrotic syndrome; a 33 percent or greater increase in serum creatinine within one month; or a threefold increase in proteinuria accompanied by hematuria.",
"      <br/>",
"      <br/>",
"      At three years, there was no significant difference between the MMF and azathioprine groups in the rate of renal relapse (19 versus 25 percent), systemic flares, or steroid withdrawal. In addition, protocol biopsies at two years revealed no significant histologic differences between the groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/73\">",
"       73",
"      </a>",
"      ]. Adverse events were similar in the two groups except for leukopenia and anemia, which occurred more frequently in the azathioprine group (14 versus 2 patients).",
"     </li>",
"     <li>",
"      The ALMS Maintenance Trial was a multinational study in which 227 patients who had achieved remission with either MMF or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      were randomly assigned to MMF (1 g twice daily) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) as maintenance therapy for 36 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/74\">",
"       74",
"      </a>",
"      ]. Results from the induction phase of the ALMS trial are discussed above. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Mycophenolate mofetil'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Among patients who responded to induction therapy with either MMF or cyclophosphamide, treatment failure at 36 months (defined by renal relapse, the need to intensify therapy, doubling of the serum creatinine, or death) was significantly lower with MMF compared with azathioprine groups (16 versus 32 percent). The superiority of MMF was independent of the type of induction therapy, race, or region.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, MMF compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    is associated with a statistically and clinically significant reduction in relapse rate, and no increase in adverse effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Initiation of maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upon completion of induction therapy with achievement of a complete or partial remission, we recommend initiation of maintenance immunosuppressive therapy. Either MMF or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    can be used for maintenance therapy, although there are some circumstances in which one or the other might be preferred:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MMF is preferred in patients who were induced into complete or partial remission with MMF. The usual maintenance dose (1000 mg twice daily) is lower than the usual induction dose (1500 mg twice daily or, if not tolerated, 1000 mg three times to two times daily).",
"     </li>",
"     <li>",
"      Based upon the preliminary results from the ALMS Maintenance Trial, we suggest MMF for patients who were induced with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      is preferred in women who are in complete remission and want to become pregnant.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      is an alternative if azathioprine is not tolerated. MMF has a boxed warning because of an increased risk of congenital malformations and spontaneous abortion.",
"     </li>",
"     <li>",
"      Patients who do not tolerate MMF or AZA should be treated with the other drug. As an example, a patient taking AZA should be switched to MMF if recurrent skin cancers develop. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10232?source=see_link&amp;anchor=H7#H7\">",
"       \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\", section on 'Adverse effects'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2855?source=see_link&amp;anchor=H4#H4\">",
"       \"Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases\", section on 'Adverse effects'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We recommend the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maintenance therapy is started two to four weeks",
"      <strong>",
"       after",
"      </strong>",
"      the last dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      when the following criteria are met: the white blood cell count is &gt;4000",
"      <span class=\"nowrap\">",
"       cells/microL,",
"      </span>",
"      and the absolute neutrophil count (ANC) is &gt;1500",
"      <span class=\"nowrap\">",
"       cells/microL.",
"      </span>",
"      The risk of infection is increased when the ANC is less than 1000",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      (",
"      <a class=\"graphic graphic_table graphicRef63903 \" href=\"mobipreview.htm?10/19/10555\">",
"       table 2",
"      </a>",
"      ). The ANC is equal to the product of the total white blood cell count and the fraction of polymorphonuclear cells and band forms noted on the differential analysis (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?12/1/12305?source=see_link\">",
"       calculator 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The usual maintenance dose of MMF is 1000 mg twice daily. The dose may be tapered over time in stable patients. In one trial, the MMF dose was 1500",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      in the first year, 1000 to 1250",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      in the second year, and 500 to 1000",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      in the third year [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      dose is 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day to a maximum of 150 to 200",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      The duration of maintenance therapy is 18 to 24 months or longer, and some expert panels suggest that maintenance therapy be continued for at least three years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Glucocorticoid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low-dose oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (or its equivalent) is continued in most patients receiving maintenance therapy. The goal is to attain the minimum prednisone dose required for control of extrarenal symptoms and varies among patients. In different trials, the maintenance prednisone dose ranged from 0.05 to 0.2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/37/37466/abstract/39,48,49,65\">",
"     39,48,49,65",
"    </a>",
"    ]. Switching to alternate day therapy can be tried, but, in our experience, patients with lupus often do not tolerate this regimen, complaining of aches and pain on the off days.",
"   </p>",
"   <p>",
"    Patients who remain asymptomatic can be slowly tapered off",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . Once the prednisone dose reaches 5",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    tapering should proceed at a rate of 1",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    reduction in dose every four weeks. However, some clinicians prefer prolonged low-dose prednisone therapy (eg, 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or less).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/49/36626?source=see_link\">",
"       \"Patient information: Lupus and kidney disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical risk factors for progression of proliferative lupus nephritis (LN) include an elevated serum creatinine at the time of renal biopsy, hypertension, nephrotic range proteinuria, anemia, patients who are black or Hispanic, and, on renal biopsy, crescents and concurrent tubulointerstitial disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk factors for progression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prompt diagnosis and therapy and attainment of clinical remission of active proliferative LN are associated with an improved long-term prognosis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Failure to achieve clinical remission'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Nonimmunosuppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonimmunosuppressive therapy is given to almost all patients with proliferative LN, even those who require treatment with immunosuppressive drugs. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Nonimmunosuppressive therapies'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with persistent proteinuria, we recommend angiotensin inhibition with an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We initiate monotherapy and target a minimum reduction in protein excretion of at least 60 percent from the baseline value with a goal of less than 500 to 1000",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      The goal blood pressure is less than",
"      <span class=\"nowrap\">",
"       130/80",
"      </span>",
"      mmHg. The supportive data are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H11#H11\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Effect of renin-angiotensin system inhibitors on progression of CKD'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H149378842#H149378842\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Proteinuria goal'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H24#H24\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Blood pressure goal'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Therapy may also be directed against dyslipidemia and hypercoagulability in patients with the nephrotic syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=see_link\">",
"       \"Lipid abnormalities in nephrotic syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=see_link\">",
"       \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Immunosuppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressive therapy for proliferative LN consists of induction and maintenance phases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Induction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induction therapy involves the administration of immunosuppressive drugs to achieve clinical remission; delayed initiation of such therapy and failure to attain clinical remission are associated with worse outcomes. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Immunosuppressive therapy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4\">",
"     'Failure to achieve clinical remission'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with mild focal proliferative LN (defined as less than 25 percent of the glomeruli affected on light microscopy and",
"      <strong>",
"       no",
"      </strong>",
"      necrotizing or crescentic lesions, normal blood pressure and serum creatinine, and subnephrotic proteinuria), we suggest one of the following options rather than glucocorticoids combined with either MMF or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The goals of therapy are loss of hematuria and reduced proteinuria. Patients who do not respond, or who progress, are treated as if they have diffuse proliferative LN:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Glucocorticoids alone &ndash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      60",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for one week, tapered to 15",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      during the first three months of therapy, and then continued for another three months. Thereafter, the prednisone dose can be gradually decreased by 2.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      every two to three weeks, assuming that there is no flare or worsening of the renal disease.",
"     </li>",
"     <li>",
"      Glucocorticoids plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      &ndash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      (using the regimen described in the preceding bullet) in combination with azathioprine 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, which is continued for at least two years (possibly indefinitely, unless serious side effects such as recurrent skin cancers occur).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who have moderate to severe focal proliferative or have diffuse proliferative LN, we recommend the initiation of immunosuppressive therapy with glucocorticoids given with either intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      or oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil (MMF) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The regimens are presented above. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Cyclophosphamide'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Mycophenolate mofetil'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice between intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and oral MMF depends upon the clinical features (eg, MMF may be preferred in blacks and Hispanics) and upon patient preference (eg, a young woman may want to avoid the potential ovarian toxicity of cyclophosphamide). We recommend intravenous cyclophosphamide in patients with more severe disease (eg, substantial elevation in serum creatinine",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      crescents on renal biopsy) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      -based therapy is chosen, we suggest a longer (higher-dose) regimen in African-Americans, Afro-Caribbeans, and Hispanics, and a shorter (lower-dose) regimen in whites (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Dosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If an MMF-based regimen is chosen, we suggest the regimen in the ALMS trial. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Mycophenolate mofetil'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with severe active disease (eg, acute renal failure, florid crescentic glomerulonephritis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severe extrarenal disease), we recommend that, in addition to intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , glucocorticoid therapy be initiated with intravenous pulse",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (500 to 1000 mg given over 30 minutes daily for three days) to induce a rapid immunosuppressive effect since conventional doses of oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      may be ineffective and a response to intravenous cyclophosphamide is not seen for 10 to 14 days (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/51/18231?source=see_link\">",
"       \"Overview of the classification and treatment of rapidly progressive (crescentic) glomerulonephritis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Maintenance",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that all patients who have completed induction therapy and attained partial or complete remission be treated with maintenance immunosuppressive therapy for 18 to 24 months or longer (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Maintenance immunosuppression'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maintenance therapy is started two to four weeks",
"      <strong>",
"       after",
"      </strong>",
"      the last dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      when the following criteria are met: the white blood cell count is &gt;4000",
"      <span class=\"nowrap\">",
"       cells/microL,",
"      </span>",
"      and the absolute neutrophil count (ANC) is &gt;1500",
"      <span class=\"nowrap\">",
"       cells/microL.",
"      </span>",
"      The risk of infection is increased when the ANC is less than 1000",
"      <span class=\"nowrap\">",
"       cells/microL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Initiation of maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have been successfully induced with MMF or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , we recommend maintenance therapy with MMF or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      rather than cyclophosphamide (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Maintenance immunosuppression'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The maintenance regimen depends upon the initial induction therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who have been successfully induced with MMF, we recommend maintenance with MMF rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The usual dose is 1000 mg twice daily.",
"     </li>",
"     <li>",
"      For patients who have been successfully induced with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , we suggest MMF rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      for maintenance therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The preferred MMF dose is 1000 mg twice daily. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Choice of maintenance agent'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Initiation of maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      is preferred to MMF in women who are in complete remission and want to become pregnant.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      is an alternative if azathioprine is not tolerated. MMF has a boxed warning because of an increased risk of congenital malformations and spontaneous abortion. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Initiation of maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who do not tolerate MMF should be treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Initiation of maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Low-dose oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (or its equivalent) at a dose of 0.05 to 0.2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day is continued in all patients receiving maintenance therapy. The goal is to attain the minimum prednisone dose required for control of extrarenal symptoms and avoid relapses and will therefore vary among patients. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Glucocorticoid therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/1\">",
"      KDIGO. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2012; 2:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/2\">",
"      Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012; 64:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/3\">",
"      Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/4\">",
"      Appel GB, Cohen DJ, Pirani CL, et al. Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am J Med 1987; 83:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/5\">",
"      Austin HA 3rd, Boumpas DT, Vaughan EM, Balow JE. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int 1994; 45:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/6\">",
"      Contreras G, Pardo V, Cely C, et al. Factors associated with poor outcomes in patients with lupus nephritis. Lupus 2005; 14:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/7\">",
"      Sis&oacute; A, Ramos-Casals M, Bov&eacute; A, et al. Outcomes in biopsy-proven lupus nephritis: evaluation of 190 white patients from a single center. Medicine (Baltimore) 2010; 89:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/8\">",
"      Schwartz MM, Lan SP, Bernstein J, et al. Role of pathology indices in the management of severe lupus glomerulonephritis. Lupus Nephritis Collaborative Study Group. Kidney Int 1992; 42:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/9\">",
"      Esdaile JM, Joseph L, MacKenzie T, et al. The benefit of early treatment with immunosuppressive agents in lupus nephritis. J Rheumatol 1994; 21:2046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/10\">",
"      Faurschou M, Starklint H, Halberg P, Jacobsen S. Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol 2006; 33:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/11\">",
"      Chagnac A, Kiberd BA, Fari&ntilde;as MC, et al. Outcome of the acute glomerular injury in proliferative lupus nephritis. J Clin Invest 1989; 84:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/12\">",
"      Korbet SM, Lewis EJ, Schwartz MM, et al. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 2000; 35:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/13\">",
"      Chen YE, Korbet SM, Katz RS, et al. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 2008; 3:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/14\">",
"      Chan TM, Tse KC, Tang CS, et al. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 2005; 14:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/15\">",
"      Korbet SM, Schwartz MM, Evans J, et al. Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol 2007; 18:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/16\">",
"      Barber CE, Geldenhuys L, Hanly JG. Sustained remission of lupus nephritis. Lupus 2006; 15:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/17\">",
"      Illei GG, Takada K, Parkin D, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002; 46:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/18\">",
"      Moroni G, Quaglini S, Maccario M, et al. \"Nephritic flares\" are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 1996; 50:2047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/19\">",
"      Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/20\">",
"      Austin HA 3rd, Muenz LR, Joyce KM, et al. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984; 25:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/21\">",
"      Schwartz MM, Lan SP, Bernstein J, et al. Irreproducibility of the activity and chronicity indices limits their utility in the management of lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 1993; 21:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/22\">",
"      Yokoyama H, Wada T, Hara A, et al. The outcome and a new ISN/RPS 2003 classification of lupus nephritis in Japanese. Kidney Int 2004; 66:2382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/23\">",
"      Mittal B, Hurwitz S, Rennke H, Singh AK. New subcategories of class IV lupus nephritis: are there clinical, histologic, and outcome differences? Am J Kidney Dis 2004; 44:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/24\">",
"      Hill GS, Delahousse M, Nochy D, Bari&eacute;ty J. Class IV-S versus class IV-G lupus nephritis: clinical and morphologic differences suggesting different pathogenesis. Kidney Int 2005; 68:2288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/25\">",
"      Markowitz GS, D'Agati VD. The ISN/RPS 2003 classification of lupus nephritis: an assessment at 3 years. Kidney Int 2007; 71:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/26\">",
"      Glassock RJ. Reclassification of lupus glomerulonephritis: back to the future. J Am Soc Nephrol 2004; 15:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/27\">",
"      Dooley MA, Hogan S, Jennette C, Falk R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int 1997; 51:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/28\">",
"      Alarc&oacute;n GS, McGwin G Jr, Bastian HM, et al. Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group. Arthritis Rheum 2001; 45:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/29\">",
"      Barr RG, Seliger S, Appel GB, et al. Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrol Dial Transplant 2003; 18:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/30\">",
"      Contreras G, Lenz O, Pardo V, et al. Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int 2006; 69:1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/31\">",
"      Lau KK, Jones DP, Hastings MC, et al. Short-term outcomes of severe lupus nephritis in a cohort of predominantly African-American children. Pediatr Nephrol 2006; 21:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/32\">",
"      Adler M, Chambers S, Edwards C, et al. An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period. Rheumatology (Oxford) 2006; 45:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/33\">",
"      Ward MM. Medical insurance, socioeconomic status, and age of onset of endstage renal disease in patients with lupus nephritis. J Rheumatol 2007; 34:2024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/34\">",
"      Valeri A, Radhakrishnan J, Estes D, et al. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study. Clin Nephrol 1994; 42:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/35\">",
"      Cheigh JS, Kim H, Stenzel KH, et al. Systemic lupus erythematosus in patients with end-stage renal disease: long-term follow-up on the prognosis of patients and the evolution of lupus activity. Am J Kidney Dis 1990; 16:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/36\">",
"      Schwartz MM, Kawala KS, Corwin HL, Lewis EJ. The prognosis of segmental glomerulonephritis in systemic lupus erythematosus. Kidney Int 1987; 32:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/37\">",
"      Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/38\">",
"      Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/39\">",
"      Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/40\">",
"      Hall CL, Fothergill NJ, Blackwell MM, et al. The natural course of gold nephropathy: long term study of 21 patients. Br Med J (Clin Res Ed) 1987; 295:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/41\">",
"      Hall CL, Jawad S, Harrison PR, et al. Natural course of penicillamine nephropathy: a long term study of 33 patients. Br Med J (Clin Res Ed) 1988; 296:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/42\">",
"      Potter EV, Lipschultz SA, Abidh S, et al. Twelve to seventeen-year follow-up of patients with poststreptococcal acute glomerulonephritis in Trinidad. N Engl J Med 1982; 307:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/43\">",
"      Steinberg AD. The treatment of lupus nephritis. Kidney Int 1986; 30:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/44\">",
"      Gourley MF, Austin HA 3rd, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996; 125:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/45\">",
"      Flanc RS, Roberts MA, Strippoli GF, et al. Treatment for lupus nephritis. Cochrane Database Syst Rev 2004; :CD002922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/46\">",
"      Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/47\">",
"      Yee CS, Gordon C, Dostal C, et al. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis 2004; 63:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/48\">",
"      Moroni G, Doria A, Mosca M, et al. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol 2006; 1:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/49\">",
"      Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46:2121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/50\">",
"      Levey AS, Lan SP, Corwin HL, et al. Progression and remission of renal disease in the Lupus Nephritis Collaborative Study. Results of treatment with prednisone and short-term oral cyclophosphamide. Ann Intern Med 1992; 116:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/51\">",
"      Houssiau FA, Vasconcelos C, D'Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010; 69:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/52\">",
"      Houssiau FA, Vasconcelos C, D'Cruz D, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004; 50:3934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/53\">",
"      Isenberg D, Appel GB, Contreras G, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) 2010; 49:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/54\">",
"      Henderson LK, Masson P, Craig JC, et al. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2013; 61:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/55\">",
"      Henderson L, Masson P, Craig JC, et al. Treatment for lupus nephritis. Cochrane Database Syst Rev 2012; 12:CD002922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/56\">",
"      Contreras G, Sosnov J. Role of mycophenolate mofetil in the treatment of lupus nephritis. Clin J Am Soc Nephrol 2007; 2:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/57\">",
"      Walsh M, James M, Jayne D, et al. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2007; 2:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/58\">",
"      Berden JH. Lupus nephritis. Kidney Int 1997; 52:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/59\">",
"      Lewis EJ, Hunsicker LG, Lan SP, et al. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med 1992; 326:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/60\">",
"      Euler HH, Schroeder JO, Harten P, et al. Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. Arthritis Rheum 1994; 37:1784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/61\">",
"      Aringer M, Smolen JS, Graninger WB. Severe infections in plasmapheresis-treated systemic lupus erythematosus. Arthritis Rheum 1998; 41:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/62\">",
"      Chen W, Tang X, Liu Q, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. Am J Kidney Dis 2011; 57:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/63\">",
"      Li X, Ren H, Zhang Q, et al. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant 2012; 27:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/64\">",
"      Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/65\">",
"      Chan TM, Tse KC, Tang CS, et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/66\">",
"      Swaak AJ, van den Brink HG, Smeenk RJ, et al. Systemic lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years: second evaluation. Lupus 2001; 10:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/67\">",
"      Ioannidis JP, Boki KA, Katsorida ME, et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000; 57:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/68\">",
"      Mosca M, Bencivelli W, Neri R, et al. Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis. Kidney Int 2002; 61:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/69\">",
"      Moroni G, Gallelli B, Quaglini S, et al. Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol Dial Transplant 2006; 21:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/70\">",
"      Grootscholten C, Berden JH. Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible? Nephrol Dial Transplant 2006; 21:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/71\">",
"      Houssiau FA, D'Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010; 69:2083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/72\">",
"      Wofsy D, Appel GB, Dooley MA. Aspreva Lupus Management Study maintenance results. Lupus 2010; 19 (Suppl):CS12.5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/73\">",
"      Stoenoiu MS, Aydin S, Tektonidou M, et al. Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial. Nephrol Dial Transplant 2012; 27:1924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/37/37466/abstract/74\">",
"      Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365:1886.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3059 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-FFFC22E1CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_37_37466=[""].join("\n");
var outline_f36_37_37466=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK FACTORS FOR PROGRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Delayed therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Failure to achieve clinical remission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Relapses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8472681\">",
"      Class of lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Race and ethnicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      NONIMMUNOSUPPRESSIVE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      IMMUNOSUPPRESSIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Focal proliferative disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Criteria for clinical remission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      INDUCTION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20804573\">",
"      Dosing according to ancestry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Plasmapheresis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18812642\">",
"      Tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8472617\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Choice of induction agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Combined diffuse proliferative and membranous LN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      MAINTENANCE IMMUNOSUPPRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Choice of maintenance agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H135586886\">",
"      - Azathioprine versus mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Initiation of maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Glucocorticoid therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Nonimmunosuppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Immunosuppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Induction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Maintenance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3059\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3059|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/27/32187\" title=\"table 1\">",
"      Side effects pulse CTX in SLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/19/10555\" title=\"table 2\">",
"      Neutropenia and infectious risk",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?12/1/12305?source=related_link\" title=\"calculator 1\">",
"      Calculator: Absolute neutrophil count",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35287?source=related_link\">",
"      Antiphospholipid syndrome and the kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=related_link\">",
"      Causes and diagnosis of membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/12/44233?source=related_link\">",
"      Clinical features and therapy of membranous lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/55/4985?source=related_link\">",
"      Clinical trials of immunosuppressive therapy in proliferative lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=related_link\">",
"      Diagnosis and classification of renal disease in systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39352?source=related_link\">",
"      End-stage renal disease due to lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/32/34314?source=related_link\">",
"      Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=related_link\">",
"      Lipid abnormalities in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2855?source=related_link\">",
"      Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/51/18231?source=related_link\">",
"      Overview of the classification and treatment of rapidly progressive (crescentic) glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/49/36626?source=related_link\">",
"      Patient information: Lupus and kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10232?source=related_link\">",
"      Pharmacology and side effects of azathioprine when used in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35304?source=related_link\">",
"      Poststreptococcal glomerulonephritis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/45/39641?source=related_link\">",
"      Pregnancy in women with systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=related_link\">",
"      Renal vein thrombosis and hypercoagulable state in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30824?source=related_link\">",
"      Statins and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/3/12345?source=related_link\">",
"      Therapy of resistant or relapsing diffuse or focal proliferative lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_37_37467="Respiratory signs symptoms ALS";
var content_f36_37_37467=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F58537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F58537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Respiratory signs and symptoms associated with amyotrophic lateral sclerosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Lower motor neuron signs",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Tachypnea",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Vocal and speech",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Reduced vocal volume",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Shortened sentences",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Frequent breath pauses",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Use of accessory respiratory muscles",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Abdominal paradox",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Lower motor neuron symptoms",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Dyspnea and/or orthopnea",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Low speech volume",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Weak cough",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Sleep disordered breathing",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Frequent nocturnal awakenings, possibly with note of dyspnea",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Excessive daytime sleepiness and/or fatigue",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Morning headache",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Confusion",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hallucinations",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_37_37467=[""].join("\n");
var outline_f36_37_37467=null;
var title_f36_37_37468="Calcium supplements PI";
var content_f36_37_37468=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F70454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F70454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Elemental calcium content per pill of different calcium supplements",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Elemental Ca/tablet",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ca compound",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vitamin D",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caltrate + D",
"       </td>",
"       <td>",
"        600 mg",
"       </td>",
"       <td>",
"        Carbonate",
"       </td>",
"       <td>",
"        800 Units&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        OsCal 500",
"       </td>",
"       <td>",
"        500 mg",
"       </td>",
"       <td>",
"        Carbonate",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        OsCal 500 + D",
"       </td>",
"       <td>",
"        500 mg",
"       </td>",
"       <td>",
"        Carbonate",
"       </td>",
"       <td>",
"        200 Units",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oscal 500 + Extra D",
"       </td>",
"       <td>",
"        500 mg",
"       </td>",
"       <td>",
"        Carbonate",
"       </td>",
"       <td>",
"        400 Units",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oscal Ultra",
"       </td>",
"       <td>",
"        600 mg",
"       </td>",
"       <td>",
"        Carbonate",
"       </td>",
"       <td>",
"        500 Units",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tums",
"       </td>",
"       <td>",
"        200 mg",
"       </td>",
"       <td>",
"        Carbonate",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tums EX",
"       </td>",
"       <td>",
"        300 mg",
"       </td>",
"       <td>",
"        Carbonate",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tums Ultra",
"       </td>",
"       <td>",
"        400 mg",
"       </td>",
"       <td>",
"        Carbonate",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Citracal Ultradense Petites",
"       </td>",
"       <td>",
"        200 mg",
"       </td>",
"       <td>",
"        Citrate",
"       </td>",
"       <td>",
"        250 Units",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Citracal caplets + D",
"       </td>",
"       <td>",
"        315 mg",
"       </td>",
"       <td>",
"        Citrate",
"       </td>",
"       <td>",
"        250 Units",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Citracal 250 + D",
"       </td>",
"       <td>",
"        250 mg",
"       </td>",
"       <td>",
"        Citrate",
"       </td>",
"       <td>",
"        200 Units",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Citracal&nbsp;+ D Slow Release&nbsp;",
"       </td>",
"       <td>",
"        600 mg&nbsp;",
"       </td>",
"       <td>",
"        Citrate&nbsp;",
"       </td>",
"       <td>",
"        500 Units&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caltrate 600 + soy",
"       </td>",
"       <td>",
"        600 mg",
"       </td>",
"       <td>",
"        Carbonate",
"       </td>",
"       <td>",
"        200 Units",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cal-100 with vitamin D",
"       </td>",
"       <td>",
"        1000 mg",
"       </td>",
"       <td>",
"        Carbonate",
"       </td>",
"       <td>",
"        400 Units",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Citracal gummy",
"       </td>",
"       <td>",
"        250 mg",
"       </td>",
"       <td>",
"        Tricalcium phosphate",
"       </td>",
"       <td>",
"        250 Units&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Viactiv plus D + K",
"       </td>",
"       <td>",
"        500 mg",
"       </td>",
"       <td>",
"        Carbonate",
"       </td>",
"       <td>",
"        500 Units",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Units: International Units.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_37_37468=[""].join("\n");
var outline_f36_37_37468=null;
var title_f36_37_37469="Low dose warfarin high risk AF";
var content_f36_37_37469=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72790&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72790&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Low-dose warfarin plus aspirin is not optimal in high risk AF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 264px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cumulative event rate of patients with atrial fibrillation (AF) at high risk for thromboembolism in the SPAF III trial. High risk was defined as the presence of at least one of the following: previous thromboembolism, female older than 75 years of age, heart failure or severe left ventricular systolic dysfunction, and systolic pressure &gt;160 mmHg. There was a much lower incidence of events with standard adjusted-dose warfarin therapy (INR 2 to 3) compared to treatment with aspirin and low-dose warfarin (INR 1.2 to 1.5) (p &lt;0.0001).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Stroke Prevention in Atrial Fibrillation Investigators. Lancet 1996; 348:633.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_37_37469=[""].join("\n");
var outline_f36_37_37469=null;
var title_f36_37_37470="Slumped posture";
var content_f36_37_37470=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The slumped posture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 335px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the forward-slumped shoulders and protruding chin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jason E Decker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_37_37470=[""].join("\n");
var outline_f36_37_37470=null;
var title_f36_37_37471="Endoscopic sinus surgery PI";
var content_f36_37_37471=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F87501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F87501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endoscopic sinus surgery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 443px; height: 427px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This drawing shows sinus endoscopy. This procedure allows doctors to see inside the sinuses and take samples of mucus from the sinuses.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_37_37471=[""].join("\n");
var outline_f36_37_37471=null;
